USRE46375E1 - 6,7-unsaturated-7-carbamoyl substituted morphinan derivative - Google Patents

6,7-unsaturated-7-carbamoyl substituted morphinan derivative Download PDF

Info

Publication number
USRE46375E1
USRE46375E1 US15/064,538 US201615064538A USRE46375E US RE46375 E1 USRE46375 E1 US RE46375E1 US 201615064538 A US201615064538 A US 201615064538A US RE46375 E USRE46375 E US RE46375E
Authority
US
United States
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
solvate
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/064,538
Inventor
Masanao Inagaki
Shin-ichiro Hara
Nobuhiro Haga
Yoshinori Tamura
Yoshihisa Goto
Tsuyoshi Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to US15/064,538 priority Critical patent/USRE46375E1/en
Application granted granted Critical
Publication of USRE46375E1 publication Critical patent/USRE46375E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D489/00Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08Oxygen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation.
A compound represented by the formula (I):
Figure USRE046375-20170425-C00001

wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,
or a pharmaceutically acceptably acceptable salt, or a solvate thereof is provided.

Description

This is a continuation of U.S. patent application Ser. No. 11/920,851, whose 35 U.S.C. §371(c) date is Mar. 10, 2009, which is the National Stage Application of PCT Application No. PCT/JP2006/310454, filed May 25, 2006, now International Publication No. WO 2006/126637, which claims priority from Japanese Patent Application No. 2005-151864, filed May 25, 2005, Japanese Patent Application No. 2006-065762, filed Mar. 10, 2006, and International Application No. PCT/JP2006/310231, filed May 23, 2006, now International Publication No. WO 2006/126529, each of which is herein incorporated by reference for all purposes.
TECHNICAL FIELD
The present invention relates to a 6,7-unsaturated-7-carbamoyl-substituted morphinan derivatives, which are useful as an agent for treating and/or preventing nausea, emesis, vomiting and/or constipation, particularly as an agent for alleviating and/or preventing a side effect (emesis, vomiting and/or constipation etc.) induced by a compound having the opioid receptor (e.g. opioid μ receptor) agonistic activity.
BACKGROUND ART
An opioid receptor agonist such as morphine and the like which is used as an analgesic is very effective in a patient having cancer pain, but as a side effect, induces severe nausea, emesis, vomiting, constipation, anuresis, and itching. Various antiemetics and anti-constipation agents are clinically used, but it can not be said that any of them exhibits the sufficient effect, and an excellent side effect alleviating agent is also demanded for improving QOL of a patient.
Patent Literatures 1 and 2, and Non-patent Literature 1 describe to the effect that a morphinan derivative is effective in treating or preventing emesis and vomiting induced by an opioid μ agonist, and Non-Patent Literature 2 describes that a 6,7-saturated-7-carbamoyl-substituted-morphinan derivatives have the opioid δ receptor antagonism. However, none of them describes or suggests the present compound.
  • [Patent Literature 1] International Patent Application Publication WO 2004-007503
  • [Patent Literature 2] International Patent Application Publication WO 95/13071
  • [Non-Patent Literature 1] Journal of Medicinal Chemistry 41, 4177-4180 (1998)
  • [Non-Patent Literature 2] Chemical and Pharmaceutical Bulletin, 52 (66) 747-750 (2004)
DISCLOSURE OF INVENTION Problems to be Solved by the Invention
We found 6,7-unsaturated-7-carbamoyl-substituted morphinan derivatives useful as a composition for treating and/or preventing emesis, vomiting and/or constipation.
Means to Solve the Problems
The present invention provides:
(1) a compound represented by the formula (I):
Figure USRE046375-20170425-C00002

wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkylsulfonyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, an optionally substituted heterocyclic group, or optionally substituted arylsulfonyl, or R1 and R2 are taken together with the nitrogen atom to which they are attached to form optionally substituted heterocycle;
R3 is hydrogen, hydroxy, optionally substituted lower alkyl, lower optionally substituted lower alkenyl, optionally substituted lower alkynyl optionally substituted lower alkoxy, mercapto, optionally substituted lower alkylthio, optionally substituted amino, optionally substituted carbamoyl, optionally substituted acyl, optionally substituted acyloxy, optionally substituted aryl, or an optionally substituted heterocyclic group,
a group represented by the formula:
Figure USRE046375-20170425-C00003

wherein ring A or ring B are each independently optionally substituted nitrogen-containing heterocycle optionally containing additional nitrogen atom, an oxygen atom, and/or a sulfur atom in the ring;
broken line indicates the presence or the absence of a bond;
when a broken line indicates the presence of a bond, p is 0;
when a broken line indicates the absence of a bond, p is 1;
Ra is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, or optionally substituted lower alkynyl;
and Rb is hydrogen or oxo;
R4 is hydrogen or lower alkyl;
R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,
or a pharmaceutically acceptable salt, or a solvate thereof, (1′) a compound represented by the formula (I):
Figure USRE046375-20170425-C00004

wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, or an optionally substituted heterocyclic group, or R1 and R2 are taken together with the nitrogen atom to which they are attached to form optionally substituted heterocycle;
R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy, mercapto, optionally substituted lower alkylthio, optionally substituted aryl, or an optionally substituted heterocyclic group;
R4 is hydrogen or lower alkyl;
and R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl;
or a pharmaceutically acceptable salt, or a solvate thereof,
(2) the compound according to (1) or (1′), wherein R3 is hydroxy,
or a pharmaceutically acceptable salt, or a solvate thereof,
(3) the compound according to (1) or (1′), wherein R3 is optionally substituted amino,
or a pharmaceutically acceptable salt, or a solvate thereof,
(4) the compound according to (1) or (1′), wherein R3 is amino substituted with optionally substituted arylsulfonyl,
or a pharmaceutically acceptable salt, or a solvate thereof,
(5) the compound according to any one of (1) to (4), and (1′), wherein R1 is hydrogen or lower alkyl, R2 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted cycloalkyl, or an optionally substituted heterocyclic group, and R5 is cyclopropylmethyl;
or a pharmaceutically acceptable salt, or a solvate thereof,
(6) the compound according to any one of (1) to (5), and (1′),
wherein R1 is hydrogen, R2 is lower alkyl optionally substituted with a heterocyclic group or lower alkoxy optionally substituted with aryl, phenyl optionally substituted with lower alkyl or lower alkoxy, cycloalkyl substituted with lower alkylcarbonyl, or a heterocyclic group substituted with lower alkoxy or aryl, R4 is hydrogen, and R5 is cyclopropylmethyl, or a pharmaceutically acceptable salt, or a solvate thereof,
(7) a pharmaceutical composition containing the compound according to any one of (1) to (6), and (1′), or a pharmaceutically acceptable salt, or a solvate thereof,
(8) a composition having opioid receptor antagonistic activity containing the compound according to (1) to (6), and (1′), or a pharmaceutically acceptable salt, or a solvate thereof,
(9) a composition for treating and/or preventing emesis, vomiting and/or constipation containing the compound according to any one of (1) to (6), and (1′), or a pharmaceutically acceptable salt, or a solvate thereof,
(10) a composition for alleviating and/or preventing a side effect induced by a compound having the opioid receptor agonistic activity, containing the compound according to any one of (1) to (6), and (1′), or a pharmaceutically acceptable salt, or a solvate thereof,
(11) a composition for treatment and/or prevention according to (10), wherein the side effect is emesis, vomiting and/or constipation,
(12) an agent for treatment and/or prevention according to (10) or (11), wherein the compound having the opioid receptor agonistic activity is morphine, oxycodone, or a pharmaceutically acceptable salt, or a solvate thereof,
(13) use of the compound according to any one of (1) to (6), and (1′), or a pharmaceutically acceptable salt, or solvate thereof for producing a medicament for treating and/or preventing emesis, vomiting and/or constipation,
(14) use of the compound according to any one of (1) to (6), and (1′), or a pharmaceutically acceptable salt, or solvate thereof, for producing a medicament for alleviating and/or preventing a side effect induced by a compound having the opioid receptor agonistic activity,
(15) a method for treating and/or preventing emesis, vomiting and/or constipation, comprising administering the compound according to any one of (1) to (6) and (1′), or a pharmaceutically acceptable salt, or a solvate thereof,
(16) a method for alleviating and/or preventing a side effect induced by a compound having the opioid receptor agonistic activity, comprising administering the compound according to any one of (1) to (6) and (1′), its pharmaceutically acceptable salt, or a solvate thereof,
(17) a composition for analgesic containing
a compound having an opioid receptor agonistic activity,
and an effective amount of compound according to any one of (1) to (6) and (1′), or a pharmaceutically acceptable salt, or a solvate thereof, for alleviating and/or preventing a side effect induced by administration of the compound having an opioid receptor agonistic activity,
(18) a composition for analgesic containing
a compound having an opioid receptor agonistic activity,
and an effective amount of compound according to any one of (1) to (6) and (1′), or a pharmaceutically acceptable salt or a solvate thereof, for treating and/or preventing emesis, vomiting and/or constipation induced by administration of the compound having an opioid receptor agonistic activity,
(19) the analgesic according to (17) or (18), wherein the compound having the opioid receptor agonistic activity, is morphine, oxycodone, its pharmaceutically acceptable salt, or a solvate thereof.
Effect of the Invention
The compound (I) of the present invention has the activity of treating/or preventing emesis, vomiting and/or constipation, particularly emesis, vomiting and/or constipation induced by a compound having the opioid receptor (e.g. opioid μ receptor) agonistic activity, and is useful as a composition for alleviating a side effect of a patient to whom a compound having the opioid receptor agonistic activity is administered or is in the middle of administration.
BEST MODE FOR CARRYING OUT THE INVENTION
As used herein, the “halogen” includes fluorine, chlorine, bromine and iodine. A halogen part of the “halogeno lower alkyl”, the “halogeno lower alkoxy”, and the “halogeno lower alkylthio” is the same.
The “lower alkyl” includes a straight or branched alkyl of a carbon number of 1 to 10, preferably a carbon number of 1 to 6, further preferably 1 to 3, and examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl and n-decyl. Preferable are methyl, ethyl, isopropyl, n-butyl, sec-butyl, tert-butyl, and 1-ethylpropyl.
Examples of a substituent of the “optionally substituted lower alkyl” include halogen, hydroxy, lower alkoxy, halogeno lower alkoxy, hydroxy lower alkoxy, lower alkylthio, lower alkylamino, acylamino, acyl, acyloxy, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, cyanocarbamoyl, lower alkylsulfonylcarbamoyl, arylsulfonylcarbamoyl, sulfamoyl, lower alkylsulfamoyl, lower alkylsulfonyl, cycloalkyl optionally substituted with one or more substituents selected from Substituent group α (wherein Substituent group α is halogen, hydroxy, lower alkyl, halogeno lower alkyl, hydroxy lower alkyl, lower alkoxy lower alkyl, carboxy lower alkyl, lower alkoxycarbonyl lower alkyl, amino lower alkyl, lower alkylamino lower alkyl, acylamino lower alkyl, cyano lower alkyl, lower alkoxy, halogeno lower alkoxy, hydroxy lower alkoxy, lower alkylthio, halogeno lower alkylthio, acyl, acyloxy, amino, lower alkylamino, acylamino, cyano, carboxy, lower alkoxycarbonyl, carbamoyl, lower alkylcarbamoyl, arylcarbamoyl, cyanocarbamoyl, lower alkylsulfonylcarbamoyl, sulfamoyl, lower alkylsulfamoyl, lower alkylsulfonyl, aryl optionally substituted with lower alkylenedioxy, and a heterocyclic group), cycloalkenyl optionally substituted with one or more substituents selected from Substituent group α, aryl optionally substituted with one or more substituents selected from Substituent group α, aryloxy optionally substituted with one or more substituents selected from Substituent group α, arylthio optionally substituted with one or more substituents selected from Substituent group α, a heterocyclic group optionally substituted with one or more substituents selected from Substituent group α, and heterocyclic oxy optionally substituted with one or more substituents selected from Substituent group α.
A lower alkyl part of the “halogeno lower alkyl”, the “hydroxy lower alkyl”, the “amino lower alkyl”, the “acylamino lower alkyl”, the “acyloxy lower alkyl”, the “cycloalkyl lower alkyl”, the “lower alkoxy”, the “halogeno lower alkoxy”, the “hydroxy lower alkoxy”, the “lower alkoxy lower alkyl”, the “lower alkoxycarbonyl”, the “carboxy lower alkyl”, the “lower alkoxycarbonyl lower alkyl”, the “lower alkylthio”, the “halogeno lower alkylthio”, the “lower alkylamino”, the “lower alkylamino lower alkyl”, the “lower alkylcarbamoyl”, the “lower alkylsulfamoyl”, the “lower alkylsulfonyl”, the “aryl lower alkyl”, the “tri lower alkylsilyl”, the “lower alkyldiarylsilyl”, the “triaryl lower alkylsilyl”, the “lower alkoxy lower alkoxy lower alkyl”, the “lower alkylthio lower alkyl”, the “aryl lower alkoxy lower alkyl”, the “lower alkylsulfonyl”, the “lower alkylsulfonylcarbamoyl”, the “lower alkylcarbonyl”, the “cyano lower alkyl”, the “lower alkoxycarbonylamino”, the “lower alkylenedioxy”, and the “heterocyclic lower alkyl” is the same as that of the aforementioned “lower alkyl”.
A substituent of the “optionally substituted lower alkoxy”, the “optionally substituted lower alkylthio”, and the “optionally substituted lower alkylsulfonyl” is the same as the aforementioned substituent of the “optionally substituted lower alkyl”.
The “lower alkenyl” includes a straight or branched alkenyl of a carbon number of 2 to 10, preferably a carbon number of 2 to 8, further preferably a carbon number of 3 to 6 having one or more double bonds at an arbitrary position. Specifically, examples include vinyl, allyl, propenyl, isopropenyl, butenyl, isobutenyl, prenyl, butadienyl, pentenyl, isopentenyl, pentadienyl, hexenyl, isohexenyl, hexadienyl, heptenyl, octenyl, nonenyl and decenyl. The lower alkenyl in R5 is preferably allyl.
The substituent of the “optionally substituted lower alkenyl” is the same as that of the “optionally substituted lower alkyl”.
The “lower alkynyl” includes straight or branched alkynyl of a carbon number of 2 to 10, preferably a carbon number of 2 to 8, further preferably a carbon number of 3 to 6 having one or more triple bonds at an arbitrary position. Specifically, examples include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, and decynyl. These may further have a double bond at an arbitrary position.
The substituent of the “optionally substituted lower alkynyl” is the same as that of the “optionally substituted lower alkyl”.
Examples of the substituent of the “optionally substituted amino” include lower alkyl optionally substituted with one or more substituents selected from Substituent group α, cycloalkyl optionally substituted with one or more substituents selected from Substituent group α, acyl optionally substituted with one or more substituents selected from Substituent group α, amino optionally substituted with one or more substituents selected from Substituent group α, aryl optionally substituted with one or more substituents selected from Substituent group α, sulfamoyl, lower alkylsulfamoyl optionally substituted with one or more substituents selected from Substituent group α, arylsulfamoyl optionally substituted with one or more substituents selected from Substituent group α, lower alkylsulfonyl optionally substituted with one or more substituents selected from Substituent group α, arylsulfonyl optionally substituted with one or more substituents selected from Substituent group α, arylamino optionally substituted with one or more substituents selected from Substituent group α, and a heterocyclic group optionally substituted with one or more substituents selected from Substituent group α.
The substituent of the “optionally substituted carbamoyl” is the same as that of the “optionally substituted amino”.
The “cycloalkyl” is a carbocyclic group of a carbon number of 3 to 10, preferably a carbon number of 3 to 8, more preferably a carbon number of 4 to 8 and, for example, includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and cyclodecyl. These may be further condensed with “aryl” described later or “heterocyclic group” described later at an arbitrary position.
As the “cycloalkyl” in R1 and R2, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl are preferable.
A cycloalkyl part of the “cycloalkyl lower alkyl” and the “cycloalkylcarbonyl” is the same as the aforementioned “cycloalkyl”.
As the “cycloalkyl lower alkyl” in R5, cyclopropylmethyl is preferable.”
Examples of the substituent of the “optionally substituted cycloalkyl” include on or more substituents selected from the aforementioned Substituent group α. The substituent can replace at an arbitrary position, and may replace at a carbon atom having a bond of cycloalkyl.
The “cycloalkenyl” includes cycloalkenyl having one or more double bonds at an arbitrary position in a ring of the aforementioned cycloalkyl, and examples include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptyl, cyclooctynyl and cyclohexadienyl.
As the “cycloalkenyl” in R1 or R2, cyclopropenyl, cyclobutenyl, cyclopentenyl, and cyclohexenyl are preferable.
A cycloalkenyl part of the “cycloalkenylcarbonyl” is the same as the aforementioned “cycloalkenyl”.
The substituent of the “optionally substituted cycloalkenyl” is the same as that of the aforementioned “optionally substituted cycloalkyl”.
The “aryl” includes phenyl, naphthyl, anthryl and phenanthryl, and phenyl is particularly preferable.
An aryl part of the “aryloxy”, the “arylthio”, the “aryl lower alkyl”, the “lower alkyldiarylsilyl”, the “triaryl lower alkylsilyl”, the “aryl lower alkyloxy lower alkyl”, the “arylsulfonyl”, the “arylsofamoyl”, the “arylamino”, the “arylcarbamoyl”, and the “arylsulfonylcarbamoyl” is the same as the aforementioned “aryl”.
Examples of the substituent of the “optionally substituted aryl”, the “optionally substituted phenyl”, and the “optionally substituted arylsulfonyl”, include the Substituent group α, phenyl substituted with one or more groups selected from Substituent group α, phenoxy substituted with one or more groups selected from Substituent group α, and lower alkylenedioxy.
The “heterocyclic group” includes a heterocyclic group having one or more heteroatoms arbitrarily selected from O, S and N in a ring, and specifically includes a 5- to 6-membered heteroaryl such as pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazolyl, triazinyl, tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl, furyl and thienyl; a bicyclic condensed heterocyclic group such as indolyl, isoindolyl, indazolyl, indolidinyl, indolinyl, isoindolinyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthridinyl, quinoxalinyl, purinyl, pteridinyl, benzopyranyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzoisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, quinazolinyl, quinolyl, isoquinolyl, naphthyridinyl, dihydropyridyl, tetrahydroquinolyl, and tetrahydrobenzothienyl; a tricyclic condensed heterocyclic group such as carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, and dibenzofuryl; a non-aromatic heterocyclic group such as dioxanyl, thiiranyl, thioranyl, thietanyl, oxilanyl, oxetanyl, oxathioranyl, azetidinyl, thianyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, dihydrofuryl, tetrahydrofuryl, tetrahydropyranyl, tetrahydrothiazolyl, and tetrahydroisothiazolyl. Preferable is a 5- to 6-membered heteroaryl or a non-aromatic heterocyclic group.
As the “heterocyclic group” in R1 and R2, pyrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, isoxazolyl, thiazolyl, thiadiazolyl, furyl, thienyl, indolyl, indazolyl, quinolyl, isoquinolyl, benzoxazolyl, benzothiazolyl, oxetanyl, tetrahydrofuryl, and tetrahydropyranyl are preferable. Pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl are more preferable. Pyridyl and pyrimidinyl are particularly preferable.
As the heterocyclic group of the “optionally substituted lower alkyl” in R1 and R2, isoxazolyl, oxazolyl, and oxadiazolyl are preferable. Oxadiazolyl is particularly preferable.
A heterocyclic part of the “heterocyclic oxy” and the “heterocyclic lower alkyl” is the same as the aforementioned “heterocyclic group”.
Examples of the substituent of the “optionally substituted heterocyclic group” include one or more groups selected from the group consisting of the Substituent group α and oxo. The substituent can replace at an arbitrary position, or may replace at a carbon atom or a nitrogen atom having a bond of the heterocyclic group.
The “acyl” includes straight or branched chain-like aliphatic acyl of a carbon number of 1 to 10, preferably a carbon number of 1 to 6, further preferably a carbon number of 1 to 4, cyclic aliphatic acyl of a carbon number of 4 to 9, preferably a carbon number of 4 to 7, aroyl and heterocyclic carbonyl. Herein, the “chain-like aliphatic” includes the aforementioned “lower alkyl”, the aforementioned “lower alkenyl”, and the aforementioned “lower alkynyl”. The “cyclic aliphatic” includes the aforementioned “cycloalkyl” and the aforementioned “cycloalkenyl”. A heterocyclic part of the heterocyclic carbonyl is the same as the aforementioned “heterocyclic group”. Examples of the acyl include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, pivaloyl, hexanoyl, acryloyl, propioloyl, methacryloyl, crotonoyl, cyclopropylcarbonyl, cyclohexylcarbonyl, cyclooctylcarbonyl, benzoyl, pyridine carbonyl, piperidinecarbonyl, piperazinecarbonyl, morpholinocarbonyl, and the like.
An acyl part of the “acyloxy”, the “acylamino”, the “acylamino lower alkyl” and the “acyloxy lower alkyl” is the same as the aforementioned “acyl”.
The substituent of the “optionally substituted acyl” or the “optionally substituted” is the same as the substituent of the aforementioned “optionally substituted lower alkyl” when the “acyl” is chain-like aliphatic acyl, and includes one or more groups selected from the Substituent group α when the “acyl” is cyclic aliphatic acyl, aroyl or heterocyclic carbonyl.
The “optionally substituted heterocycle” formed when R1 and R2 are taken together with the nitrogen atom to which they are attached, includes a 5-membered or 6-membered heterocycle containing the nitrogen atom to which R1 and R2 are attached and, further, optionally containing one or more heteroatoms selected from N, S and O. For example, the case where
Figure USRE046375-20170425-C00005

wherein R6, R7 and R8 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, acyl, acyloxy, amino, lower alkylamino, acylamino, lower alkoxycarbonylamino, carboxy or lower alkoxycarbonyl,
is included and the preferable is a saturated heterocycle group such as morpholine ring, pyrrolidine ring, piperidine ring, piperazine ring, and the like optionally substituted with hydrogen, halogen, hydroxy or lower alkyl.
The substituent of the “optionally substituted heterocycle, which is formed when R1 and R2 are taken together with the nitrogen atom to which they are attached” is the same as the substituent of the “optionally substituted heterocyclic group”.
Figure USRE046375-20170425-C00006

includes, for example, the following:
Figure USRE046375-20170425-C00007
Figure USRE046375-20170425-C00008
Figure USRE046375-20170425-C00009

wherein Ra is as defined above, and R is hydrogen or a group selected from Substituent group α.
Herein, the “solvate” includes, for example, a solvate with an organic solvent, a hydrate and the like. When a hydrate is formed, any number of water molecules may be coordinated.
The compound (I) includes a pharmaceutically acceptable salt. Examples include salts with alkali metals (lithium, sodium or potassium), alkaline earth metals (magnesium or calcium), ammonium, organic bases or amino acids, and salts with inorganic acids (hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid, phosphoric acid and hydroiodic acid), or organic acids (acetic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, or ethanesulfonic acid). Particularly, hydrochloric acid, phosphoric acid, tartaric acid, or methanesulfonic acid is preferable. These salts can be formed by a conventional method.
In addition, the compound (I) is not limited to a specific isomer, but includes all possible isomers and racemates. For example, when R3 of the compound (I) is hydroxy, the compound (I) includes other tautomer, that is, the following compound (I′).
Figure USRE046375-20170425-C00010
The present compound (I) can be produced by the following process.
(A Process)
Figure USRE046375-20170425-C00011

wherein RA is an ester residue, RB is hydrogen or hydroxy protecting group, and other symbols are as defined above.
Herein, the ester residue includes lower alkyl such as methyl, ethyl and the like, aryl lower alkyl such as benzyl, phenethyl and the like, acyloxy lower alkyl such as acetyloxymethyl and the like, etc.
The hydroxy protecting group is not limited to, but includes lower alkyl (methyl, tert-butyl etc.), aryl lower alkyl (triphenylmethyl, benzyl etc.), tri lower alkylsilyl (trimethylsilyl, tert-butyldimethylsilyl, triethylsilyl, triisopropylsilyl etc.), lower alkyldiarylsilyl (tert-butyldiphenylsilyl etc.), triaryl lower alkylsilyl (tribenzylsilyl etc.), lower alkoxy lower alkyl (methoxymethyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl etc.), lower alkoxy lower alkoxy lower alkyl (methoxyethoxymethyl etc.), lower alkylthio lower alkyl (methylthiomethyl etc.), optionally substituted tetrahydropyranyl (tetrahydropyran-2-yl, 4-methoxytetrahydropyran-4-yl etc.), tetrahydrothiopyranyl (tetrahydrothiopyran-2-yl etc.), tetrahydrofuranyl (tetrahydrofuran-2-yl etc.), tetrahydrothiofuranyl (tetrahydrothiofuran-2-yl etc.), aryl lower alkyloxy lower alkyl (benzyloxymethyl etc.), lower alkylsulfonyl (methanesulfonyl, ethanesulfonyl etc.), acyl (acetyl etc.) and arylsulfonyl (p-toluenesulfonyl etc.).
(First Step)
First, the known compound or compound (IV) derived therefrom is deprotected by a conventional method.
For example, when a protecting group is benzyl, the compound is dissolved or suspended in a suitable solvent (ethyl acetate, methanol, ethanol, tetrahydrofuran, dioxane, dimethylformamide, acetic acid, dilute hydrochloric acid, or a mixture thereof), and a hydrogenation reaction using a palladium catalyst (palladium hydroxide, palladium-carbon, palladium-barium sulfate, palladium-aluminum oxide, palladium black etc.) affords compound (III). A reaction may be performed at about 0° C. to about 100° C., preferably about 20° C. to about 50° C. for about 15 minutes to about 24 hours, preferably about 1 hour to about 5 hours.
(Second Step)
Then, the resulting compound (III) is directly amidated to obtain compound (Ia).
For example, compound (III) and compound (II) may be reacted by heating in a suitable solvent (methanol, ethanol, tetrahydrofuran, dimethylformamide, diethyl ether, dichloromethane, dichloroethane, toluene, xylene, chlorobenzene, orthodichlorobenzene, 2-methoxyethanol or diethylene glycol dimethyl ether or a mixture thereof) or without a solvent at about 0° C. to about 250° C., preferably about 80° C. to about 200° C. for about 30 minutes to about 24 hours, preferably about 1 to 12 hours in the presence or the absence of an amine compound (ammonia, dimethylamine, triethylamine, pyridine, dimethylaniline, dimethylaminopyridine, lutidine etc.).
In order to effectively carry a reaction forward, the reaction may be performed by microwave irradiation. A reaction temperature, and an irradiation time are not particularly limited, but are about 100° C. to about 200° C. and about 5 minutes to about 5 hours, preferably about 10 minutes to about 1 hour. It is preferable to use, as a solvent, a polar solvent such as methanol, ethanol, 1-propanol, ethylene glycol, glycerin, 2-methoxyethanol, 2-ethoxyethanol, N,N-dimethylformamide, diethylene glycol dimethyl ether and the like.
When R4 of objective compound (I) is lower alkyl, an objective compound can be obtained by the conventional etherization reaction at an arbitrary stage.
Figure USRE046375-20170425-C00012

wherein R3a is hydroxy, or optionally substituted lower alkoxy, and other symbols are as defined above.
(First Step)
When R3 of objective compound (I) is optionally substituted lower alkoxy, first, the known compound (IV) is etherized by a conventional method.
For example, the compound is reacted with an alkylating agent or an alcohol having a R3a group corresponding to an objective compound in the presence of a base (sodium hydride, potassium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, barium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, cesium carbonate, sodium methoxide, sodium ethoxide, potassium tert-butoxide, sodium bicarbonate or metal sodium), or under the condition of Mitsunobu reaction in a suitable solvent (N,N-dimethylformamide, dimethyl sulfoxide, toluene, benzene, xylene, a mixture thereof, or the like) cyclohexane, hexane, dichloromethane, 1,2-dichloroethane, tetrahydrofuran, dioxane, acetone, methyl ethyl ketone, acetonitrile, water or a mixture thereof) to obtain compound (VII). The reaction may be performed at −70 to 180° C., preferably about 0 to 150° C. for about 15 minutes to about 24 hours, preferably about 1 hour to about 5 hours.
(Second Step)
Then, compound (VII) is hydrolyzed to obtain compound (VI). The reaction may be performed under ice-cooling to at a reflux temperature of a solvent for about 15 minutes to about 24 hours, preferably, 1 hour to about 5 hours using an inorganic base (sodium hydroxide, lithium hydroxide or potassium hydroxide) in a suitable solvent (methanol, ethanol, tetrahydrofuran, dioxane, dimethylformamide or a mixture thereof).
(Third Step and Fourth Step)
Then, compound (VI) is amidated, and the resulting compound (V) is deprotected to obtain objective compound (Ib). These reactions may be performed by the same methods as those of the second step and the first step in A process, respectively. In an amidation step, the reaction may be performed, if necessary, in the presence of a condensing agent (N,N′-dicyclohexylcarbodiimide, N-dimethylaminopropyl-N′-ethylcarbodiimide, diethyl phosphoryl cyanide, diphenyl phosphoryl azide etc.).
In addition, when R4 of objective compound (I) is lower alkyl, an etherization reaction may be performed at an arbitrary stage as described above.
Figure USRE046375-20170425-C00013

wherein L is a leaving group, R3b is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy, mercapto, optionally substituted lower alkylthio, optionally substituted amino, optionally substituted carbamoyl, optionally substituted aryl, or optionally substituted heterocyclic group, and other symbols are as defined above.
(First Step)
When R3 of objective compound (I) is the R3b, a leaving group L (e.g. trifluoromethanesulfonyl, methanesulfonyl, phosphoric acid ester etc.) is introduced into the known compound (IV). For example, the compound is reacted with trifluoromethanesulfonic anhydride, trifluoromethanesulfonyl chloride, methanesulfonyl chloride, methanesulfonic anhydride, p-toluenesulfonyl chloride, N-phenyltrifluoromethanesulfonimide or various phosphoric acid esterifying reagents in the presence of a base (pyridine, triethylamine, ammonia, dimethylamine, dimethylaniline, dimethylaminopyridine, 2,6-lutidine or 2,6-di-tert-butylpyridine) using dichloromethane, chloroform, tetrahydrofuran, benzene, toluene, dimethylformamide, ethyl acetate or a mixture thereof as a solvent.
(Second Step)
The thus obtained compound (VIII) is subjected to the known substituent introducing reaction to obtain compound (IX).
(Third Step, Fourth Step and Fifth Step)
The compound (IX) is hydrolyzed, amidated, and deprotected by the same methods as those of the second step in B process, the second step in A process and the first step in A step, respectively, to obtain objective the compound (Ic).
In addition, when R4 of the objective compound (I) is lower alkyl, an etherization reaction may be performed at an arbitrary stage as described above.
(D Process)
compound (VIII) is obtained by the first step in C process, amidated according to the method of the fourth step in C process, and subjected to introduction of a substituent R3b, deprotection, and a hydrolysis reaction according to the methods of the second step, third step and fifth step in C process, respectively, thereby, objective compound (I) may be also obtained.
All of thus obtained present compounds have the opioid receptor antagonistic activity, and are useful as a drug, and among compounds represented by the formula (I), the following compounds are particularly preferable.
a) a compound in which R1 is hydrogen or lower alkyl,
b) a compound in which R1 is hydrogen or C1-C3 alkyl,
c) a compound in which R2 is:
(c-i) lower alkyl optionally substituted with one or more groups selected from Substituent group β (herein, Substituent group β is cycloalkyl optionally substituted with hydroxy, halogen, hydroxy, lower alkoxy, halogeno lower alkoxy, lower alkylthio, amino, lower alkylamino, carboxy, lower alkoxycarbonyl, cyano, lower alkylsulfonyl, aryl, aryloxy and lower alkylenedioxy),
(c-ii) phenyl optionally substituted with one or more groups selected from group consisting of Substituent group β, lower alkyl and halogeno lower alkyl,
(c-iii) aryl lower alkyl optionally substituted with one or more groups selected from Substituent group β,
(c-iv) cycloalkyl optionally substituted with one or more groups selected from Substituent group β,
(c-v) heterocyclic group optionally substituted with one or more groups selected from Substituent group β, or
(c-vi) heterocyclic lower alkyl optionally substituted with one or more groups selected from Substituent group β,
d) a compound in which R2 is:
(d-i) lower alkyl optionally substituted with hydroxy, cycloalkyl optionally substituted with hydroxy, lower alkoxy, lower alkylthio, lower alkylamino or aryloxy,
(d-ii) phenyl optionally substituted with halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, halogeno lower alkoxy, lower alkylthio, amino, lower alkylamino, cyano, lower alkylsulfonyl or lower alkylenedioxy,
(d-iii) aryl lower alkyl optionally substituted with lower alkoxy or lower alkylthio,
(d-iv) cycloalkyl optionally substituted with lower alkyl, carboxy or lower alkoxycarbonyl,
(d-v) a heterocyclic group optionally substituted with lower alkyl, lower alkoxy or phenyl, or
(d-vi) heterocyclic lower alkyl optionally substituted with lower alkyl or aryl,
e) a compound in which R1 and R2 are taken together with a N atom to which they bind to form a 5-membered or 6-membered saturated heterocycle,
f) a compound in which R3 is hydroxy or lower alkoxy,
g) a compound in which R3 is hydroxy,
h) a compound in which R3 is amino optionally substituted with one or more groups selected from Substituent group α,
i) a compound in which R3 is halogen, lower alkyl, or amino substituted with arylsulfonyl optionally substituted with lower alkoxy,
j) a compound in which R4 is hydrogen or methoxy,
k) a compound in which R5 is cycloalkyl lower alkyl or lower alkenyl,
l) a compound in which R5 is cyclopropylmethyl or allyl,
m) a compound in which R5 is cyclopropylmethyl,
n) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-i), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
o) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-i), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
p) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-i), R3 is halogen, lower alkyl, or amino substituted with arylsulfonyl optionally substituted with lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
q) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-i), R3 is halogen, lower alkyl, or amino substituted with arylsulfonyl optionally substituted with lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
r) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-ii), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
s) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-ii), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
t) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-iii), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
u) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-iii), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
v) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-iv), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
w) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-iv), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
x) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-v), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
y) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-v), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
z) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-vi), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl or lower alkenyl,
aa) a compound in which R1 is hydrogen or lower alkyl, R2 is the (d-vi), R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
ab) a compound in which R1 and R2 are taken together with a N atom to which they bind to form a 5-membered or 6-membered saturated heterocycle, R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cycloalkyl lower alkyl group or lower alkenyl,
ac) a compound in which R1 and R2 are taken together with a N atom to which they bind to form a 5-membered or 6-membered saturated heterocycle, R3 is hydroxy or lower alkoxy, R4 is hydrogen, and R5 is cyclopropylmethyl,
or a pharmaceutically acceptable salt or a solvate thereof.
In a compound represented by the formula (I), a compound in which R4 is hydrogen, R5 is cyclopropylmethyl, and a combination of NR1R2 and R3 (NR1R2, R3) is the following.
TABLE 1
Figure USRE046375-20170425-C00014
NR1R2 CR9R10
AA —NHiPr
AB
Figure USRE046375-20170425-C00015
AC
Figure USRE046375-20170425-C00016
AD
Figure USRE046375-20170425-C00017
AE
Figure USRE046375-20170425-C00018
AF
Figure USRE046375-20170425-C00019
AG —NHCR9R10CONH2 Ra
AH —NHCR9R10CONH2 Rb
AT —NHCR9R10CONH2 Rc
AJ —NHCR9R10CONH2 Rd
AK —NHCR9R10CONH2 Re
AL —NHCR9R10CONH2 Rf
AM —NHCR9R10CONH2 Rg
AN —NHCR9R10CONH2 Rh
AO —NHCR9R10CONH2 Ri
AP —NHCR9R10CONH2 Rj
AQ —NHCR9R10CONH2 Rk
AR —NHCR9R10CONH2 Rl
AS —NHCR9R10CONH2 Rm
AT —NHCR9R10CONH2 Rn
AU —NHCR9R10CONH2 Ro
AV —NHCR9R10CONH2 Rp
AW —NHCR9R10CONH2 Rq
AX —NHCR9R10CONH2 Rr
AY —NHCR9R10CONH2 Rs
AZ —NHCR9R10CONH2 Rt
BA —NHCR9R10CONMe2 Ra
BB —NHCR9R10CONMe2 Rb
BC —NHCR9R10CONMe2 Rc
BD —NHCR9R10CONMe2 Rd
BE —NHCR9R10CONMe2 Re
BF —NHCR9R10CONMe2 Rf
BG —NHCR9R10CONMe2 Rg
BH —NHCR9R10CONMe2 Rh
BI —NHCR9R10CONMe2 Ri
BJ —NHCR9R10CONMe2 Rj
BK —NHCR9R10CONMe2 Rk
BL —NHCR9R10CONMe2 Rl
BM —NHCR9R10CONMe2 Rm
BN —NHCR9R10CONMe2 Rn
BO —NHCR9R10CONMe2 Ro
BP —NHCR9R10CONMe2 Rp
BQ —NHCR9R10CONMe2 Rq
BR —NHCR9R10CONMe2 Rr
BS —NHCR9R10CONMe2 Rs
BT —NHCR9R10CONMe2 Rt
BU —NHCR9R10COOH Ra
BV —NHCR9R10COOH Rb
BW —NHCR9R10COOH Rc
BX —NHCR9R10COOH Rd
BY —NHCR9R10COOH Re
BZ —NHCR9R10COOH Rf
CA —NHCR9R10COOH Rg
CB —NHCR9R10COOH Rh
CC —NHCR9R10COOH Ri
CD —NHCR9R10COOH Rj
CE —NHCR9R10COOH Rk
CF —NHCR9R10COOH Rl
CG —NHCR9R10COOH Rm
CH —NHCR9R10COOH Rn
CI —NHCR9R10COOH Ro
CJ —NHCR9R10COOH Rp
CK —NHCR9R10COOH Rq
CL —NHCR9R10COOH Rr
CM —NHCR9R10COOH Rs
CN —NHCR9R10COOH Rt
CO —NHCR9R10COOMe Ra
CP —NHCR9R10COOMe Rb
CQ —NHCR9R10COOMe Rc
CR —NHCR9R10COOMe Rd
TABLE 2
NR1R2 CR9R10
CS —NHCR9R10COOMe Re
CT —NHCR9R10COOMe Rf
CU —NHCR9R10COOMe Rg
CV —NHCR9R10COOMe Rh
CW —NHCR9R10COOMe Ri
CX —NHCR9R10COOMe Rj
CY —NHCR9R10COOMe Rk
CZ —NHCR9R10COOMe Rl
DA —NHCR9R10COOMe Rm
DB —NHCR9R10COOMe Rn
DC —NHCR9R10COOMe Ro
DD —NHCR9R10COOMe Rp
DE —NHCR9R10COOMe Rq
DF —NHCR9R10COOMe Rr
DG —NHCR9R10COOMe Rs
DH —NHCR9R10COOMe Rt
DI —NHCR9R10COOEt Ra
DJ —NHCR9R10COOEt Rb
DK —NHCR9R10COOEt Rc
DL —NHCR9R10COOEt Rd
DM —NHCR9R10COOEt Re
DN —NHCR9R10COOEt Rf
DO —NHCR9R10COOEt Rg
DP —NHCR9R10COOEt Rh
DQ —NHCR9R10COOEt Ri
DR —NHCR9R10COOEt Rj
DS —NHCR9R10COOEt Rk
DT —NHCR9R10COOEt Rl
DU —NHCR9R10COOEt Rm
DV —NHCR9R10COOEt Rn
DW —NHCR9R10COOEt Ro
DX —NHCR9R10COOEt Rp
DY —NHCR9R10COOEt Rq
DZ —NHCR9R10COOEt Rr
EA —NHCR9R10COOEt Rs
EB —NHCR9R10COOEt Rt
EC —NHCR9R10COOiPr Ra
ED —NHCR9R10COOiPr Rb
EE —NHCR9R10COOiPr Rc
EF —NHCR9R10COOiPr Rd
EG —NHCR9R10COOiPr Re
EH —NHCR9R10COOiPr Rf
EI —NHCR9R10COOiPr Rg
EJ —NHCR9R10COOiPr Rh
EK —NHCR9R10COOiPr Ri
EL —NHCR9R10COOiPr Rj
EM —NHCR9R10COOiPr Rk
EN —NHCR9R10COOiPr Rl
EO —NHCR9R10COOiPr Rm
EP —NHCR9R10COOiPr Rn
EQ —NHCR9R10COOiPr Ro
ER —NHCR9R10COOiPr Rp
ES —NHCR9R10COOiPr Rq
ET —NHCR9R10COOiPr Rr
EU —NHCR9R10COOiPr Rs
EV —NHCR9R10COOiPr Rt
EW —NHCR9R10CONHMe Ra
EX —NHCR9R10CONHMe Rb
EY —NHCR9R10CONHMe Rc
EZ —NHCR9R10CONHMe Rd
FA —NHCR9R10CONHMe Re
FB —NHCR9R10CONHMe Rf
FC —NHCR9R10CONHMe Rg
FD —NHCR9R10CONHMe Rh
FE —NHCR9R10CONHMe Ri
FF —NHCR9R10CONHMe Rj
FG —NHCR9R10CONHMe Rk
FH —NHCR9R10CONHMe Rl
FI —NHCR9R10CONHMe Rm
FJ —NHCR9R10CONHMe Rn
FK —NHCR9R10CONHMe Ro
FL —NHCR9R10CONHMe Rp
FM —NHCR9R10CONHMe Rq
FN —NHCR9R10CONHMe Rr
FO —NHCR9R10CONHMe Rs
FP —NHCR9R10CONHMe Rt
FQ —NHCR9R10CONHiPr Ra
FR —NHCR9R10CONHiPr Rb
FS —NHCR9R10CONHiPr Rc
FT —NHCR9R10CONHiPr Rd
FU —NHCR9R10CONHiPr Re
FV —NHCR9R10CONHiPr Rf
FW —NHCR9R10CONHiPr Rg
FX —NHCR9R10CONHiPr Rh
FY —NHCR9R10CONHiPr Ri
FZ —NHCR9R10CONHiPr Rj
GA —NHCR9R10CONHiPr Rk
GB —NHCR9R10CONHiPr Rl
GC —NHCR9R10CONHiPr Rm
GD —NHCR9R10CONHiPr Rn
GE —NHCR9R10CONHiPr Ro
GF —NHCR9R10CONHiPr Rp
GG —NHCR9R10CONHiPr Rq
GH —NHCR9R10CONHiPr Rr
GI —NHCR9R10CONHiPr Rs
GJ —NHCR9R10CONHiPr Rt
GK —NHCR9R10CONHPh Ra
GL —NHCR9R10CONHPh Rb
GM —NHCR9R10CONHPh Rc
GN —NHCR9R10CONHPh Rd
GO —NHCR9R10CONHPh Re
GP —NHCR9R10CONHPh Rf
GQ —NHCR9R10CONHPh Rg
GR —NHCR9R10CONHPh Rh
GS —NHCR9R10CONHPh Ri
GT —NHCR9R10CONHPh Rj
GU —NHCR9R10CONHPh Rk
GV —NHCR9R10CONHPh Rl
GW —NHCR9R10CONHPh Rm
GX —NHCR9R10CONHPh Rn
GY —NHCR9R10CONHPh Ro
GZ —NHCR9R10CONHPh Rp
HA —NHCR9R10CONHPh Rq
HB —NHCR9R10CONHPh Rr
HC —NHCR9R10CONHPh Rs
HD —NHCR9R10CONHPh Rt
TABLE 3
NR1R2 CR9R10
HE —NHCR9R10CONHCN Ra
HF —NHCR9R10CONHCN Rb
HG —NHCR9R10CONHCN Rc
HH —NHCR9R10CONHCN Rd
HI —NHCR9R10CONHCN Re
HJ —NHCR9R10CONHCN Rf
HK —NHCR9R10CONHCN Rg
HL —NHCR9R10CONHCN Rh
HM —NHCR9R10CONHCN Ri
HN —NHCR9R10CONHCN Rj
HO —NHCR9R10CONHCN Rk
HP —NHCR9R10CONHCN Rl
HQ —NHCR9R10CONHCN Rm
HR —NHCR9R10CONHCN Rn
HS —NHCR9R10CONHCN Ro
HT —NHCR9R10CONHCN Rp
HU —NHCR9R10CONHCN Rq
HV —NHCR9R10CONHCN Rr
HW —NHCR9R10CONHCN Rs
HX —NHCR9R10CONHCN Rt
HY —NHCR9R10CONHSO2Me Ra
HZ —NHCR9R10CONHSO2Me Rb
IA —NHCR9R10CONHSO2Me Rc
IB —NHCR9R10CONHSO2Me Rd
IC —NHCR9R10CONHSO2Me Re
ID —NHCR9R10CONHSO2Me Rf
IE —NHCR9R10CONHSO2Me Rg
IF —NHCR9R10CONHSO2Me Rh
IG —NHCR9R10CONHSO2Me Ri
IH —NHCR9R10CONHSO2Me Rj
II —NHCR9R10CONHSO2Me Rk
IJ —NHCR9R10CONHSO2Me Rl
IK —NHCR9R10CONHSO2Me Rm
IL —NHCR9R10CONHSO2Me Rn
IM —NHCR9R10CONHSO2Me Ro
IN —NHCR9R10CONHSO2Me Rp
IO —NHCR9R10CONHSO2Me Rq
IP —NHCR9R10CONHSO2Me Rr
IQ —NHCR9R10CONHSO2Me Rs
IR —NHCR9R10CONHSO2Me Rt
IS —NHCR9R10CH2OMe Ra
IT —NHCR9R10CH2OMe Rb
IU —NHCR9R10CH2OMe Rc
IV —NHCR9R10CH2OMe Rd
IW —NHCR9R10CH2OMe Re
IX —NHCR9R10CH2OMe Rf
IY —NHCR9R10CH2OMe Rg
IZ —NHCR9R10CH2OMe Rh
JA —NHCR9R10CH2OMe Ri
JB —NHCR9R10CH2OMe Rj
JC —NHCR9R10CH2OMe Rk
JD —NHCR9R10CH2OMe Rl
JE —NHCR9R10CH2OMe Rm
IF —NHCR9R10CH2OMe Rn
JG —NHCR9R10CH2OMe Ro
JH —NHCR9R10CH2OMe Rp
JI —NHCR9R10CH2OMe Rq
JJ —NHCR9R10CH2OMe Rr
JK —NHCR9R10CH2OMe Rs
JL —NHCR9R10CH2OMe Rt
JM
Figure USRE046375-20170425-C00020
Ra
JN
Figure USRE046375-20170425-C00021
Rb
JO
Figure USRE046375-20170425-C00022
Rc
JP
Figure USRE046375-20170425-C00023
Rd
JQ
Figure USRE046375-20170425-C00024
Re
JR
Figure USRE046375-20170425-C00025
Rf
JS
Figure USRE046375-20170425-C00026
Rg
JT
Figure USRE046375-20170425-C00027
Rh
TABLE 4
NR1R2 CR9R10
JU
Figure USRE046375-20170425-C00028
Ri
JV
Figure USRE046375-20170425-C00029
Rj
JW
Figure USRE046375-20170425-C00030
Rk
JX
Figure USRE046375-20170425-C00031
Rl
JY
Figure USRE046375-20170425-C00032
Rm
JZ
Figure USRE046375-20170425-C00033
Rn
KA
Figure USRE046375-20170425-C00034
Ro
KB
Figure USRE046375-20170425-C00035
Rp
KC
Figure USRE046375-20170425-C00036
Rq
KD
Figure USRE046375-20170425-C00037
Rr
KE
Figure USRE046375-20170425-C00038
Rs
KF
Figure USRE046375-20170425-C00039
Rt
KG
Figure USRE046375-20170425-C00040
Ra
KH
Figure USRE046375-20170425-C00041
Rb
KI
Figure USRE046375-20170425-C00042
Rc
KJ
Figure USRE046375-20170425-C00043
Rd
KK
Figure USRE046375-20170425-C00044
Re
KL
Figure USRE046375-20170425-C00045
Rf
KM
Figure USRE046375-20170425-C00046
Rg
KN
Figure USRE046375-20170425-C00047
Rh
KO
Figure USRE046375-20170425-C00048
Ri
KP
Figure USRE046375-20170425-C00049
Rj
KQ
Figure USRE046375-20170425-C00050
Rk
KR
Figure USRE046375-20170425-C00051
Rl
KS
Figure USRE046375-20170425-C00052
Rm
KT
Figure USRE046375-20170425-C00053
Rn
KU
Figure USRE046375-20170425-C00054
Ro
KV
Figure USRE046375-20170425-C00055
Rp
KW
Figure USRE046375-20170425-C00056
Rq
KX
Figure USRE046375-20170425-C00057
Rr
KY
Figure USRE046375-20170425-C00058
Rs
KZ
Figure USRE046375-20170425-C00059
Rt
TABLE 5
NR1R2 CR9R10
LA
Figure USRE046375-20170425-C00060
Ra
LB
Figure USRE046375-20170425-C00061
Rb
LC
Figure USRE046375-20170425-C00062
Rc
LD
Figure USRE046375-20170425-C00063
Rd
LE
Figure USRE046375-20170425-C00064
Re
LF
Figure USRE046375-20170425-C00065
Rf
LG
Figure USRE046375-20170425-C00066
Rg
LH
Figure USRE046375-20170425-C00067
Rh
LI
Figure USRE046375-20170425-C00068
Ri
LJ
Figure USRE046375-20170425-C00069
Rj
LK
Figure USRE046375-20170425-C00070
Rk
LL
Figure USRE046375-20170425-C00071
Rl
LM
Figure USRE046375-20170425-C00072
Rm
LN
Figure USRE046375-20170425-C00073
Rn
LO
Figure USRE046375-20170425-C00074
Ro
LP
Figure USRE046375-20170425-C00075
Rp
LQ
Figure USRE046375-20170425-C00076
Rq
LR
Figure USRE046375-20170425-C00077
Rr
LS
Figure USRE046375-20170425-C00078
Rs
LT
Figure USRE046375-20170425-C00079
Rt
LU
Figure USRE046375-20170425-C00080
Ra
LV
Figure USRE046375-20170425-C00081
Rb
LW
Figure USRE046375-20170425-C00082
Rc
LX
Figure USRE046375-20170425-C00083
Rd
LY
Figure USRE046375-20170425-C00084
Re
LZ
Figure USRE046375-20170425-C00085
Rf
MA
Figure USRE046375-20170425-C00086
Rg
MB
Figure USRE046375-20170425-C00087
Rh
MC
Figure USRE046375-20170425-C00088
Ri
MD
Figure USRE046375-20170425-C00089
Rj
ME
Figure USRE046375-20170425-C00090
Rk
MF
Figure USRE046375-20170425-C00091
Rl
TABLE 6
NR1R2 CR9R10
MG
Figure USRE046375-20170425-C00092
Rm
MH
Figure USRE046375-20170425-C00093
Rn
MI
Figure USRE046375-20170425-C00094
Ro
MJ
Figure USRE046375-20170425-C00095
Rp
MK
Figure USRE046375-20170425-C00096
Rq
ML
Figure USRE046375-20170425-C00097
Rr
MM
Figure USRE046375-20170425-C00098
Rs
MN
Figure USRE046375-20170425-C00099
Rt

In the above Tables, CR9CR10 is represented by the following symbol.
TABLE 7
CR9R10
Ra
Figure USRE046375-20170425-C00100
Rb
Figure USRE046375-20170425-C00101
Rc
Figure USRE046375-20170425-C00102
Rd
Figure USRE046375-20170425-C00103
Re
Figure USRE046375-20170425-C00104
Rf
Figure USRE046375-20170425-C00105
Rg
Figure USRE046375-20170425-C00106
Rh
Figure USRE046375-20170425-C00107
Ri
Figure USRE046375-20170425-C00108
Rj
Figure USRE046375-20170425-C00109
Rk
Figure USRE046375-20170425-C00110
Rl
Figure USRE046375-20170425-C00111
Rm
Figure USRE046375-20170425-C00112
Rn
Figure USRE046375-20170425-C00113
Ro
Figure USRE046375-20170425-C00114
Rp
Figure USRE046375-20170425-C00115
Rq
Figure USRE046375-20170425-C00116
Rr
Figure USRE046375-20170425-C00117
Rs
Figure USRE046375-20170425-C00118
Rt
Figure USRE046375-20170425-C00119
TABLE 8
R3
VA H
VB Me
VC OH
VD OMe
VE CONH2
VF CONHiPr
VG NH2
VH NHAc
VI NHSO2Me
VJ Ph
VK
Figure USRE046375-20170425-C00120
VL
Figure USRE046375-20170425-C00121
VM
Figure USRE046375-20170425-C00122
VN
Figure USRE046375-20170425-C00123
VO
Figure USRE046375-20170425-C00124
VP
Figure USRE046375-20170425-C00125
VQ
Figure USRE046375-20170425-C00126
VR
Figure USRE046375-20170425-C00127
VS NHSO2Ph
VT NHCOPh
VU CONHMe
VV CONMe2
VW NHMe
VX NHiPr
VY NHPh
VZ
Figure USRE046375-20170425-C00128
WA
Figure USRE046375-20170425-C00129
WB
Figure USRE046375-20170425-C00130
WC
Figure USRE046375-20170425-C00131

(AA,VA), (AA,VB), (AA,VC), (AA,VD), (AA,VE), (AA,VF), (AA,VG), (AA,VH), (AA,VI), (AA,VJ), (AA,VK), (AA,VL), (AA,VM), (AA,VN), (AA,VO), (AA,VP), (AA,VQ), (AA,VR), (AA,VS), (AA,VT), (AA,VU), (AA,VV), (AA,VW), (AA,VX), (AB,VY), (AA,VZ), (AA,WA), (AA,WB), (AA,WC), (AB,VA), (AB,VB), (AB,VC), (AB,VD), (AB,VE), (AB,VF), (AB,VG), (AB,VH), (AB,VI), (AB,VJ), (AB,VK), (AB,VL), (AB,VM), (AB,VN), (AB,VO), (AB,VP), (AB,VQ), (AB,VR), (AB,VS), (AB,VT), (AB,VU), (AB,VV), (AB,VW), (AB,VX), (AB,VY), (AB,VZ), (AB,WA), (AB,WB), (AB,WC), (AC,VA), (AC,VB), (AC,VC), (AC,VD), (AC,VE), (AC,VF), (AC,VG), (AC,VH), (AC,VI), (AC,VJ), (AC,VK), (AC,VL), (AC,VM), (AC,VN), (AC,VO), (AC,VP), (AC,VQ), (AC,VR), (AC,VS), (AC,VT), (AC,VU), (AC,VV), (AC,VW), (AC,VX), (AC,VY), (AC,VZ), (AC,WA), (AC,WB), (AC,WC), (AD,VA), (AB,VB), (AD,VC), (AD,VD), (AD,VE), (AC,VF), (AD,VG), (AD,VH), (AD,VI), (AD,VJ), (AD,VK), (AD,VL), (AD,VM), (AD,VN), (AD,VO), (AD,VP), (AD,VQ), (AD,VR), (AD,VS), (AD,VT), (AD,VU), (AD,VV), (AD,VW), (AC,VX), (AD,VY), (AD,VZ), (AD,WA), (AD,WB), (AD,WC), (AE,VA), (AE,VB), (AB,VC), (AE,VD), (AE,VE), (AE,VF), (AE,VG), (AE,VH), (AE,VI), (AE,VJ), (AE,VK), (AE,VL), (AE,VM), (AE,VN), (AE,VO), (AE,VP), (AE,VQ), (AE,VR), (AE,VS), (AE,VT), (AE,VU), (AE,VV), (AE,VW), (AE,VX), (AB,VY), (AB,VZ), (AE,WA), (AE,WB), (AA,WC), (AF,VA), (AF,VB), (AF,VC), (AF,VD), (AF,VE), (AF,VF), (AF,VG), (AF,VH), (AF,VI), (AF,VJ), (AF,VK), (AF,VL), (AF,VM), (AF,VN), (AF,VO), (AF,VP), (AF,VQ), (AF,VR), (AF,VS), (AF,VT), (AF,VU), (AF,VV), (AF,VW), (AF,VX), (AF,VY), (AF,VZ), (AF,WA), (AF,WB), (AF,WC), (AG,VA), (AG,VB), (AB,VC), (AG,VD), (AG,VE), (AG,VF), (AG,VG), (AG,VH), (AG,VI), (AB,VJ), (AG,VK), (AG,VL), (AB,VM), (AG,VN), (AG,VO), (AG,VP), (AG,VQ), (AG,VR), (AC,VS), (AG,VT), (AG,VU), (AG,VV), (AG,VW), (AF,VX), (AG,VY), (AG,VZ), (AG,WA), (AG,WB), (AA,WC), (AH,VA), (AH,VB), (AB,VC), (AH,VD), (AH,VE), (AH,VF), (AH,VG), (AH,VH), (AH,VI), (AH,VJ), (AH,VK), (AH,VL), (AH,VM), (AH,VN), (AH,VO), (AH,VP), (AH,VQ), (AH,VR), (AH,VS), (AH,VT), (AH,VU), (AH,VV), (AH,VW), (AH,VX), (AH,VY), (AH,VZ), (AH,WA), (AH,WB), (AA,WC), (AI,VA), (AI,VB), (AI,VC), (AI,VD), (AI,VE), (AI,VF), (AI,VG), (AI,VH), (AI,VI), (AI,VJ), (AI,VK), (AI,VL), (AI,VM), (AI,VN), (AI,VO), (AI,VP), (AI,VQ), (AI,VR), (AI,VS), (AI,VT), (AI,VU), (AI,VV), (AI,VW), (AI,VX), (AI,VY), (AI,VZ), (AI,WA), (AI,WB), (AI,WC), (AJ,VA), (AJ,VB), (AJ,VC), (AJ,VD), (AJ,VE), (AJ,VF), (AJ,VG), (AJ,VH), (AJ,VI), (AJ,VJ), (AJ,VK), (AJ,VL), (AJ,VM), (AJ,VN), (AJ,VO), (AJ,VP), (AJ,VQ), (AJ,VR), (AJ,VS), (AJ,VT), (AJ,VU), (AJ,VV), (AJ,VW), (AF,VX), (AJ,VY), (AJ,VZ), (AJ,WA), (AJ,WB), (AJ,WC), (AK,VA), (AK,VB), (AB,VC), (AK,VD), (AK,VE), (AK,VF), (AK,VG), (AK,VH), (AK,VI), (AK,VJ), (AK,VK), (AK,VL), (AK,VM), (AK,VN), (AK,VO), (AK,VP), (AK,VQ), (AK,VR), (AK,VS), (AK,VT), (AK,VU), (AK,VV), (AH,VW), (AK,VX), (AK,VY), (AK,VZ), (AK,WA), (AK,WB), (AK,WC), (AL,VA), (AL,VB), (AB,VC), (AL,VD), (AL,VE), (AL,VF), (AL,VG), (AL,VH), (AL,VI), (AL,VJ), (AL,VK), (AL,VL), (AL,VM), (AL,VN), (AL,VO), (AL,VP), (AL,VQ), (AL,VR), (AL,VS), (AL,VT), (AL,VU), (AL,VV), (AL,VW), (AF,VX), (AL,VY), (AL,VZ), (AL,WA), (AL,WB), (AL,WC), (AM,VA), (AM,VB), (AM,VC), (AM,VD), (AM,VE), (AM,VF), (AM,VG), (AM,VH), (AM,VI), (AM,VJ), (AK,VK), (AM,VL), (AM,VM), (AM,VN), (AM,VO), (AM,VP), (AM,VQ), (AM,VR), (AM,VS), (AM,VT), (AM,VU), (AM,VV), (AM,VW), (AM,VX), (AM,VY), (AM,VZ), (AM,WA), (AM,WB), (AM,WC), (AN,VA), (AN,VB), (AN,VC), (AN,VD), (AN,VE), (AN,VF), (AN,VG), (AN,VH), (AN,VI), (AN,VJ), (AN,VK), (AN,VL), (AN,VM), (AN,VN), (AN,VO), (AN,VP), (AN,VQ), (AN,VR), (AN,VS), (AN,VT), (AN,VU), (AN,VV), (AN,VW), (AN,VX), (AN,VY), (AN,VZ), (AN,WA), (AN,WB), (AN,WC), (AO,VA), (AO,VB), (AO,VC), (AO,VD), (AO,VE), (AO,VF), (AO,VG), (AO,VH), (AO,VI), (AO,VJ), (AO,VK), (AO,VL), (AO,VM), (AO,VN), (AO,VO), (AO,VP), (AO,VQ), (AO,VR), (AO,VS), (AO,VT), (AO,VU), (AO,VV), (AO,VW), (AO,VX), (AO,VY), (AO,VZ), (AO,WA), (AO,WB), (AO,WC), (AP,VA), (AP,VB), (AP,VC), (AP,VD), (AP,VE), (AP,VF), (AP,VG), (AP,VH), (AP,VI), (AP,VJ), (AP,VK), (AP,VL), (AP,VM), (AP,VN), (AP,VO), (AP,VP), (AP,VQ), (AP,VR), (AP,VS), (AP,VT), (AP,VU), (AP,VV), (AP,VW), (AP,VX), (AP,VY), (AP,VZ), (AP,WA), (AP,WB), (AP,WC), (AQ,VA), (AQ,VB), (AQ,VC), (AQ,VD), (AQ,VE), (AQ,VF), (AQ,VG), (AQ,VH), (AQ,VI), (AQ,VJ), (AQ,VK), (AQ,VL), (AQ,VM), (AQ,VN), (AQ,VO), (AQ,VP), (AQ,VQ), (AQ,VR), (AQ,VS), (AQ,VT), (AQ,VU), (AQ,VV), (AQ,VW), (AQ,VX), (AQ,VY), (AQ,VZ), (AQ,WA), (AQ,WB), (AQ,WC), (AR,VA), (AR,VB), (AR,VC), (AR,VD), (AR,VE), (AR,VF), (AR,VG), (AR,VH), (AR,VI), (AR,VJ), (AR,VK), (AR,VL), (AR,VM), (AR,VN), (AR,VO), (AR,VP), (AR,VQ), (AR,VR), (AR,VS), (AR,VT), (AR,VU), (AR,VV), (AR,VW), (AR,VX), (AR,VY), (AR,VZ), (AR,WA), (AR,WB), (AR,WC), (AS,VA), (AS,VB), (AS,VC), (AS,VD), (AS,VE), (AS,VF), (AS,VG), (AS,VH), (AS,VI), (AS,VJ), (AS,VK), (AS,VL), (AS,VM), (AS,VN), (AS,VO), (AS,VP), (AS,VQ), (AS,VR), (AS,VS), (AS,VT), (AS,VU), (AS,VV), (AS,VW), (AS,VX), (AS,VY), (AS,VZ), (AS,WA), (AS,WB), (AS,WC), (AT,VA), (AT,VB), (AT,VC), (AT,VD), (AT,VE), (AT,VF), (AT,VG), (AT,VH), (AT,VI), (AT,VJ), (AT,VK), (AT,VL), (AT,VM), (AT,VN), (AT,VO), (AT,VP), (AT,VQ), (AT,VR), (AT,VS), (AT,VT), (AT,VU), (AT,VV), (AT,VW), (AT,VX), (AT,VY), (AT,VZ), (AT,WA), (AT,WB), (AT,WC), (AU,VA), (AU,VB), (AU,VC), (AU,VD), (AU,VE), (AU,VF), (AU,VG), (AU,VH), (AU,VI), (AU,VJ), (AU,VK), (AU,VL), (AU,VM), (AU,VN), (AU,VO), (AU,VP), (AU,VQ), (AU,VR), (AU,VS), (AU,VT), (AU,VU), (AU,VV), (AU,VW), (AU,VX), (AU,VY), (AU,VZ), (AU,WA), (AU,WB), (AU,WC), (AV,VA), (AV,VB), (AV,VC), (AV,VD), (AV,VE), (AV,VF), (AV,VG), (AV,VH), (AV,VI), (AV,VJ), (AV,VK), (AV,VL), (AV,VM), (AV,VN), (AV,VO), (AV,VP), (AV,VQ), (AV,VR), (AV,VS), (AV,VT), (AV,VU), (AV,VV), (AV,VW), (AV,VX), (AV,VY), (AV,VZ), (AV,WA), (AV,WB), (AV,WC), (AW,VA), (AW,VB), (AW,VC), (AW,VD), (AW,VE), (AW,VF), (AW,VG), (AW,VH), (AW,VI), (AW,VJ), (AW,VK), (AW,VL), (AW,VM), (AW,VN), (AW,VO), (AW,VP), (AW,VQ), (AW,VR), (AW,VS), (AW,VT), (AW,VU), (AW,VV), (AW,VW), (AW,VX), (AW,VY), (AW,VZ), (AW,WA), (AW,WB), (AW,WC), (AX,VA), (AX,VB), (AX,VC), (AX,VD), (AX,VE), (AX,VF), (AX,VG), (AX,VH), (AX,VI), (AX,VJ), (AX,VK), (AX,VL), (AX,VM), (AX,VN), (AX,VO), (AX,VP), (AX,VQ), (AX,VR), (AX,VS), (AX,VT), (AX,VU), (AX,VV), (AX,VW), (AX,VX), (AX,VY), (AX,VZ), (AX,WA), (AX,WB), (AX,WC), (AY,VA), (AY,VB), (AY,VC), (AY,VD), (AY,VE), (AY,VF), (AY,VG), (AY,VH), (AY,VI), (AY,VJ), (AY,VK), (AY,VL), (AY,XM), (AY,VN), (AY,VO), (AY,VP), (AY,VQ), (AY,VR), (AY,VS), (AY,VT), (AY,VU), (AY,VV), (AY,VW), (AY,VX), (AY,VY), (AY,VZ), (AY,WA), (AY,WB), (AY,WC), (AZ,VA), (AZ,VB), (AZ,VC), (AZ,VD), (AZ,VE), (AZ,VF), (AZ,VG), (AZ,VH), (AZ,VI), (AZ,VJ), (AZ,VK), (AZ,VL), (AZ,VM), (AZ,VN), (AZ,VO), (AZ,VP), (AZ,VQ), (AZ,VR), (AZ,VS), (AZ,VT), (AZ,VU), (AZ,VV), (AZ,VW), (AZ,VX), (AZ,VY), (AZ,VZ), (AZ,WA), (AZ,WB), (AZ,WC),
(BA,VA), (BA,VB), (BA,VC), (BA,VD), (BA,VE), (BA,VF), (BA,VG), (BA,VH), (BA,VI), (BA,VJ), (BA,VK), (BA,VL), (BN,VM), (BA,VN), (BA,VO), (BA,VP), (BA,VQ), (BA,VR), (BA,VS), (BA,VT), (BA,VU), (BA,VV), (BA,VW), (BA,VX), (BA,VY), (BA,VZ), (BA,WA), (BA,WB), (BA,WC), (BB,VA), (BB,VB), (BB,VC), (BB,VD), (BB,VE), (BB,VF), (BB,VG), (BB,VH), (BB,VI), (BB,VJ), (BB,VK), (BB,VL), (BB,VM), (BB,VN), (BB,VO), (BB,VP), (BB,VQ), (BB,VR), (BB,VS), (BB,VT), (BB,VU), (BB,VV), (BB,VW), (BB,VX), (BB,VY), (BB,VZ), (BB,WA), (BB,WB), (BB,WC), (BC,VA), (BC,VB), (BC,VC), (BC,VD), (BC,VE), (BC,VF), (BC,VG), (BC,VH), (BC,VI), (BC,VJ), (BC,VK), (BC,VL), (BC,VM), (BC,VN), (BC,VO), (BC,VP), (BC,VQ), (BC,VR), (BC,VS), (BC,VT), (BC,VU), (BC,VV), (BC,VW), (BC,VX), (BC,VY), (BC,VZ), (BC,WA), (BC,WB), (BB,WC), (BD,VA), (BD,VB), (BD,VC), (BD,VD), (BD,VE), (BD,VF), (BD,VG), (BD,VH), (BD,VI), (BD,VJ), (BD,VK), (BD,VL), (BD,VM), (BD,VN), (BD,VO), (BD,VP), (BD,VQ), (BD,VR), (BD,VS), (BD,VT), (BD,VU), (BD,VV), (BD,VW), (BD,VX), (BD,VY), (BD,VZ), (BD,WA), (BD,WB), (BD,WC), (BE,VA), (BE,VB), (BE,VC), (BE,VD), (BE,VE), (BE,VF), (BE,VG), (BE,VH), (BE,VI), (BE,VJ), (BE,VK), (BE,VL), (BE,VM), (BE,VN), (BE,VO), (BE,VP), (BE,VQ), (BE,VR), (BE,VS), (BE,VT), (BE,VU), (BE,VV), (BE,VW), (BE,VX), (BE,VY), (BE,VZ), (BE,WA), (BE,WB), (BE,WC), (BF,VA), (BF,VB), (BF,VC), (BF,VD), (BF,VE), (BF,VF), (BF,VG), (BF,VH), (BF,VI), (BF,VJ), (BF,VK), (BF,VL), (BF,VM), (BF,VN), (BF,VO), (BF,VP), (BF,VQ), (BF,VR), (BF,VS), (BF,VT), (BF,VU), (BF,VV), (BF,VW), (BF,VX), (BF,VY), (BF,VZ), (BF,WA), (BF,WB), (BF,WC), (BG,VA), (BG,VB), (BG,VC), (BG,VD), (BG,VE), (BG,VF), (BG,VG), (BG,VH), (BG,VI), (BG,VJ), (BG,VK), (BG,VL), (BN,VM), (BG,VN), (BG,VO), (BG,VP), (BG,VQ), (BG,VR), (BG,VS), (BG,VT), (BG,VU), (BE,VV), (BG,VW), (BG,VX), (BG,VY), (BG,VZ), (BG,WA), (BG,WB), (BG,WC), (BH,VA), (BH,VB), (BH,VC), (BH,VD), (BH,VE), (BH,VF), (BH,VG), (BH,VH), (BH,VI), (BH,VJ), (BH,VK), (BH,VL), (BH,VM), (BH,VN), (BH,VO), (BH,VP), (BH,VQ), (BH,VR), (BH,VS), (BH,VT), (BH,VU), (BH,VV), (BH,VW), (BH,VX), (BH,VY), (BH,VZ), (BH,WA), (BH,WB), (BH,WC), (BI,VA), (BI,VB), (BI,VC), (BI,VD), (BI,VE), (BI,VF), (BI,VG), (BI,VH), (BI,VI), (BI,VJ), (BI,VK), (BI,VL), (BI,VM), (BI,VN), (BI,VO), (BI,VP), (BI,VQ), (BI,VR), (BI,VS), (BI,VT), (BI,VU), (BI,VV), (BI,VW), (BI,VX), (BI,VY), (BI,VZ), (BI,WA), (BI,WB), (BI,WC), (BJ,VA), (BJ,VB), (BJ,VC), (BJ,VD), (BJ,VE), (BJ,VF), (BJ,VG), (BJ,VH), (BJ,VI), (BJ,VJ), (BJ,VK), (BJ,VL), (BJ,VM), (BJ,VN), (BJ,VO), (BJ,VP), (BJ,VQ), (BJ,VR), (BJ,VS), (BJ,VT), (BJ,VU), (BJ,VV), (BJ,VW), (BJ,VX), (BJ,VY), (BJ,VZ), (BJ,WA), (BJ,WB), (BJ,WC), (BK,VA), (BK,VB), (BK,VC), (BK,VD), (BK,VE), (BK,VF), (BK,VG), (BK,VH), (BK,VI), (BK,VJ), (BK,VK), (BK,VL), (BN,VM), (BK,VN), (BK,VO), (BK,VP), (BK,VQ), (BK,VR), (BK,VS), (BK,VT), (BK,VU), (BK,VV), (BK,VW), (BK,VX), (BK,VY), (BK,VZ), (BK,WA), (BK,WB), (BK,WC), (BL,VA), (BL,VB), (BL,VC), (BL,VD), (BL,VE), (BL,VF), (BL,VG), (BL,VH), (BL,VI), (BL,VJ), (BL,VK), (BL,VL), (BL,VM), (BL,VN), (BL,VO), (BL,VP), (BL,VQ), (BL,VR), (BL,VS), (BL,VT), (BL,VU), (BL,VV), (BL,VW), (BL,VX), (BL,VY), (BL,VZ), (BL,WA), (BL,WB), (BL,WC), (BM,VA), (BM,VB), (BM,VC), (BM,VD), (BM,VE), (BM,VF), (BM,VG), (BM,VH), (BM,VI), (BM,VJ), (BM,VK), (BM,VL), (BM,VM), (BM,VN), (BM,VO), (BM,VP), (BM,VQ), (BM,VR), (BM,VS), (BM,VT), (BM,VU), (BM,VV), (BM,VW), (BM,VX), (BM,VY), (BM,VZ), (BM,WA), (BM,WB), (BM,WC), (BN,VA), (BN,VB), (BN,VC), (BN,VD), (BN,VE), (BN,VF), (BN,VG), (BN,VH), (BN,VI), (BN,VJ), (BN,VK), (BN,VL), (BN,VM), (BN,VN), (BN,VO), (BN,VP), (BN,VQ), (BN,VR), (BN,VS), (BN,VT), (BN,VU), (BN,VV), (BN,VW), (BN,VX), (BN,VY), (BN,VZ), (BN,WA), (BN,WB), (BN,WC), (BO,VA), (BO,VB), (BO,VC), (BO,VD), (BO,VE), (BO,VF), (BO,VG), (BO,VH), (BO,VI), (BO,VJ), (BO,VK), (BO,VL), (BO,VM), (BO,VN), (BO,VO), (BO,VP), (BO,VQ), (BO,VR), (BO,VS), (BO,VT), (BO,VU), (BO,VV), (BO,VW), (BO,VX), (BO,VY), (BO,VZ), (BO,WA), (BO,WB), (BO,WC), (BP,VA), (BP,VB), (BP,VC), (BP,VD), (BP,VE), (BP,VF), (BP,VG), (BP,VH), (BP,VI), (BP,VJ), (BP,VK), (BP,VL), (BP,VM), (BP,VN), (BP,VO), (BP,VP), (BP,VQ), (BP,VR), (BP,VS), (BP,VT), (BP,VU), (BP,VV), (BP,VW), (BP,VX), (BP,VY), (BP,VZ), (BP,WA), (BP,WB), (BP,WC), (BQ,VA), (BQ,VB), (BQ,VC), (BQ,VD), (BQ,VE), (BQ,VF), (BQ,VG), (BQ,VH), (BQ,VI), (BQ,VJ), (BQ,VK), (BQ,VL), (BQ,VM), (BQ,VN), (BQ,VO), (BQ,VP), (BQ,VQ), (BQ,VR), (BQ,VS), (BQ,VT), (BQ,VU), (BQ,VV), (BQ,VW), (BQ,VX), (BQ,VY), (BQ,VZ), (BQ,WA), (BQ,WB), (BQ,WC), (BR,VA), (BR,VB), (BR,VC), (BR,VD), (BR,VE), (BR,VF), (BR,VG), (BR,VH), (BR,VI), (BR,VJ), (BR,VK), (BR,VL), (BR,VM), (BR,VN), (BR,VO), (BR,VP), (BR,VQ), (BR,VR), (BR,VS), (BR,VT), (BR,VU), (BR,VV), (BR,VW), (BR,VX), (BR,VY), (BR,VZ), (BR,WA), (BR,WB), (BR,WC), (BS,VA), (BS,VB), (BS,VC), (BS,VD), (BS,VE), (BS,VF), (BS,VG), (BS,VH), (BS,VI), (BS,VJ), (BR,VK), (BS,VL), (BS,VM), (BS,VN), (BS,VO), (BR,VP), (BS,VQ), (BS,VR), (BS,VS), (BS,VT), (BS,VU), (BS,VV), (BS,VW), (BS,VX), (BS,VY), (BS,VZ), (BS,WA), (BS,WB), (BP,WC), (BT,VA), (BT,VB), (BT,VC), (BT,VD), (BT,VE), (BT,VF), (BT,VG), (BT,VH), (BT,VI), (BT,VJ), (BT,VK), (BT,VL), (BT,VM), (BT,VN), (BT,VO), (BT,VP), (BT,VQ), (BT,VR), (BT,VS), (BT,VT), (BT,VU), (BT,VV), (BT,VW), (BT,VX), (BT,VY), (BT,VZ), (BT,WA), (BT,WB), (BT,WC), (BU,VA), (BU,VB), (BU,VC), (BU,VD), (BU,VE), (BR,VF), (BU,VG), (BU,VH), (BU,VI), (BU,VJ), (BU,VK), (BU,VL), (BU,VM), (BR,VN), (BU,VO), (BU,VP), (BU,VQ), (BU,VR), (BU,VS), (BU,VT), (BU,VU), (BU,VV), (BU,VW), (BU,VX), (BU,VY), (BU,VZ), (BU,WA), (BU,WB), (BU,WC), (BV,VA), (BR,VB), (BV,VC), (BV,VD), (BV,VE), (BV,VF), (BV,VG), (BV,VH), (BV,VI), (BV,VJ), (BV,VK), (BV,VL), (BV,VM), (BV,VN), (BV,VO), (BV,VP), (BV,VQ), (BV,VR), (BR,VS), (BV,VT), (BV,VU), (BV,VV), (BV,VW), (BV,VX), (BV,VY), (BV,VZ), (BV,WA), (BV,WB), (BV,WC), (BW,VA), (BW,VB), (BW,VC), (BW,VD), (BW,VE), (BW,VF), (BW,VG), (BW,VH), (BW,VI), (BW,VJ), (BW,VK), (BW,VL), (BW,VM), (BW,VN), (BW,VO), (BW,VP), (BW,VQ), (BW,VR), (BW,VS), (BW,VT), (BW,VU), (BW,VV), (BW,VW), (BW,VX), (BW,VY), (BW,VZ), (BW,WA), (BW,WB), (BW,WC), (BX,VA), (BX,VB), (BX,VC), (BX,VD), (BX,VE), (BX,VF), (BX,VG), (BX,VH), (BX,VI), (BX,VJ), (BX,VK), (BX,VL), (BX,VM), (BX,VN), (BX,VO), (BX,VP), (BX,VQ), (BX,VR), (BX,VS), (BX,VT), (BX,VU), (BX,VV), (BX,VW), (BX,VX), (BX,VY), (BX,VZ), (BX,WA), (BX,WB), (BX,WC), (BY,VA), (BY,VB), (BY,VC), (BY,VD), (BY,VE), (BY,VF), (BY,VG), (BY,VH), (BY,VI), (BY,VJ), (BY,VK), (BY,VL), (BY,VM), (BX,VN), (BY,VO), (BY,VP), (BY,VQ), (BY,VR), (BY,VS), (BY,VT), (BY,VU), (BY,VV), (BY,VW), (BY,VX), (BY,VY), (BY,VZ), (BY,WA), (BY,WB), (BY,WC), (BZ,VA), (BZ,VB), (BZ,VC), (BZ,VD), (BZ,VE), (BZ,VF), (BZ,VG), (BZ,VH), (BZ,VI), (BZ,VJ), (BZ,VK), (BZ,VL), (BZ,VM), (BZ,VN), (BZ,VO), (BZ,VP), (BZ,VQ), (BZ,VR), (BZ,VS), (BZ,VT), (BZ,VU), (BZ,VV), (BZ,VW), (BZ,VX), (BZ,VY), (BZ,VZ), (BZ,WA), (BZ,WB), (BZ,WC), (CA,VA), (CA,VB), (CA,VC), (CA,VD), (CA,VE), (CA,VF), (CA,VG), (CA,VH), (CA,VI), (CA,VJ), (CA,VK), (CA,VL), (CA,VM), (CA,VN), (CA,VO), (CA,VP), (CA,VQ), (CA,VR), (CA,VS), (CA,VT), (CA,VU), (CA,VV), (CA,VW), (CA,VX), (CA,VY), (CA,VZ), (CA,WA), (CA,WB), (CA,WC), (CB,VA), (CB,VB), (CB,VC), (CB,VD), (CB,VE), (CB,VF), (CB,VG), (CB,VH), (CB,VI), (CB,VJ), (CB,VK), (CB,VL), (CB,VM), (CB,VN), (CB,VO), (CB,VP), (CB,VQ), (CB,VR), (CB,VS), (CB,VT), (CB,VU), (CB,VV), (CB,VW), (CB,VX), (CB,VY), (CB,VZ), (CB,WA), (CB,WB), (CB,WC), (CC,VA), (CB,VB), (CC,VC), (CA,VD), (CC,VE), (CC,VF), (CC,VG), (CC,VH), (CC,VI), (CC,VJ), (CC,VK), (CC,VL), (CC,VM), (CC,VN), (CC,VO), (CC,VP), (CC,VQ), (CC,VR), (CC,VS), (CC,VT), (CC,VU), (CC,VV), (CC,VW), (CC,VX), (CC,VY), (CC,VZ), (CC,WA), (CC,WB), (CC,WC), (CD,VA), (CD,VB), (CD,VC), (CD,VD), (CD,VE), (CD,VF), (CD,VG), (CD,VH), (CD,VI), (CD,VJ), (CD,VK), (CD,VL), (CD,VM), (CD,VN), (CD,VO), (CD,VP), (CD,VQ), (CD,VR), (CD,VS), (CD,VT), (CD,VU), (CD,VV), (CD,VW), (CD,VX), (CD,VY), (CD,VZ), (CD,WA), (CD,WB), (CD,WC), (CE,VA), (CE,VB), (CE,VC), (CE,VD), (CE,VE), (CE,VF), (CE,VG), (CE,VH), (CE,VI), (CE,VJ), (CE,VK), (CE,VL), (CE,VM), (CE,VN), (CE,VO), (CE,VP), (CE,VQ), (CE,VR), (CE,VS), (CE,VT), (CE,VU), (CE,VV), (CE,VW), (CE,VX), (CE,VY), (CE,VZ), (CE,WA), (CE,WB), (CE,WC), (CF,VA), (CF,VB), (CF,VC), (CF,VD), (CF,VE), (CF,VF), (CF,VG), (CF,VH), (CF,VI), (CF,VJ), (CF,VK), (CF,VL), (CF,VM), (CF,VN), (CF,VO), (CF,VP), (CF,VQ), (CF,VR), (CF,VS), (CF,VT), (CF,VIJ), (CF,VV), (CF,VW), (CF,VX), (CF,VY), (CF,VZ), (CF,WA), (CF,WB), (CF,WC), (CG,VA), (CG,VB), (CG,VC), (CG,VD), (CG,VE), (CG,VF), (CG,VG), (CG,VH), (CG,VI), (CG,VJ), (CG,VK), (CG,VL), (CG,VM), (CG,VN), (CG,VO), (CG,VP), (CG,VQ), (CG,VR), (CG,VS), (CG,VT), (CG,VU), (CG,VV), (CG,VW), (CG,VX), (CG,VY), (CG,VZ), (CG,WA), (CG,WB), (CG,WC), (CH,VA), (CH,VB), (CH,VC), (CH,VD), (CH,VE), (CH,VF), (CH,VG), (CH,VH), (CH,VI), (CH,VJ), (CH,VK), (CH,VL), (CH,VM), (CH,VN), (CH,VO), (CH,VP), (CH,VQ), (CH,VR), (CH,VS), (CH,VT), (CH,VU), (CH,VV), (CH,VW), (CH,VX), (CH,VY), (CH,VZ), (CH,WA), (CH,WB), (CH,WC), (CI,VA), (CI,VB), (CI,VC), (CI,VD), (CI,VE), (CI,VF), (CI,VG), (CI,VH), (CI,VJ), (CI,VK), (CI,VL), (CI,VM), (CI,VN), (CI,VO), (CI,VP), (CI,VQ), (CI,VR), (CI,VS), (CI,VT), (CI,VU), (CI,VV), (CI,VW), (CI,VX), (CI,VY), (CI,VZ), (CI,WA), (CI,WB), (CI,WC), (CJ,VA), (CJ,VB), (CJ,VC), (CJ,VD), (CJ,VE), (CJ,VF), (CJ,VG), (CJ,VH), (CJ,VI), (CJ,VJ), (CJ,VK), (CJ,VL), (CJ,VM), (CJ,VN), (CJ,VO), (CJ,VP), (CJ,VQ), (CJ,VR), (CJ,VS), (CJ,VT), (CJ,VU), (CJ,VV), (CJ,VW), (CJ,VX), (CJ,VY), (CJ,VZ), (CJ,WA), (CJ,WB), (CJ,WC), (CK,VA), (CK,VB), (CK,VC), (CK,VD), (CK,VE), (CK,VF), (CK,VG), (CK,VH), (CK,VI), (CK,VJ), (CK,VK), (CK,VL), (CK,VM), (CK,VN), (CK,VO), (CK,VP), (CK,VQ), (CK,VR), (CK,VS), (CK,VT), (CK,VU), (CK,VV), (CK,VW), (CK,VX), (CK,VY), (CK,VZ), (CK,WA), (CK,WB), (CK,WC), (CL,VA), (CL,VB), (CL,VC), (CL,VD), (CL,VE), (CL,VF), (CL,VG), (CL,VH), (CL,VI), (CL,VJ), (CL,VK), (CL,VL), (CL,VM), (CL,VN), (CL,VO), (CL,VP), (CL,VQ), (CL,VR), (CL,VS), (CL,VT), (CL,VU), (CL,VV), (CL,VW), (CL,VX), (CL,VY), (CL,VZ), (CL,WA), (CL,WB), (CL,WC), (CM,VA), (CM,VB), (CM,VC), (CM,VD), (CM,VE), (CM,VF), (CM,VG), (CM,VH), (CM,VI), (CM,VJ), (CM,VK), (CM,VL), (CM,VM), (CM,VN), (CM,VO), (CM,VP), (CM,VQ), (CM,VR), (CM,VS), (CM,VT), (CM,VU), (CM,VV), (CM,VW), (CM,VX), (CM,VY), (CM,VZ), (CM,WA), (CM,WB), (CM,WC), (CN,VA), (CN,VB), (CN,VC), (CN,VD), (CN,VE), (CN,VF), (CN,VG), (CN,VH), (CN,VI), (CN,VJ), (CN,VK), (CN,VL), (CN,VM), (CN,VN), (CN,VO), (CN,VP), (CN,VQ), (CN,VR), (CN,VS), (CN,VT), (CN,VU), (CN,VV), (CN,VW), (CN,VX), (CN,VY), (CN,VZ), (CN,WA), (CN,WB), (CN,WC), (CO,VA), (CO,VB), (CO,VC), (CO,VD), (CO,VE), (CO,VF), (CO,VG), (CO,VH), (CO,VI), (CO,VJ), (CO,VK), (CO,VL), (CO,VM), (CO,VN), (CO,VO), (CO,VP), (CO,VQ), (CO,VR), (CO,VS), (CO,VT), (CO,VU), (CO,VV), (CO,VW), (CO,VX), (CO,VY), (CO,VZ), (CO,WA), (CO,WB), (CO,WC), (CP,VA), (CP,VB), (CP,VC), (CP,VD), (CP,VE), (CP,VF), (CP,VG), (CP,VH), (CP,VI), (CP,VJ), (CP,VK), (CP,VL), (CP,VM), (CP,VN), (CP,VO), (CP,VP), (CP,VQ), (CP,VR), (CP,VS), (CP,VT), (CP,VU), (CP,VV), (CP,VW), (CP,VX), (CP,VY), (CP,VZ), (CP,WA), (CP,WB), (CP,WC), (CQ,VA), (CQ,VB), (CQ,VC), (CQ,VD), (CQ,VE), (CQ,VF), (CQ,VG), (CQ,VH), (CQ,VI), (CQ,VJ), (CQ,VK), (CQ,VL), (CQ,VM), (CQ,VN), (CQ,VO), (CQ,VP), (CQ,VQ), (CQ,VR), (CQ,VS), (CQ,VT), (CK,VU), (CQ,VV), (CQ,VW), (CQ,VX), (CQ,VY), (CQ,VZ), (CQ,WA), (CQ,WB), (CQ,WC), (CR,VA), (CR,VB), (CR,VC), (CR,VD), (CR,VE), (CR,VF), (CR,VG), (CR,VH), (CR,VI), (CR,VJ), (CR,VK), (CR,VL), (CR,VM), (CR,VN), (CR,VO), (CR,VP), (CR,VQ), (CR,VR), (CR,VS), (CR,VT), (CR,VU), (CR,VV), (CR,VW), (CR,VX), (CR,VY), (CR,VZ), (CR,WA), (CR,WB), (CR,WC), (CS,VA), (CS,VB), (CS,VC), (CS,VD), (CS,VE), (CS,VF), (CS,VG), (CS,VH), (CS,VI), (CS,VJ), (CS,VK), (CS,VL), (CS,VM), (CS,VN), (CS,VO), (CS,VP), (CS,VQ), (CS,VR), (CR,VS), (CS,VT), (CS,VU), (CS,VV), (CS,VW), (CS,VX), (CS,VY), (CS,VZ), (CS,WA), (CS,WB), (CR,WC), (CT,VA), (CT,VB), (CT,VC), (CT,VD), (CT,VE), (CT,VF), (CT,VG), (CT,VH), (CT,VI), (CT,VJ), (CT,VK), (CT,VL), (CT,VM), (CT,VN), (CT,VO), (CT,VP), (CT,VQ), (CT,VR), (CT,VS), (CT,VT), (CT,VU), (CT,VV), (CT,VW), (CT,VX), (CT,VY), (CT,VZ), (CT,WA), (CT,WB), (CT,WC), (CU,VA), (CU,VB), (CU,VC), (CU,VD), (CU,VE), (CU,VF), (CU,VG), (CU,VH), (CU,VI), (CU,VJ), (CU,VK), (CU,VL), (CU,VM), (CU,VN), (CU,VO), (CU,VP), (CU,VQ), (CU,VR), (CU,VS), (CU,VT), (CU,VU), (CU,VV), (CU,VW), (CU,VX), (CU,VY), (CU,VZ), (CU,WA), (CU,WB), (CU,WC), (CV,VA), (CV,VB), (CR,VC), (CV,VD), (CV,VE), (CV,VF), (CV,VG), (CV,VH), (CV,VI), (CV,VJ), (CV,VK), (CV,VL), (CV,VM), (CV,VN), (CV,VO), (CT,VP), (CV,VQ), (CV,VR), (CR,VS), (CR,VT), (CV,VU), (CV,VV), (CV,VW), (CV,VX), (CV,VY), (CV,VZ), (CV,WA), (CV,WB), (CV WC), (CW,VA), (CW,VB), (CW,VC), (CW,VD), (CW,VE), (CW,VF), (CW,VG), (CW,VH), (CW,VI), (CW,VJ), (CW,VK), (CW,VL), (CW,VM), (CW,VN), (CW,VO), (CW,VP), (CW,VQ), (CW,VR), (CW,VS), (CW,VT), (CW,VU), (CW,VV), (CW,VW), (CW,VX), (CW,VY), (CW,VZ), (CW,WA), (CW,WB), (CW,WC), (CX,VA), (CX,VB), (CX,VC), (CX,VD), (CX,VE), (CX,VF), (CX,VG), (CX,VH), (CX,VI), (CX,VJ), (CX,VK), (CX,VL), (CX,VM), (CX,VN), (CX,VO), (CX,VP), (CX,VQ), (CX,VR), (CX,VS), (CX,VT), (CX,VU), (CX,VV), (CX,VW), (CX,VX), (CX,VY), (CX,VZ), (CX,WA), (CX,WB), (CX,WC), (CY,VA), (CY,VB), (CY,VC), (CY,VD), (CY,VE), (CY,VF), (CY,VG), (CY,VH), (CY,VI), (CY,VJ), (CY,VK), (CY,VL), (CY,VM), (CY,VN), (CY,VO), (CY,XP), (CY,VQ), (CY,VR), (CY,VS), (CY,VT), (CY,VU), (CY,VV), (CY,VW), (CY,VX), (CY,VY), (CY,VZ), (CY,WA), (CY,WB), (CY,WC), (CZ,VA), (CZ,VB), (CZ,VC), (CZ,VD), (CZ,VE), (CZ,VF), (CZ,VG), (CZ,VH), (CZ,VI), (CZ,VJ), (CZ,VK), (CZ,VL), (CZ,VM), (CZ,VN), (CZ,VO), (CZ,VP), (CZ,VQ), (CZ,VR), (CZ,VS), (CZ,VT), (CZ,VU), (CZ,VV), (CZ,VW), (CZ,VX), (CZ,VY), (CZ,VZ), (CZ,WA), (CZ,WB), (CZ,WC),
(DA,VA), (DA,VB), (DN,VC), (DN,VD), (DA,VE), (DA,VF), (DA,VG), (DA,VH), (DA,VI), (DA,VJ), (DA,VK), (DA,VL), (DA,VM), (DA,VN), (DA,VO), (DA,VP), (DA,VQ), (DA,VR), (DA,VS), (DA,VT), (DA,VU), (DA,VV), (DA,VW), (DA,VX), (DA,VY), (DA,VZ), (DA,WA), (DA,WB), (DA,WC), (DB,VA), (DB,VB), (DB,VC), (DB,VD), (DB,VE), (DB,VF), (DB,VG), (DB,VH), (DB,VI), (DB,VJ), (DB,VK), (DB,VL), (DB,VM), (DB,VN), (DB,VO), (DB,VP), (DB,VQ), (DB,VR), (DB,VS), (DB,VT), (DB,VU), (DB,VV), (DB,VW), (DB,VX), (DB,VY), (DB,VZ), (DB,WA), (DB,WB), (DB,WC), (DC,VA), (DC,VA), (DC,VB), (DC,VB), (DC,VC), (DC,VD), (DC,VE), (DC,VF), (DC,VG), (DC,VH), (DC,VI), (DC,VJ), (DC,VK), (DC,VL), (DC,VM), (DC,VN), (DC,VO), (DC,VP), (DC,VQ), (DC,VR), (DC,VS), (DC,VT), (DC,VU), (DC,VV), (DC,VW), (DC,VX), (DC,VY), (DC,VZ), (DC,WA), (DC,WB), (DC,WC), (DD,VC), (DD,VD), (DD,VE), (DD,VF), (DD,VG), (DD,VH), (DD,VI), (DD,VJ), (DD,VK), (DD,VL), (DD,VM), (DD,VN), (DD,VO), (DD,VP), (DD,VQ), (DD,VR), (DD,VS), (DD,VT), (DD,VU), (DD,VV), (DD,VW), (DD,VX), (DD,VY), (DD,VZ), (DD,WA), (DD,WB), (DD,WC), (DE,VA), (DE,VB), (DE,VC), (DE,VD), (DE,VE), (DE,VF), (DE,VG), (DE,VH), (DE,VI), (DE,VJ), (DE,VK), (DE,VL), (DE,VM), (DE,VN), (DE,VO), (DE,VP), (DE,VQ), (DE,VR), (DE,VS), (DE,VT), (DE,VU), (DE,VV), (DE,VW), (DE,VX), (DE,VY), (DE,VZ), (DE,WA), (DE,WB), (DE,WC), (DF,VA), (DF,VB), (DF,VC), (DF,VD), (DF,VE), (DF,VF), (DF,VG), (DF,VH), (DF,VI), (DF,VJ), (DF,VK), (DF,VL), (DF,VM), (DF,VN), (DF,VO), (DF,VP), (DF,VQ), (DF,VR), (DF,VS), (DF,VT), (DF,VU), (DF,VV), (DF,VW), (DF,VX), (DF,VY), (DF,VZ), (DF,WA), (DF,WB), (DF,WC), (DG,VA), (DG,VB), (DG,VC), (DG,VD), (DG,VE), (DG,VF), (DG,VG), (DG,VH), (DG,VI), (DG,VJ), (DG,VK), (DG,VL), (DG,VM), (DG,VN), (DG,VO), (DG,VP), (DG,VQ), (DG,VR), (DG,VS), (DG,VT), (DG,VU), (DG,VV), (DG,VW), (DG,VX), (DG,VY), (DG,VZ), (DG,WA), (DG,WB), (DG,WC), (DH,VA), (DH,VB), (DH,VC), (DH,VD), (DH,VE), (DH,VF), (DH,VG), (DH,VH), (DH,VI), (DH,VJ), (DH,VK), (DH,VL), (DH,VM), (DH,VN), (DH,VO), (DH,VP), (DH,VQ), (DH,VR), (DH,VS), (DH,VT), (DH,VU), (DH,VV), (DH,VW), (DH,VX), (DH,VY), (DH,VZ), (DH,WA), (DH,WB), (DH,WC), (DI,VA), (DI,VB), (DI,VC), (DI,VE), (DI,VF), (DI,VG), (DI,VH), (DI,VJ), (DI,VK), (DI,VL), (DI,VM), (DI,VN), (DI,VO), (DI,VP), (DI,VQ), (DI,VR), (DI,VS), (DI,VT), (DI,VU), (DI,VV), (DI,VW), (DI,VX), (DI,VY), (DI,VZ), (DI,WA), (DI,WB), (DI,WC), (DJ,VA), (DJ,VB), (DJ,VC), (DJ,VD), (DJ,VE), (DJ,VF), (DJ,VG), (DJ,VH), (DJ,VI), (DJ,VJ), (DJ,VK), (DJ,VL), (DJ,VM), (DJ,VN), (DJ,VO), (DJ,VP), (DJ,VQ), (DJ,VR), (DJ,VS), (DJ,VT), (DJ,VU), (DJ,VV), (DJ,VW), (DJ,VX), (DJ,VY), (DJ,VZ), (DJ,WA), (DJ,WB), (DJ,WC), (DK,VA), (DK,VB), (DN,VC), (DN,VD), (DK,VE), (DK,VI), (DK,VG), (DK,VH), (DK,VI), (DK,VJ), (DK,VK), (DK,VL), (DK,VM), (DK,VN), (DK,VO), (DK,VP), (DK,VQ), (DK,VR), (DK,VS), (DK,VT), (DK,VU), (DK,VV), (DK,VW), (DK,VX), (DK,VY), (DK,VZ), (DK,WA), (DK,WB), (DK,WC), (DL,VA), (DL,VB), (DL,VC), (DL,VD), (DL,VE), (DL,VF), (DL,VG), (DL,VH), (DL,VI), (DL,VJ), (DL,VK), (DL,VL), (DL,VM), (DG,VN), (DL,VO), (DL,VP), (DL,VQ), (DL,VR), (DL,VS), (DL,VT), (DL,VU), (DL,VV), (DL,VW), (DL,VX), (DL,VY), (DL,VZ), (DL,WA), (DL,WB), (DL,WC), (DM,VA), (DM,VB), (DM,VC), (DM,VD), (DM,VE), (DM,VF), (DM,VG), (DM,VH), (DM,VI), (DM,VJ), (DM,VK), (DM,VL), (DM,VM), (DM,VN), (DM,VO), (DM,VP), (DM,VQ), (DM,VR), (DM,VS), (DM,VT), (DM,VU), (DM,VV), (DM,VW), (DM,VX), (DM,VY), (DM,VZ), (DM,WA), (DM,WB), (DM,WC), (DN,VA), (DN,VB), (DN,VC), (DN,VD), (DN,VE), (DN,VF), (DN,VG), (DN,VH), (DN,VI), (DN,VJ), (DN,VK), (DN,VL), (DN,VM), (DN,VN), (DN,VO), (DN,VP), (DN,VQ), (DN,VR), (DN,VS), (DN,VT), (DN,VU), (DN,VV), (DN,VW), (DN,VX), (DN,VY), (DN,VZ), (DN,WA), (DN,WB), (DN,WC), (DO,VA), (DO,VB), (DO,VC), (DO,VD), (DO,VE), (DO,VF), (DO,VG), (DO,VH), (DO,VI), (DO,VJ), (DO,VK), (DO,VL), (DO,VM), (DO,VN), (DO,VO), (DO,VP), (DO,VQ), (DO,VR), (DO,VS), (DO,VT), (DO,VU), (DO,VV), (DO,VW), (DO,VX), (DO,VY), (DO,VZ), (DO,WA), (DO,WB), (DO,WC), (DP,VA), (DP,VB), (DP,VC), (DP,VD), (DP,VE), (DP,VF), (DP,VG), (DP,VH), (DP,VI), (DP,VJ), (DP,VK), (DP,VL), (DP,VM), (DP,VN), (DP,VO), (DP,VP), (DP,VQ), (DP,VR), (DP,VS), (DP,VT), (DP,VU), (DP,VV), (DP,VW), (DP,VX), (DP,VY), (DP,VZ), (DP,WA), (DP,WB), (DP,WC), (DQ,VA), (DQ,VB), (DQ,VC), (DQ,VD), (DQ,VE), (DQ,VF), (DQ,VG), (DQ,VH), (DQ,VI), (DQ,VJ), (DQ,VK), (DQ,VL), (DQ,VM), (DQ,VN), (DQ,VO), (DQ,VP), (DQ,VQ), (DQ,VR), (DQ,VS), (DQ,VT), (DQ,VU), (DQ,VV), (DQ,VW), (DQ,VX), (DQ,VY), (DQ,VZ), (DQ,WA), (DQ,WB), (DQ,WC), (DR,VA), (DR,VB), (DR,VC), (DR,VD), (DR,VE), (DR,VF), (DR,VG), (DR,VH), (DR,VI), (DR,VJ), (DR,VK), (DR,VL), (DR,VM), (DR,VN), (DR,VO), (DR,VP), (DR,VQ), (DR,VR), (DR,VS), (DR,VT), (DR,VU), (DR,VV), (DR,VW), (DR,VX), (DR,VY), (DR,VZ), (DR,WA), (DR,WB), (DR,WC), (DS,VA), (DS,VB), (DS,VC), (DS,VD), (DS,VE), (DS,VF), (DS,VG), (DS,VH), (DS,VI), (DS,VJ), (DS,VK), (DS,VL), (DS,VM), (DS,VN), (DS,VO), (DS,VP), (DS,VQ), (DS,VR), (DS,VS), (DS,VT), (DS,VU), (DS,VV), (DS,VW), (DS,VX), (DS,VY), (DS,VZ), (DS,WA), (DS,WB), (DS,WC), (DT,VA), (DT,VB), (DT,VC), (DT,VD), (DT,VE), (DT,VF), (DT,VG), (DT,VH), (DT,VI), (DT,VJ), (DT,VK), (DT,VL), (DT,VM), (DT,VN), (DT,VO), (DT,VP), (DT,VQ), (DS,VR), (DT,VS), (DT,VT), (DT,VU), (DT,VV), (DT,VW), (DT,VX), (DT,VY), (DT,VZ), (DT,WA), (DT,WB), (DT,WC), (DO,VA), (DO,VB), (DO,VC), (DO,VD), (DU,VE), (DO,VF), (DU,VG), (DO,VH), (DO,VI), (DO,VJ), (DO,VK), (DO,VL), (DO,VM), (DO,VN), (DU,VO), (DU,VP), (DO,VQ), (DN,VR), (DN,VS), (DN,VT), (DU,VU), (DU,VV), (DN,VW), (DU,VX), (DU,VY), (DN,VZ), (DU,WA), (DO,WB), (DN,WC), (DV,VA), (DV,VB), (DV,VC), (DV,VD), (DV,VE), (DV,VF), (DV,VG), (DV,VH), (DV,VI), (DV,VJ), (DV,VK), (DV,VL), (DV,VM), (DV,VN), (DV,VO), (DV,VP), (DV,VQ), (DS,VR), (DT,VS), (DV,VT), (DV,VU), (DV,VV), (DV,VW), (DV,VX), (DR,VY), (DV,VZ), (DV,WA), (DR,WB), (DR,WC), (DW,VA), (DW,VB), (DW,VC), (DW,VD), (DW,VE), (DW,VF), (DW,VG), (DW,VH), (DW,VI), (DW,VJ), (DW,VK), (DW,VL), (DW,VM), (DW,VN), (DW,VO), (DW,VP), (DW,VQ), (DW,VR), (DW,VS), (DW,VT), (DW,VU), (DW,VV), (DW,VW), (DW,VX), (DW,VY), (DW,VZ), (DW,WA), (DW,WB), (DW,WC), (DX,VA), (DX,VB), (DX,VC), (DX,VD), (DX,VE), (DX,VF), (DX,VG), (DX,VH), (DX,VI), (DX,VJ), (DX,VK), (DX,VL), (DX,VM), (DX,VN), (DX,VO), (DX,VP), (DX,VQ), (DX,VR), (DX,VS), (DX,VT), (DX,VU), (DX,VV), (DX,VW), (DX,VX), (DX,VY), (DX,VZ), (DX,WA), (DX,WB), (DX,WC), (DY,VA), (DY,VB), (DY,VC), (DY,VD), (DY,VE), (DY,VF), (DY,VG), (DY,VH), (DY,VI), (DY,VJ), (DY,VK), (DY,VL), (DS,VM), (DY,VN), (DY,VO), (DY,VP), (DY,VQ), (DY,VR), (DY,VS), (DY,VT), (DY,VU), (DY,VV), (DY,VW), (DY,VX), (DY,VY), (DY,VZ), (DY,WA), (DY,WB), (DY,WC), (DZ,VA), (DZ,VB), (DZ,VC), (DZ,VD), (DZ,VE), (DZ,VF), (DZ,VG), (DZ,VH), (DZ,VI), (DZ,VJ), (DZ,VK), (DZ,VL), (DZ,VM), (DZ,VN), (DZ,VO), (DZ,VP), (DZ,VQ), (DZ,VR), (DZ,VS), (DZ,VT), (DZ,VU), (DZ,VV), (DZ,VW), (DZ,VX), (DZ,VY), (DZ,VZ), (DZ,WA), (DZ,WB), (DZ,WC),
(EA,VA), (EA,VB), (EA,VC), (EA,VD), (EA,VE), (EA,VF), (EA,VG), (EA,VH), (EA,VI), (EA,VJ), (EA,VK), (EA,VL), (EA,VM), (EA,VN), (EA,VO), (EA,VP), (EA,VQ), (EA,VR), (EA,VS), (EA,VT), (EA,VU), (EA,VV), (EA,VW), (EA,VX), (EA,VY), (EA,VZ), (EA,WA), (EA,WB), (EA,WC), (EB,VA), (EB,VB), (EB,VC), (EB,VD), (EB,VE), (EB,VF), (EB,VG), (EB,VH), (EB,VI), (EB,VJ), (EB,VK), (EB,VL), (EB,VM), (EB,VN), (EB,VO), (EB,VP), (EB,VQ), (EB,VR), (EB,VS), (EB,VT), (EB,VU), (EB,VV), (EB,VW), (EB,VX), (EB,VY), (EB,VZ), (EB,WA), (EB,WB), (EB,WC), (EC,VA), (EC,VA), (EC,VB), (EC,VB), (EC,VC), (EC,VD), (EC,VE), (EC,VF), (EC,VG), (EC,VH), (EA,VI), (EC,VJ), (EC,VK), (EC,VL), (EC,VM), (EC,VN), (EC,VO), (EC,VP), (EC,VQ), (EC,VR), (EC,VS), (EC,VT), (EC,VU), (EC,VV), (EC,VW), (EC,VX), (EC,VY), (EC,VZ), (EC,WA), (EC,WB), (EC,WC), (ED,VC), (ED,VD), (ED,VE), (ED,VF), (ED,VG), (ED,VH), (ED,VI), (ED,VJ), (ED,VK), (ED,VL), (ED,VM), (EA,VN), (ED,VO), (ED,VP), (EA,VQ), (ED,VR), (ED,VS), (ED,VT), (ED,VU), (ED,VV), (ED,VW), (ED,VX), (ED,VY), (ED,VZ), (ED,WA), (ED,WB), (ED,WC), (EE,VA), (EE,VB), (EE,VC), (EE,VD), (EE,VE), (EE,VF), (EE,VG), (EE,VH), (EE,VI), (EE,VJ), (EE,VK), (EE,VL), (EE,VM), (EE,VN), (EE,VO), (EE,VP), (EE,VQ), (EE,VR), (EE,VS), (EE,VT), (EE,VU), (EE,VV), (EE,VW), (EE,VX), (EE,VY), (EE,VZ), (EE,WA), (EE,WB), (EE,WC), (EF,VA), (EF,VB), (EF,VC), (EF,VD), (EF,VE), (EF,VF), (EF,VG), (EF,VH), (EF,VI), (EF,VJ), (EF,VK), (EF,VL), (EF,VM), (EF,VN), (EF,VO), (EF,VP), (EF,VQ), (EF,VR), (EF,VS), (EF,VT), (EF,VU), (EF,VV), (EF,VW), (EF,VX), (EF,VY), (EF,VZ), (EF,WA), (EF,WB), (EF,WC), (EB,VA), (EB,VB), (EB,VC), (EB,VD), (EB,VE), (EB,VF), (EA,VG), (EA,VH), (EA,VI), (EG,VJ), (EA,VK), (EA,VL), (EA,VM), (EG,VN), (EG,VO), (EA,VP), (EG,VQ), (EA,VR), (EA,VS), (EA,VT), (EG,VU), (EG,VV), (EA,VW), (EG,VX), (EA,VY), (EA,VZ), (EA,WA), (EB,WB), (EA,WC), (EH,VA), (EH,VB), (EH,VC), (EH,VD), (EH,VE), (EH,VF), (EH,VG), (EH,VH), (EH,VI), (EH,VJ), (EH,VK), (EH,VL), (EH,VM), (EH,VN), (EH,VO), (EH,VP), (EH,VQ), (EH,VR), (EH,VS), (EH,VT), (EH,VU), (EH,VV), (EH,VW), (EH,VX), (EH,VY), (EH,VZ), (EH,WA), (EH,WB), (EH,WC), (EI,VA), (EI,VB), (EI,VC), (EI,VD), (EI,VE), (EI,VF), (EI,VG), (EI,VH), (EI,VI), (EI,VJ), (EI,VK), (EI,VL), (EI,VM), (EI,VN), (EI,VO), (EI,VP), (EI,VQ), (EI,VR), (EI,VS), (EI,VT), (EI,VU), (EI,VV), (EI,VW), (EI,VX), (EI,VY), (EI,VZ), (EI,WA), (EI,WB), (EI,WC), (EJ,VA), (EJ,VB), (EJ,VC), (EJ,VD), (EJ,VE), (EJ,VF), (EJ,VG), (EJ,VH), (EJ,VI), (EJ,VJ), (EJ,VK), (EJ,VL), (EJ,VM), (EJ,VN), (EJ,VO), (EJ,VP), (EJ,VQ), (EJ,VR), (EJ,VS), (EJ,VT), (EJ,VU), (EJ,VV), (EJ,VW), (EJ,VX), (EJ,VY), (EJ,VZ), (EJ,WA), (EJ,WB), (EJ,WC), (EB,VA), (EB,VB), (EB,VC), (EB,VD), (EB,VE), (EB,VF), (EA,VG), (EA,VH), (EA,VI), (EK,VJ), (EA,VK), (EA,VL), (EA,VM), (EA,VN), (EK,VO), (EA,VP), (EK,VQ), (EA,VR), (EA,VS), (EA,VT), (EK,VU), (EK,VV), (EA,VW), (EK,VX), (EA,VY), (EA,VZ), (EA,WA), (EB,WB), (EA,WC), (EL,VA), (EL,VB), (EL,VC), (EF,VD), (EL,VE), (EL,VF), (EL,VG), (EL,VH), (EL,VI), (EL,VJ), (EL,VK), (EL,VL), (EL,VM), (EL,VN), (EL,VO), (EL,VP), (EL,VQ), (EL,VR), (EL,VS), (EL,VT), (EL,VU), (EL,VV), (EL,VW), (EL,VX), (EL,VY), (EL,VZ), (EL,WA), (EL,WB), (EL,WC), (EM,VA), (EM,VB), (EM,VC), (EM,VD), (EM,VE), (EM,VF), (EM,VG), (EM,VH), (EM,VI), (EM,VJ), (EM,VK), (EM,VL), (EM,VM), (EM,VN), (EM,VO), (EM,VP), (EM,VQ), (EM,VR), (EM,VS), (EM,VT), (EM,VU), (EM,VV), (EM,VW), (EM,VX), (EM,VY), (EM,VZ), (EM,WA), (EM,WB), (EM,WC), (EN,VA), (EN,VB), (EN,VC), (EN,VD), (EN,VE), (EN,VF), (EN,VG), (EN,VH), (EN,VI), (EN,VJ), (EN,VK), (EN,VL), (EN,VM), (EN,VN), (EN,VO), (EN,VP), (EN,VQ), (EN,VR), (EN,VS), (EN,VT), (EN,VU), (EN,VV), (EN,VW), (EN,VX), (EN,VY), (EN,VZ), (EN,WA), (EN,WB), (EN,WC), (EO,VA), (EO,VB), (EO,VC), (EO,VD), (EO,VE), (EO,VF), (EO,VG), (EO,VH), (EO,VI), (EO,VJ), (EO,VK), (EO,VL), (EO,VM), (EO,VN), (EO,VO), (EO,VP), (EO,VQ), (EO,VR), (EO,VS), (EO,VT), (EO,VU), (EO,VV), (EO,VW), (EO,VX), (EO,VY), (EO,VZ), (EO,WA), (EO,WB), (EO,WC), (EP,VA), (EP,VB), (EP,VC), (EP,VD), (EP,VE), (EP,VF), (EP,VG), (EP,VH), (EP,VI), (EP,VJ), (EP,VK), (EP,VL), (EP,VM), (EP,VN), (EP,VO), (EP,VP), (EP,VQ), (EP,VR), (EP,VS), (EP,VT), (EP,VU), (EP,VV), (EP,VW), (EP,VX), (EP,VY), (EP,VZ), (EP,WA), (EP,WB), (EP,WC), (EQ,VA), (EQ,VB), (EQ,VC), (EQ,VD), (EQ,VE), (EQ,VF), (EQ,VG), (EQ,VH), (EQ,VI), (EQ,VJ), (EQ,VK), (EQ,VL), (EQ,VM), (EQ,VN), (EQ,VO), (EQ,VP), (EQ,VQ), (EQ,VR), (EQ,VS), (EQ,VT), (EQ,VU), (EQ,VV), (EQ,VW), (EQ,VX), (EQ,VY), (EQ,VZ), (EQ,WA), (EQ,WB), (EQ,WC), (ER,VA), (ER,VB), (ER,VC), (ER,VD), (ER,VE), (ER,VF), (ER,VG), (ER,VH), (ER,VI), (ER,VJ), (ER,VK), (ER,VL), (ER,VM), (ER,VN), (ER,VO), (ER,VP), (ER,VQ), (ER,VR), (ER,VS), (ER,VT), (ER,VU), (ER,VV), (ER,VW), (ER,VX), (ER,VY), (ER,VZ), (ER,WA), (ER,WB), (ER,WC), (ES,VA), (ES,VB), (ES,VC), (ES,VD), (ES,VE), (ES,VF), (ES,VG), (ES,VH), (ES,VI), (ES,VJ), (ES,VK), (ES,VL), (ES,VM), (ES,VN), (ES,VO), (ES,VP), (ES,VQ), (ES,VR), (ES,VS), (ES,VT), (ES,VU), (ES,VV), (ES,VW), (ES,VX), (ES,VY), (ES,VZ), (ES,WA), (ES,WB), (ES,WC), (ET,VA), (ET,VB), (ET,VC), (ET,VD), (ET,VE), (ET,VF), (ET,VG), (ET,VH), (ET,VI), (ET,VJ), (ET,VK), (ET,VL), (ET,VM), (ET,VN), (ET,VO), (ET,VP), (ET,VQ), (ET,VR), (ET,VS), (ET,VT), (ET,VU), (ET,VV), (ET,VW), (ET,VX), (ET,VY), (ET,VZ), (ET,WA), (ET,WB), (ET,WC), (EU,VA), (EU,VB), (EU,VC), (EU,VD), (EU,VE), (EU,VF), (EU,VG), (EU,VH), (EU,VI), (EU,VJ), (EU,VK), (EU,VL), (EU,VM), (EU,VN), (EU,VO), (EU,VP), (EU,VQ), (EU,VR), (EU,VS), (EU,VT), (EU,VU), (EU,VV), (EU,VW), (EU,VX), (EU,VY), (EU,VZ), (EU,WA), (EU,WB), (EU,WC), (EV,VA), (EV,VB), (EV,VC), (EV,VD), (EV,VE), (EV,VF), (EV,VG), (EV,VH), (ET,VI), (EV,VJ), (EV,VK), (EV,VL), (EV,VM), (EV,VN), (EV,VO), (EVXP), (ET,VQ), (EV,VR), (EV,VS), (EV,VT), (EV,VU), (EV,VV), (EV,VW), (EV,VX), (ET,VY), (EV,VZ), (EV,WA), (EV,WB), (EV,WC), (EW,VA), (EW,VB), (EW,VC), (EW,VD), (EW,VE), (EW,VF), (EW,VG), (EW,VH), (EW,VI), (EW,VJ), (EW,VK), (EW,VL), (EW,VM), (EW,VN), (EW,VO), (EW,VP), (EW,VQ), (EW,VR), (EW,VS), (EW,VT), (EW,VU), (EW,VV), (EW,VW), (EW,VX), (EW,VY), (EW,VZ), (EW,WA), (EW,WB), (EW,WC), (EX,VA), (EX,VB), (EX,VC), (EX,VD), (EX,VE), (EX,VF), (EX,VG), (EX,VH), (EX,VI), (EX,VJ), (EX,VK), (EX,VL), (EX,VM), (EX,VN), (EX,VO), (EX,VP), (EX,VQ), (EX,VR), (EX,VS), (EX,VT), (EX,VU), (EX,VV), (EX,VW), (EX,VX), (EX,VY), (EX,VZ), (EX,WA), (EX,WB), (EX,WC), (EY,VA), (EY,VB), (EY,VC), (EY,VD), (EY,VE), (EY,VF), (EY,VG), (EY,VH), (EY,VI), (EY,VJ), (EY,VK), (EY,VO, (EY,VM), (EY,VN), (EY,VO), (EY,VP), (EY,VQ), (EY,VR), (EY,VS), (ET,VT), (EY,VU), (EY,VV), (EY,VW), (EY,VX), (EY,VY), (EY,VZ), (EY,WA), (EY,WB), (EY,WC), (EZ,VA), (EZ,VB), (EZ,VC), (EZ,VD), (EZ,VE), (EZ,VF), (EZ,VG), (EZ,VH), (EZ,VI), (EZ,VJ), (EZ,VK), (EZ,VL), (EZ,VM), (EZ,VN), (EZ,VO), (EZ,VP), (EZ,VQ), (EZ,VR), (EZ,VS), (EZ,VT), (EZ,VU), (EZ,VV), (EZ,VW), (EZ,VX), (EZ,VY), (EZ,VZ), (EZ,WA), (EZ,WB), (EZ,WC),
(FA,VA), (FA,VB), (FA,VC), (FA,VD), (FA,VE), (FA,VF), (FA,VG), (FA,VH), (FA,VI), (FA,VJ), (FA,VK), (FA,VL), (FA,VM), (FA,VN), (FA,VO), (FA,VP), (FA,VQ), (FA,VR), (FA,VS), (FA,VT), (FA,VU), (FA,VV), (FA,VW), (FA,VX), (FA,VY), (FA,VZ), (FA,WA), (FA,WB), (FA,WC), (FB,VA), (FB,VB), (FB,VC), (FB,VD), (FB,VE), (FB,VF), (FB,VG), (FB,VH), (FB,VI), (FB,VJ), (FB,VK), (FB,VL), (FB,VM), (FB,VN), (FB,VO), (FB,VP), (FB,VQ), (FB,VR), (FB,VS), (FB,VT), (FB,VU), (FB,VV), (FB,VW), (FB,VX), (FB,VY), (FB,VZ), (FB,WA), (FB,WB), (FB,WC), (FC,VA), (FC,VA), (FC,VB), (FC,VB), (FC,VC), (FC,VD), (FC,VE), (FC,VF), (FC,VG), (FC,VH), (FC,VI), (FC,VJ), (FC,VK), (FC,VL), (FC,VM), (FC,VN), (FC,VO), (FC,VP), (FC,VQ), (FC,VR), (FC,VS), (FC,VT), (FC,VU), (FC,VV), (FC,VW), (FA,VX), (FC,VY), (FC,VZ), (FC,WA), (FC,WB), (FC,WC), (FD,VC), (FD,VD), (FD,VE), (FD,VF), (FD,VG), (FD,VH), (FD,VI), (FD,VJ), (FD,VK), (FD,VL), (FD,VM), (FD,VN), (FD,VO), (FD,VP), (FD,VQ), (FD,VR), (FD,VS), (FD,VT), (FD,VU), (FD,VV), (FD,VW), (FD,VX), (FD,VY), (FD,VZ), (FD,WA), (FD,WB), (FD,WC), (FE,VA), (FE,VB), (FE,VC), (FE,VD), (FE,VE), (FE,VF), (FE,VG), (FE,VH), (FE,VI), (FE,VJ), (FE,VK), (FE,VL), (FE,VM), (FE,VN), (FE,VO), (FE,VP), (FE,VQ), (FE,VR), (FE,VS), (FE,VT), (FE,VU), (FE,VV), (FE,VW), (FE,VX), (FE,VY), (FE,VZ), (FE,WA), (FE,WB), (FE,WC), (FF,VA), (FF,VB), (FF,VC), (FF,VD), (FF,VE), (FF,VF), (FF,VG), (FF,VH), (FF,VI), (FF,VJ), (FF,VK), (FF,VL), (FF,VM), (FF,VN), (FF,VO), (FF,VP), (FF,VQ), (FF,VR), (FF,VS), (FF,VT), (FF,VU), (FF,VV), (FF,VW), (FF,VX), (FF,VY), (FF,VZ), (FF,WA), (FF,WB), (FF,WC), (FG,VA), (FG,VB), (FG,VC), (FG,VD), (FG,VE), (FG,VF), (FG,VG), (FG,VH), (FG,VI), (FG,VJ), (FG,VK), (FG,VL), (FG,VM), (FG,VN), (FG,VO), (FG,VP), (FD,VQ), (FG,VR), (FG,VS), (FG,VT), (FG,VU), (FG,VV), (FG,VW), (FG,VX), (FG,VY), (FG,VZ), (FG,WA), (FG,WB), (FG,WC), (FH,VA), (FH,VB), (FH,VC), (FH,VD), (FH,VE), (FH,VF), (FH,VG), (FH,VH), (FH,VI), (FH,VJ), (FH,VK), (FH,VL), (FH,VM), (FH,VN), (FH,VO), (FH,VP), (FH,VQ), (FH,VR), (FH,VS), (FH,VT), (FH,VU), (FH,VV), (FH,VW), (FH,VX), (FH,VY), (FH,VZ), (FH,WA), (FH,WB), (FH,WC), (FI,VA), (FI,VB), (FI,VC), (FI,VD), (FI,VE), (FI,VF), (FI,VG), (FI,VH), (FI,VJ), (FI,VK), (FI,VL), (FI,VM), (FI,VN), (FI,VO), (FI,VP), (FI,VQ), (FI,VR), (FI,VS), (FI,VT), (FI,VU), (FI,VV), (FI,VW), (FI,VX), (FI,VY), (FI,VZ), (FI,WA), (FI,WB), (FI WC), (FJ,VA), (FJ,VB), (FJ,VC), (FJ,VD), (FJ,VE), (FJ,VF), (FJ,VG), (FJ,VH), (FJ,VI), (FJ,VJ), (FJ,VK), (FJ,VL), (FJ,VM), (FJ,VN), (FJ,VO), (FJ,VP), (FJ,VQ), (FJ,VR), (FJ,VS), (FJ,VT), (FJ,VU), (FJ,VV), (FJ,VW), (FJ,VX), (FJ,VY), (FJ,VZ), (FJ,WA), (FJ,WB), (FJ,WC), (FK,VA), (FK,VB), (FK,VC), (FK,VD), (FK,VE), (FK,VF), (FK,VG), (FK,VH), (FK,VI), (FK,VJ), (FK,VK), (FK,VL), (FK,VM), (FK,VN), (FK,VO), (FK,VP), (FK,VQ), (FK,VR), (FK,VS), (FK,VT), (FK,VU), (FK,VV), (FK,VW), (FK,VX), (FK,VY), (FK,VZ), (FK,WA), (FK,WB), (FK,WC), (FL,VA), (FL,VB), (FL,VC), (FL,VD), (FL,VE), (FL,VF), (FL,VG), (FL,VH), (FL,VI), (FL,VJ), (FL,VK), (FL,VL), (FL,VM), (FL,VN), (FL,VO), (FL,VP), (FL,VQ), (FL,VR), (FL,VS), (FL,VT), (FL,VU), (FL,VV), (FL,VW), (FL,VX), (FL,VY), (FL,VZ), (FL,WA), (FL,WB), (FL,WC), (FM,VA), (FM,VB), (FM,VC), (FM,VD), (FM,VE), (FM,VF), (FM,VG), (FM,VH), (FM,VI), (FM,VJ), (FM,VK), (FM,VL), (FM,VM), (FM,VN), (FM,VO), (FM,VP), (FM,VQ), (FM,VR), (FM,VS), (FM,VT), (FM,VU), (FM,VV), (FM,VW), (FM,VX), (FM,VY), (FM,VZ), (FM,WA), (FM,WB), (FM,WC), (FN,VA), (FN,VB), (FN,VC), (FN,VD), (FN,VE), (FN,VF), (FN,VG), (FN,VH), (FN,VI), (FN,VJ), (FN,VK), (FN,VL), (FN,VM), (FN,VN), (FN,VO), (FN,VP), (FD,VQ), (FN,VR), (FN,VS), (FN,VT), (FN,VU), (FN,VV), (FN,VW), (FN,VX), (FN,VY), (FN,VZ), (FN,WA), (FN,WB), (FN,WC), (FO,VA), (FO,VB), (FO,VC), (FO,VD), (FO,VE), (FO,VF), (FO,VG), (FO,VH), (FO,VI), (FO,VJ), (FO,VK), (FO,VL), (FO,VM), (FO,VN), (FO,VO), (FO,VP), (FO,VQ), (FO,VR), (FO,VS), (FO,VT), (FO,VU), (FO,VV), (FO,VW), (FO,VX), (FO,VY), (FO,VZ), (FO,WA), (FO,WB), (FO,WC), (FP,VA), (FP,VB), (FP,VC), (FP,VD), (FP,VE), (FP,VF), (FP,VG), (FP,VH), (FP,VI), (FP,VJ), (FP,VK), (FP,VL), (FP,VM), (FP,VN), (FP,VO), (FP,VP), (FP,VQ), (FP,VR), (FP,VS), (FP,VT), (FP,VU), (FP,VV), (FP,VW), (FP,VX), (FP,VY), (FP,VZ), (FP,WA), (FP,WB), (FP,WC), (FQ,VA), (FQ,VB), (FQ,VC), (FQ,VD), (FQ,VE), (FQ,VF), (FQ,VG), (FQ,VH), (FQ,VI), (FQ,VJ), (FQ,VK), (FQ,VL), (FQ,VM), (FQ,VN), (FQ,VO), (FQ,VP), (FQ,VQ), (FQ,VR), (FQ,VS), (FQ,VT), (FQ,VU), (FQ,VV), (FQ,VW), (FQ,VX), (FQ,VY), (FQ,VZ), (FQ,WA), (FQ,WB), (FQ,WC), (FR,VA), (FR,VB), (FR,VC), (FR,VD), (FR,VE), (FR,VF), (FR,VG), (FR,VH), (FR,VI), (FR,VJ), (FR,VK), (FR,VL), (FR,VM), (FR,VN), (FR,VO), (FR,VP), (FR,VQ), (FR,VR), (FR,VS), (FR,VT), (FR,VU), (FR,VV), (FR,VW), (FR,VX), (FR,VY), (FR,VZ), (FR,WA), (FR,WB), (FR,WC), (FS,VA), (FS,VB), (FS,VC), (FS,VD), (FS,VE), (FS,VF), (FS,VG), (FS,VH), (FS,VI), (FS,VJ), (FS,VK), (FS,VL), (FS,VM), (FS,VN), (FS,VO), (FS,VP), (FS,VQ), (FS,VR), (FS,VS), (FS,VT), (FS,VU), (FS,VV), (FS,VW), (FS,VX), (FS,VY), (FS,VZ), (FS,WA), (FS,WB), (FS,WC), (FT,VA), (FT,VB), (FT,VC), (FP,VD), (FT,VE), (FT,VF), (FT,VG), (FT,VH), (FT,VI), (FT,VJ), (FT,VK), (FT,VL), (FT,VM), (FT,VN), (FT,VO), (FT,VP), (FT,VQ), (FT,VR), (FT,VS), (FT,VT), (FT,VU), (FT,VV), (FT,VW), (FT,VX), (FT,VY), (FT,VZ), (FT,WA), (FT,WB), (FT,WC), (FU,VA), (FU,VB), (FU,VC), (FU,VD), (FU,VE), (FU,VF), (FU,VG), (FU,VH), (FU,VI), (FU,VJ), (FU,VK), (FU,VL), (FU,VM), (FU,VN), (FU,VO), (FU,VP), (FU,VQ), (FU,VR), (FU,VS), (FU,VT), (FU,VU), (FU,VV), (FU,VW), (FU,VX), (FU,VY), (FU,VZ), (FU,WA), (FU,WB), (FU,WC), (FV,VA), (FV,VB), (FV,VC), (FV,VD), (FV,VE), (FV,VF), (FV,VG), (FV,VH), (FV,VI), (FV,VJ), (FV,VK), (FV,VL), (FV,VM), (FV,VN), (FV,VO), (FV,VP), (FV,VQ), (FV,VR), (FV,VS), (FV,VT), (FV,VU), (FV,VV), (FV,VW), (FV,VX), (FV,VY), (FV,VZ), (FV,WA), (FV,WB), (FV,WC), (FW,VA), (FW,VB), (FW,VC), (FW,VD), (FW,VE), (FW,VF), (FW,VG), (FW,VH), (FW,VI), (FW,VJ), (FW,VK), (FW,VL), (FW,VM), (FW,VN), (FW,VO), (FW,VP), (FW,VQ), (FW,VR), (FW,VS), (FW,VT), (FW,VU), (FW,VV), (FW,VW), (FW,VX), (FW,VY), (FW,VZ), (FW,WA), (FW,WB), (FW,WC), (FX,VA), (FX,VB), (FX,VC), (FX,VD), (FX,VE), (FX,VF), (FX,VG), (FX,VH), (FX,VI), (FX,VJ), (FX,VK), (FX,VL), (FX,VM), (FX,VN), (FX,VO), (FX,VP), (FX,VQ), (FX,VR), (FX,VS), (FX,VT), (FX,VU), (FX,VV), (FX,VW), (FX,VX), (FX,VY), (FX,VZ), (FX,WA), (FX,WB), (FX,WC), (FY,VA), (FY,VB), (FY,VC), (FY,VD), (FY,VE), (FY,VF), (FY,VG), (FY,VH), (FY,VI), (FY,VJ), (FY,VK), (FY,VL), (FY,VM), (FY,VN), (FY,VO), (FY,VP), (FY,VQ), (FY,VR), (FY,VS), (FY,VT), (FY,VU), (FY,VV), (FY,VW), (FY,VX), (FY,VY), (FY,VZ), (FY,WA), (FY,WB), (FY,WC), (FZ,VA), (FZ,VB), (FZ,VC), (FZ,VD), (FZ,VE), (FZ,VF), (FZ,VG), (FZ,VH), (FZ,VI), (FZ,VJ), (FZ,VK), (FZ,VL), (FZ,VM), (FZ,VN), (FZ,VO), (FZ,VP), (FZ,VQ), (FZ,VR), (FZ,VS), (FZ,VT), (FZ,VU), (FZ,VV), (FZ,VW), (FZ,VX), (FZ,VY), (FZ,VZ), (FZ,WA), (FZ,WB), (FZ,WC), (GA,VA), (GA,VB), (GA,VC), (GA,VD), (GA,VE), (GA,VF), (GA,VG), (GA,VH), (GA,VI), (GA,VJ), (GA,VK), (GA,VL), (GA,VM), (GA,VN), (GA,VO), (GA,VP), (GA,VQ), (GA,VR), (GA,VS), (GA,VT), (GA,VU), (GA,VV), (GA,VW), (GA,VX), (GA,VY), (GA,VZ), (GA,WA), (GA,WB), (GA,WC), (GB,VA), (GB,VB), (GB,VC), (GB,VD), (GB,VE), (GB,VF), (GB,VG), (GB,VH), (GB,VI), (GB,VJ), (GB,VK), (GB,VL), (GB,VM), (GB,VN), (GB,VO), (GB,VP), (GB,VQ), (GB,VR), (GB,VS), (GB,VT), (GB,VU), (GB,VV), (GB,VW), (GB,VX), (GB,VY), (GB,VZ), (GB,WA), (GB,WB), (GB,WC), (GC,VA), (GC,VA), (GC,VB), (GC,VB), (GC,VC), (GB,VD), (GC,VE), (GC,VF), (GC,VG), (GC,VH), (GC,VI), (GC,VJ), (GC,VK), (GC,VL), (GC,VM), (GC,VN), (GC,VO), (GC,VP), (GC,VQ), (GC,VR), (GC,VS), (GC,VT), (GC,VU), (GC,VV), (GC,VW), (GC,VX), (GC,VY), (GC,VZ), (GC,WA), (GC,WB), (GC,WC), (GD,VC), (GD,VD), (GD,VE), (GD,VF), (GD,VG), (GD,VH), (GD,VI), (GD,VJ), (GD,VK), (GD,VL), (GD,VM), (GD,VN), (GD,VO), (GD,VP), (GD,VQ), (GD,VR), (GD,VS), (GD,VT), (GD,VU), (GD,VV), (GD,VW), (GD,VX), (GD,VY), (GD,VZ), (GD,WA), (GD,WB), (GD,WC), (GE,VA), (GE,VB), (GE,VC), (GE,VD), (GE,VE), (GE,VF), (GE,VG), (GE,VH), (GE,VI), (GE,VJ), (GE,VK), (GE,VL), (GE,VM), (GE,VN), (GE,VO), (GE,VP), (GE,VQ), (GE,VR), (GE,VS), (GE,VT), (GE,VU), (GE,VV), (GE,VW), (GE,VX), (GE,VY), (GE,VZ), (GE,WA), (GE,WB), (GE,WC), (GF,VA), (GF,VB), (GF,VC), (GF,VD), (GF,VE), (GF,VF), (GF,VG), (GF,VH), (GF,VI), (GF,VJ), (GF,VK), (GF,VL), (GF,VM), (GF,VN), (GF,VO), (GF,VP), (GF,VQ), (GF,VR), (GF,VS), (GF,VT), (GF,VU), (GF,VV), (GF,VW), (GF,VX), (GA,VY), (GF,VZ), (GF,WA), (GF,WB), (GF,WC), (GG,VA), (GG,VB), (GG,VC), (GG,VD), (GG,VE), (GG,VF), (GG,VG), (GG,VH), (GG,VI), (GG,VJ), (GG,VK), (GG,VL), (GG,VM), (GN,VN), (GG,VO), (GG,VP), (GG,VQ), (GG,VR), (GG,VS), (GG,VT), (GG,VU), (GG,VV), (GG,VW), (GG,VX), (GG,VY), (GG,VZ), (GG,WA), (GG,WB), (GG,WC), (GH,VA), (GH,VB), (GH,VC), (GH,VD), (GH,VE), (GH,VF), (GH,VG), (GH,VH), (GH,VI), (GH,VJ), (GH,VK), (GH,VL), (GH,VM), (GH,VN), (GH,VO), (GH,VP), (GH,VQ), (GH,VR), (GH,VS), (GH,VT), (GH,VU), (GH,VV), (GH,VW), (GH,VX), (GH,VY), (GH,VZ), (GH,WA), (GH,WB), (GH,WC), (GI,VA), (GI,VB), (GI,VC), (GI,VD), (GI,VE), (GI,VF), (GI,VG), (GI,VH), (GI,VI), (GI,VJ), (GI,VK), (GI,VL), (GI,VM), (GI,VN), (GI,VO), (GI,VP), (GI,VQ), (GI,VR), (GI,VS), (GI,VT), (GI,VU), (GI,VV), (GI,VW), (GI,VX), (GI,VY), (GI,VZ), (GI,WA), (GI,WB), (GI,WC), (GJ,VA), (GJ,VB), (GJ,VC), (GJ,VD), (GJ,VE), (GJ,VF), (GJ,VG), (GJ,VH), (GJ,VI), (GJ,VJ), (GJ,VK), (GJ,VL), (GJ,VM), (GJ,VN), (GJ,VO), (GJ,VP), (GJ,VQ), (GJ,VR), (GJ,VS), (GJ,VT), (GJ,VU), (GJ,VV), (GJ,VW), (GJ,VX), (GJ,VY), (GJ,VZ), (GJ,WA), (GJ,WB), (GJ,WC), (GK,VA), (GK,VB), (GK,VC), (GK,VD), (GK,VE), (GK,VF), (GK,VG), (GK,VH), (GK,VI), (GK,VJ), (GK,VK), (GK,VL), (GK,VM), (GK,VN), (GK,VO), (GK,VP), (GK,VQ), (GK,VR), (GK,VS), (GK,VT), (GK,VU), (GK,VV), (GK,VW), (GK,VX), (GK,VY), (GK,VZ), (GK,WA), (GK,WB), (GK,WC), (GL,VA), (GJ,VB), (GL,VC), (GL,VD), (GL,VE), (GL,VF), (GL,VG), (GL,VH), (GL,VI), (GL,VJ), (GL,VK), (GL,VL), (GL,VM), (GL,VN), (GL,VO), (GL,VP), (GL,VQ), (GL,VR), (GL,VS), (GL,VT), (GL,VU), (GL,VV), (GL,VW), (GL,VX), (GL,VY), (GL,VZ), (GL,WA), (GL,WB), (GL,WC), (GM,VA), (GM,VB), (GM,VC), (GM,VD), (GM,VE), (GM,VF), (GM,VG), (GM,VH), (GM,VI), (GM,VJ), (GM,VK), (GM,VL), (GM,VM), (GM,VN), (GM,VO), (GM,VP), (GM,VQ), (GM,VR), (GM,VS), (GM,VT), (GM,VU), (GM,VV), (GM,VW), (GM,VX), (GM,VY), (GM,VZ), (GM,WA), (GM,WB), (GM,WC), (GN,VA), (GN,VB), (GN,VC), (GN,VD), (GN,VE), (GN,VF), (GN,VG), (GN,VH), (GN,VI), (GN,VJ), (GN,VK), (GN,VL), (GN,VM), (GN,VN), (GN,VO), (GN,VP), (GN,VQ), (GN,VR), (GN,VS), (GN,VT), (GN,VU), (GN,VV), (GN,VW), (GN,VX), (GN,VY), (GN,VZ), (GN,WA), (GN,WB), (GN,WC), (GO,VA), (GO,VB), (GO,VC), (GO,VD), (GO,VE), (GO,VF), (GO,VG), (GO,VH), (GO,VI), (GO,VJ), (GO,VK), (GO,VL), (GO,VM), (GO,VN), (GO,VO), (GO,VP), (GO,VQ), (GO,VR), (GO,VS), (GO,VT), (GO,VU), (GO,VV), (GO,VW), (GO,VX), (GO,VY), (GO,VZ), (GO,WA), (GO,WB), (GO,WC), (GP,VA), (GP,VB), (GP,VC), (GP,VD), (GP,VE), (GP,VF), (GP,VG), (GP,VH), (GP,VI), (GP,VJ), (GP,VK), (GP,VL), (GP,VM), (GP,VN), (GP,VO), (GP,VP), (GP,VQ), (GP,VR), (GP,VS), (GP,VT), (GP,VU), (GP,VV), (GP,VW), (GP,VX), (GP,VY), (GP,VZ), (GP,WA), (GP,WB), (GP,WC), (GQ,VA), (GQ,VB), (GQ,VC), (GQ,VD), (GQ,VE), (GQ,VF), (GQ,VG), (GQ,VH), (GQ,VI), (GQ,VJ), (GQ,VK), (GQ,VL), (GQ,VM), (GQ,VN), (GQ,VO), (GQ,VP), (GQ,VQ), (GQ,VR), (GQ,VS), (GQ,VT), (GQ,VU), (GQ,VV), (GQ,VW), (GQ,VX), (GQ,VY), (GQ,VZ), (GQ,WA), (GQ,WB), (GQ,WC), (GR,VA), (GR,VB), (GR,VC), (GR,VD), (GR,VE), (GR,VF), (GR,VG), (GR,VH), (GR,VI), (GR,VJ), (GR,VK), (GR,VL), (GR,VM), (GR,VN), (GR,VO), (GR,VP), (GR,VQ), (GR,VR), (GR,VS), (GR,VT), (GR,VU), (GR,VV), (GR,VW), (GR,VX), (GR,VY), (GR,VZ), (GR,WA), (GR,WB), (GR,WC), (GS,VA), (GS,VB), (GS,VC), (GS,VD), (GS,VE), (GS,VF), (GS,VG), (GP,VH), (GP,VI), (GS,VJ), (GS,VK), (GS,VL), (GS,VM), (GS,VN), (GS,VO), (GS,VP), (GS,VQ), (GS,VR), (GS,VS), (GS,VT), (GS,VU), (GS,VV), (GS,VW), (GS,VX), (GS,VY), (GS,VZ), (GS,WA), (GS,WB), (GS,WC), (GT,VA), (GT,VB), (GT,VC), (GT,VD), (GT,VE), (GT,VF), (GT,VG), (GT,VH), (GT,VI), (GT,VJ), (GT,VK), (GT,VL), (GT,VM), (GT,VN), (GT,VO), (GT,VP), (GT,VQ), (GT,VR), (GT,VS), (GT,VT), (GT,VU), (GT,VV), (GT,VW), (GT,VX), (GT,VY), (GT,VZ), (GT,WA), (GT,WB), (GT,WC), (GU,VA), (GU,VB), (GU,VC), (GU,VD), (GU,VE), (GU,VF), (GU,VG), (GU,VH), (GU,VI), (GU,VJ), (GU,VK), (GU,VL), (GU,VM), (GU,VN), (GU,VO), (GU,VP), (GU,VQ), (GU,VR), (GU,VS), (GU,VT), (GU,VU), (GU,VV), (GU,VW), (GU,VX), (GU,VY), (GU,VZ), (GU,WA), (GU,WB), (GU,WC), (GV,VA), (GV,VB), (GV,VC), (GV,VD), (GV,VE), (GV,VF), (GV,VG), (GV,VH), (GV,VI), (GV,VJ), (GV,VK), (GV,VL), (GV,VM), (GV,VN), (GV,VO), (GV,VP), (GV,VQ), (GV,VR), (GV,VS), (GV,VT), (GV,VU), (GV,VV), (GV,VW), (GV,VX), (GV,VY), (GV,VZ), (GV,WA), (GV,WB), (GV,WC), (GW,VA), (GW,VB), (GW,VC), (GW,VD), (GW,VE), (GW,VF), (GW,VG), (GW,VH), (GW,VI), (GW,VJ), (GW,VK), (GW,VL), (GW,VM), (GW,VN), (GW,VO), (GW,VP), (GW,VQ), (GW,VR), (GW,VS), (GW,VT), (GW,VU), (GW,VV), (GW,VW), (GW,VX), (GW,VY), (GW,VZ), (GW,WA), (GW,WB), (GW,WC), (GX,VA), (GX,VB), (GX,VC), (GX,VD), (GX,VE), (GX,VF), (GX,VG), (GX,VH), (GX,VI), (GX,VJ), (GX,VK), (GX,VL), (GX,VM), (GX,VN), (GX,VO), (GX,VP), (GX,VQ), (GX,VR), (GX,VS), (GX,VT), (GX,VU), (GX,VV), (GX,VW), (GX,VX), (GX,VY), (GX,VZ), (GX,WA), (GX,WB), (GX,WC), (GY,VA), (GY,VB), (GY,VC), (GY,VD), (GY,VE), (GY,VF), (GY,VG), (GY,VH), (GY,VI), (GY,VJ), (GY,VK), (GY,VL), (GY,VM), (GY,VN), (GY,VO), (GY,VP), (GY,VQ), (GY,VR), (GY,VS), (GY,VT), (GY,VU), (GY,VV), (GY,VW), (GX,VX), (GY,VY), (GY,VZ), (GY,WA), (GY,WB), (GY,WC), (GZ,VA), (GZ,VB), (GZ,VC), (GZ,VD), (GZ,VE), (GZ,VF), (GZ,VG), (GZ,VH), (GZ,VI), (GZ,VJ), (GZ,VK), (GZ,VL), (GZ,VM), (GZ,VN), (GZ,VO), (GZ,VP), (GZ,VQ), (GZ,VR), (GZ,VS), (GZ,VT), (GZ,VU), (GZ,VV), (GZ,VW), (GZ,VX), (GZ,VY), (GZ,VZ), (GZ,WA), (GZ,WB), (GZ,WC),
(HA,VA), (HA,VB), (HA,VC), (HA,VD), (HA,VE), (HA,VF), (HA,VG), (HA,VH), (HA,VI), (HA,VJ), (HA,VK), (HA,VL), (HA,VM), (HA,VN), (HA,VO), (HA,VP), (HA,VQ), (HA,VR), (HA,VS), (HA,VT), (HA,VU), (HA,VV), (HA,VW), (HA,VX), (HA,VY), (HA,VZ), (HA,WA), (HA,WB), (HA,WC), (HB,VA), (HB,VB), (HB,VC), (HB,VD), (HB,VE), (HB,VF), (HB,VG), (HB,VH), (HB,VI), (HB,VJ), (HB,VK), (HB,VL), (HB,VM), (HB,VN), (HB,VO), (HB,VP), (HB,VQ), (HB,VR), (HB,VS), (HB,VT), (HB,VU), (HB,VV), (HB,VW), (HB,VX), (HB,VY), (HB,VZ), (HB,WA), (HB,WB), (HB,WC), (HC,VA), (HC,VA), (HC,VB), (HC,VB), (HC,VC), (HC,VD), (HC,VE), (HC,VF), (HC,VG), (HC,VH), (HC,VI), (HC,VJ), (HC,VK), (HC,VL), (HC,VM), (HC,VN), (HC,VO), (HC,VP), (HC,VQ), (HC,VR), (HC,VS), (HC,VT), (HC,VU), (HC,VV), (HC,VW), (HC,VX), (HC,VY), (HC,VZ), (HC,WA), (HC,WB), (HB,WC), (HD,VC), (HD,VD), (HD,VE), (HD,VF), (HD,VG), (HD,VH), (HD,VI), (HD,VJ), (HD,VK), (HD,VL), (HD,VM), (HD,VN), (HD,VO), (HD,VP), (HD,VQ), (HB,VR), (HD,VS), (HD,VT), (HD,VU), (HD,VV), (HD,VW), (HD,VX), (HD,VY), (HD,VZ), (HD,WA), (HD,WB), (HD,WC), (HE,VA), (HE,VB), (HE,VC), (HE,VD), (HE,VE), (HE,VF), (HE,VG), (HE,VH), (HE,VI), (HE,VJ), (HE,VK), (HE,VL), (HE,VM), (HE,VN), (HE,VO), (HE,VP), (HE,VQ), (HE,VR), (HE,VS), (HE,VT), (HE,VU), (HE,VV), (HE,VW), (HE,VX), (HE,VY), (HE,VZ), (HE,WA), (HE,WB), (HE,WC), (HF,VA), (HF,VB), (HF,VC), (HF,VD), (HF,VE), (HF,VF), (HF,VG), (HF,VH), (HF,VI), (HF,VJ), (HF,VK), (HF,VL), (HF,VM), (HF,VN), (HF,VO), (HF,VP), (HF,VQ), (HF,VR), (HF,VS), (HF,VT), (HF,VU), (HF,VV), (HF,VW), (HF,VX), (HF,VY), (HF,VZ), (HF,WA), (HF,WB), (HF,WC), (HG,VA), (HG,VB), (HC,VC), (HG,VD), (HC,VE), (HG,VF), (HG,VG), (HG,VH), (HC,VI), (HG,VJ), (HG,VK), (HG,VL), (HG,VM), (HN,VN), (HG,VO), (HG,VP), (HG,VQ), (HG,VR), (HB,VS), (HG,VT), (HG,VU), (HG,VV), (HG,VW), (HG,VX), (HG,VY), (HG,VZ), (HG,WA), (HG,WB), (HG,WC), (HH,VA), (HH,VB), (HH,VC), (HH,VD), (HH,VE), (HH,VF), (HH,VG), (HH,VH), (HH,VI), (HH,VJ), (HH,VK), (HH,VL), (HH,VM), (HH,VN), (HH,VO), (HH,VP), (HH,VQ), (HH,VR), (HH,VS), (HH,VT), (HH,VU), (HH,VV), (HH,VW), (HH,VX), (HH,VY), (HH,VZ), (HH,WA), (HH,WB), (HH,WC), (HI,VA), (HI,VB), (HI,VC), (HI,VD), (HI,VE), (HI,VF), (HI,VG), (HI,VH), (HI,VI), (HI,VJ), (HI,VK), (HI,VL), (HI,VM), (HI,VN), (HI,VO), (HI,VP), (HI,VQ), (HI,VR), (HI,VS), (HI,VT), (HI,VU), (HI,VV), (HI,VW), (HI,VX), (HI,VY), (HI,VZ), (HI,WA), (HI,WB), (HI,WC), (HJ,VA), (HJ,VB), (HJ,VC), (HJ,VD), (HJ,VE), (HJ,VF), (HJ,VG), (HJ,VH), (HJ,VI), (HJ,VJ), (HJ,VK), (HJ,VL), (HJ,VM), (HJ,VN), (HJ,VO), (HJ,VP), (HJ,VQ), (HJ,VR), (HJ,VS), (HJ,VT), (HJ,VU), (HJ,VV), (HJ,VW), (HJ,VX), (HJ,VY), (HJ,VZ), (HJ,WA), (HJ,WB), (HJ,WC), (HK,VA), (HK,VB), (HK,VC), (HK,VD), (HK,VE), (HK,VF), (HK,VG), (HK,VH), (HK,VI), (HK,VJ), (HK,VK), (HK,VL), (HK,VM), (HK,VN), (HK,VO), (HK,VP), (HK,VQ), (HK,VR), (HK,VS), (HK,VT), (HK,VU), (HK,VV), (HK,VW), (HK,VX), (HK,VY), (HK,VZ), (HK,WA), (HK,WB), (HK,WC), (HL,VA), (HL,VB), (HL,VC), (HL,VD), (HL,VE), (HL,VF), (HL,VG), (HL,VH), (HL,VI), (HL,VJ), (HL,VK), (HL,VL), (HL,VM), (HL,VN), (HL,VO), (HL,VP), (HL,VQ), (HL,VR), (HL,VS), (HL,VT), (HL,VU), (HL,VV), (HL,VW), (HL,VX), (HL,VY), (HL,VZ), (HL,WA), (HL,WB), (HL,WC), (HM,VA), (HM,VB), (HM,VC), (HM,VD), (HM,VE), (HM,VF), (HM,VG), (HM,VH), (HM,VI), (HM,VJ), (HM,VK), (HM,VL), (HM,VM), (HM,VN), (HM,VO), (HM,VP), (HM,VQ), (HM,VR), (HM,VS), (HM,VT), (HM,VU), (HM,VV), (HM,VW), (HM,VX), (HM,VY), (HM,VZ), (HM,WA), (HM,WB), (HM,WC), (HN,VA), (HN,VB), (HN,VC), (HN,VD), (HN,VE), (HN,VF), (HN,VG), (HN,VH), (HN,VI), (HN,VJ), (HN,VK), (HN,VL), (HN,VM), (HN,VN), (HN,VO), (HN,VP), (HN,VQ), (HN,VR), (HN,VS), (HN,VT), (HN,VU), (HN,VV), (HN,VW), (HN,VX), (HN,VY), (HN,VZ), (HN,WA), (HN,WB), (HN,WC), (HO,VA), (HO,VB), (HO,VC), (HO,VD), (HO,VE), (HO,VF), (HO,VG), (HO,VH), (HO,VI), (HO,VJ), (HO,VK), (HO,VL), (HO,VM), (HO,VN), (HO,VO), (HO,VP), (HO,VQ), (HO,VR), (HO,VS), (HO,VT), (HO,VU), (HO,VV), (HO,VW), (HO,VX), (HO,VY), (HO,VZ), (HO,WA), (HO,WB), (HO,WC), (HP,VA), (HP,VB), (HP,VC), (HP,VD), (HP,VE), (HP,VF), (HP,VG), (HP,VH), (HP,VI), (HP,VJ), (HP,VK), (HP,VL), (HP,VM), (HP,VN), (HP,VO), (HP,VP), (HP,VQ), (HP,VR), (HP,VS), (HP,VT), (HP,VU), (HP,VV), (HP,VW), (HP,VX), (HP,VY), (HP,VZ), (HP,WA), (HP,WB), (HP,WC), (HQ,VA), (HQ,VB), (HQ,VC), (HQ,VD), (HQ,VE), (HQ,VF), (HQ,VG), (HQ,VH), (HQ,VI), (HQ,VJ), (HQ,VK), (HQ,VL), (HQ,VM), (HQ,VN), (HQ,VO), (HQ,VP), (HQ,VQ), (HQ,VR), (HQ,VS), (HQ,VT), (HQ,VU), (HQ,VV), (HQ,VW), (HQ,VX), (HQ,VY), (HQ,VZ), (HQ,WA), (HQ,WB), (HQ,WC), (HR,VA), (HR,VB), (HR,VC), (HR,VD), (HR,VE), (HR,VF), (HR,VG), (HR,VH), (HR,VS), (HR,VJ), (HR,VK), (HR,VL), (HR,VM), (HR,VN), (HR,VO), (HR,VP), (HR,VQ), (HR,VR), (HR,VS), (HR,VT), (HR,VU), (HR,VV), (HR,VW), (HR,VX), (HR,VY), (HR,VZ), (HR,WA), (HR,WB), (HR,WC), (HS,VA), (HS,VB), (HS,VC), (HS,VD), (HS,VE), (HS,VF), (HS,VG), (HS,VH), (HS,VS), (HS,VJ), (HS,VK), (HS,VL), (HS,VM), (HS,VN), (HS,VO), (HS,VP), (HS,VQ), (HS,VR), (HS,VS), (HS,VT), (HS,VU), (HS,VV), (HS,VW), (HS,VX), (HS,VY), (HS,VZ), (HS,WA), (HS,WB), (HP,WC), (HT,VA), (HT,VB), (HT,VC), (HT,VD), (HT,VE), (HT,VF), (HT,VG), (HT,VH), (HT,VI), (HT,VJ), (HT,VK), (HT,VL), (HT,VM), (HT,VN), (HT,VO), (HT,VP), (HT,VQ), (HT,VR), (HP,VS), (HT,VT), (HT,VU), (HT,VV), (HT,VW), (HT,VX), (HT,VY), (HT,VZ), (HT,WA), (HT,WB) (HT,WC), (HU,VA), (HU,VB), (HU,VC), (HU,VD), (HU,VE), (HU,VF), (HU,VG), (HU,VH), (HU,VS), (HU,VJ), (HU,VK), (HU,VL), (HU,VM), (HU,VN), (HU,VO), (HU,VP), (HU,VQ), (HU,VR), (HU,VS), (HU,VT), (HU,VU), (HU,VV), (HU,VW), (HU,VX), (HU,VY), (HU,VZ), (HU,WA), (HU,WB), (HU,WC), (HV,VA), (HV,VB), (HP,VC), (HP,VD), (HV,VE), (HP,VF), (HP,VG), (HV,VH), (HV,VI), (HV,VJ), (HV,VK), (HV,VL), (HV,VM), (HV,VN), (HV,VO), (HV,VP), (HV,VQ), (HR,VR), (HV,VS), (HV,VT), (HV,VU), (HV,VV), (HX,VW), (HV,VX), (HV,VY), (HV,VZ), (HX,WA), (HV,WB), (HV,WC), (HW,VA), (HW,VB), (HW,VC), (HW,VD), (HW,VE), (HW,VF), (HW,VG), (HW,VH), (HW,VI), (HW,VJ), (HW,VK), (HW,VL), (HW,VM), (HW,VN), (HW,VO), (HW,VP), (HW,VQ), (HW,VR), (HW,VS), (HW,VT), (HW,VU), (HW,VV), (HW,VW), (HW,VX), (HW,VY), (HW,VZ), (HW,WA), (HW,WB), (HW,WC), (HX,VA), (HX,VB), (HX,VC), (HX,VD), (HX,VE), (HX,VF), (HX,VG), (HX,VH), (HX,VS), (HX,VJ), (HX,VK), (HX,VL), (HX,VM), (HX,VN), (HX,VO), (HX,VP), (HX,VQ), (HX,VR), (HX,VS), (HX,VT), (HX,VU), (HX,VV), (HX,VW), (HX,VX), (HX,VY), (HX,VZ), (HX,WA), (HX,WB), (HX,WC), (HY,VA), (HY,VB), (HY,VC), (HY,VD), (HY,VE), (HY,VF), (HY,VG), (HY,VH), (HY,VI), (HY,VJ), (HY,VK), (HY,VL), (HY,VM), (HY,VN), (HY,VO), (HY,VP), (HY,VQ), (HY,VR), (HY,VS), (HY,VT), (HY,VU), (HY,VV), (HY,VW), (HY,VX), (HY,VY), (HY,VZ), (HY,WA), (HY,WB), (HY,WC), (HZ,VA), (HZ,VB), (HZ,VC), (HZ,VD), (HZ,VE), (HZ,VF), (HZ,VG), (HZ,VH), (HZ,VS), (HZ,VJ), (HZ,VK), (HZ,VL), (HZ,VM), (HZ,VN), (HZ,VO), (HZ,VP), (HZ,VQ), (HZ,VR), (HZ,VS), (HZ,VT), (HZ,VU), (HZ,VV), (HZ,VW), (HZ,VX), (HZ,VY), (HZ,VZ), (HZ,WA), (HZ,WB), (HZ,WC),
(IA,VA), (IA,VB), (IA,VC), (IA,VD), (IA,VE), (IA,VF), (IA,VG), (IA,VH), (IA,VI), (IA,VJ), (IA,VK), (IA,VL), (IA,VM), (IA,VN), (IA,VO), (IA,VP), (IA,VQ), (IA,VR), (IA,VS), (IA,VT), (IA,VU), (IA,VV), (IA,VW), (IA,VX), (IA,VY), (IA,VZ), (IA,WA), (IA,WB), (IA,WC), (IB,VA), (IB,VB), (IB,VC), (IB,VD), (IB,VE), (IB,VF), (IB,VG), (IB,VH), (IB,VI), (IB,VJ), (IB,VK), (IB,VL), (IB,VM), (IB,VN), (IB,VO), (IB,VP), (IB,VQ), (IB,VR), (IB,VS), (IB,VT), (IB,VU), (IB,VV), (IB,VW), (IB,VX), (IB,VY), (IB,VZ), (IB,WA), (IB,WB), (IB,WC), (IC,VA), (IC,VA), (IC,VB), (IC,VB), (IC,VC), (IC,VD), (IC,VE), (IC,VF), (IC,VG), (IC,VH), (IC,VI), (IC,VJ), (IC,VK), (IC,VL), (IC,VM), (IC,VN), (IC,VO), (IC,VP), (IC,VQ), (IC,VR), (IC,VS), (IC,VT), (IC,VU), (IC,VV), (IC,VW), (IC,VX), (IC,VY), (IC,VZ), (IC,WA), (IC,WB), (IC,WC), (ID,VC), (ID,VD), (ID,VE), (ID,VF), (ID,VG), (ID,VH), (ID,VI), (ID,VJ), (ID,VK), (ID,VL), (ID,VM), (ID,VN), (ID,VO), (ID,VP), (ID,VQ), (ID,VR), (ID,VS), (ID,VT), (ID,VU), (ID,VV), (ID,VW), (ID,VX), (ID,VY), (ID,VZ), (ID,WA), (ID,WB), (ID,WC), (SE,VA), (IE,VB), (IE,VC), (SE,VD), (SE,VE), (SE,VF), (IE,VG), (IE,VH), (SE,VI), (IE,VJ), (SE,VK), (IE,VL), (IE,VM), (IE,VN), (SE,VO), (IE,VP), (SE,VQ), (IE,VR), (SE,VS), (IE,VT), (SE,VU), (IE,VV), (SE,VW), (IE,VX), (IE,VY), (IE,VZ), (IE,WA), (IE,WB), (IE,WC), (IF,VA), (IF,VB), (IF,VC), (IF,VD), (IF,VE), (IF,VF), (IF,VG), (IF,VH), (IF,VI), (IF,VJ), (IF,VK), (IF,VL), (IF,VM), (IF,VN), (IF,VO), (IF,VP), (IF,VQ), (IF,VR), (IF,VS), (IF,VT), (IF,VU), (IF,VV), (IF,VW), (IF,VX), (IF,VY), (IF,VZ), (IF,WA), (IF,WB), (IF,WC), (IG,VA), (IG,VB), (IG,VC), (IG,VD), (IC,VE), (IG,VF), (IG,VG), (IG,VH), (IG,VJ), (IG,VK), (IG,VL), (IC,VM), (IG,VN), (IG,VO), (IG,VP), (IG,VQ), (IG,VR), (IG,VS), (IG,VT), (IG,VU), (IG,VV), (IG,VW), (IG,VX), (IG,VY), (IG,VZ), (IG,WA), (IG,WB), (IG,WC), (IH,VA), (IH,VB), (IH,VC), (IH,VD), (IH,VE), (IH,VF), (IH,VG), (IH,VH), (IH,VI), (IH,VJ), (IH,VK), (IH,VL), (IH,VM), (IH,VN), (IH,VO), (IH,VP), (IH,VQ), (IH,VR), (IH,VS), (IH,VT), (IH,VU), (IH,VV), (IH,VW), (IH,VX), (IH,VY), (IH,VZ), (IH,WA), (IH,WB), (IH,WC), (II,VB), (II,VC), (II,VD), (II,VE), (II,VF), (II,VH), (II,VI), (II,VJ), (II,VM), (II,VO), (II,VP), (II,VQ), (II,VR), (II,VS), (II,VU), (II,VY), (II,VZ), (II,WB), (II,WC), (IJ,VA), (IJ,VB), (IJ,VC), (IJ,VD), (IJ,VE), (IJ,VF), (IJ,VG), (IJ,VH), (IJ,VI), (IJ,VJ), (IJ,VK), (IJ,VL), (IJ,VM), (IJ,VN), (IJ,VO), (IJ,VP), (IJ,VQ), (IJ,VR), (IJ,VS), (IJ,VT), (IJ,VU), (IJ,VV), (IJ,VW), (IJ,VX), (IJ,VY), (IJ,VZ), (IJ,WA), (IJ,WB), (IJ,WC), (IK,VA), (IK,VB), (IK,VC), (IK,VD), (IK,VE), (IK,VF), (IK,VG), (IK,VH), (IK,VJ), (IK,VK), (IK,VL), (IK,VM), (IK,VN), (IK,VO), (IK,VP), (IK,VQ), (IK,VR), (IK,VS), (IK,VT), (IK,VU), (IK,VV), (IK,VW), (IK,VX), (IK,VY), (IK,VZ), (IK,WA), (IK,WB), (IK,WC), (IL,VA), (IL,VB), (IL,VC), (IL,VD), (IL,VE), (IL,VF), (IL,VG), (IL,VH), (IL,VI), (IL,VJ), (IL,VK), (IL,VL), (IL,VM), (IL,VN), (IL,VO), (IL,VP), (IL,VQ), (L,VR), (IL,VS), (IL,VT), (IL,VU), (IL,VV), (IL,VW), (IL,VX), (IL,VY), (IL,VZ), (IL,WA), (IL,WB), (IL,WC), (IM,VA), (IM,VB), (IM,VC), (IM,VD), (IM,VE), (IM,VF), (IM,VG), (IM,VH), (IM,VI), (IM,VJ), (IM,VK), (IM,VL), (IM,VM), (IM,VN), (IM,VO), (IM,VP), (IM,VQ), (IM,VR), (IM,VS), (IM,VT), (IM,VU), (IM,VV), (IM,VW), (IM,VX), (IM,VY), (IM,VZ), (IM,WA), (IM,WB), (IM,WC), (IN,VA), (IN,VB), (IN,VC), (IN,VD), (IN,VE), (IN,VF), (IN,VG), (IN,VH), (IN,VI), (IN,VJ), (IN,VK), (IN,VL), (IN,VM), (IN,VN), (IN,VO), (IN,VP), (IN,VQ), (IN,VR), (IN,VS), (IN,VT), (IN,VU), (IN,VV), (IN,VW), (IN,VX), (IN,VY), (IN,VZ), (IN,WA), (IN,WB), (IN,WC), (IO,VA), (IO,VB), (IO,VC), (IO,VD), (IO,VE), (IO,VF), (IO,VG), (IO,VH), (IO,VI), (IO,VJ), (IO,VK), (IO,VL), (IO,VM), (IO,VN), (IO,VO), (IO,VP), (IO,VQ), (IO,VR), (IO,VS), (IO,VT), (IO,VU), (IO,VV), (IO,VW), (IO,VX), (IO,VY), (IO,VZ), (IO,WA), (IO,WB), (IO,WC), (IP,VA), (IP,VB), (IP,VC), (IP,VD), (IP,VE), (IP,VF), (IP,VG), (IP,VH), (IP,VI), (IP,VJ), (IP,VK), (IP,VL), (IP,VM), (IP,VN), (IP,VO), (IP,VP), (IP,VQ), (IP,VR), (IP,VS), (IP,VT), (IP,VU), (IP,VV), (IP,VW), (IP,VX), (IP,VY), (IP,VZ), (IP,WA), (IP,WB), (IP,WC), (IQ,VA), (IQ,VB), (IQ,VC), (IQ,VD), (IQ,VE), (IQ,VF), (IQ,VG), (IQ,VH), (Q,VI), (Q,VJ), (IQ,VK), (IQ,VL), (IQ,VM), (IQ,VN), (IQ,VO), (IQ,VP), (IQ,VQ), (IQ,VR), (IQ,VS), (IQ,VT), (IQ,VU), (IQ,VV), (IQ,VW), (IQ,VX), (IQ,VY), (IQ,VZ), (IQ,WA), (IQ,WB), (IQ,WC), (IR,VA), (IR,VB), (IR,VC), (IR,VD), (IR,VE), (IR,VF), (IR,VG), (IR,VH), (IR,VI), (IR,VJ), (IR,VK), (IR,VL), (IR,VM), (IR,VN), (IR,VO), (IR,VP), (IR,VQ), (IR,VR), (IR,VS), (IR,VT), (IR,VU), (IR,VV), (IR,VW), (IR,VX), (IR,VY), (IR,VZ), (IR,WA), (IR,WB), (IR,WC), (IS,VA), (IS,VB), (IS,VC), (IR,VD), (IS,VE), (IS,VF), (IS,VG), (IS,VH), (IS,VI), (IS,VJ), (IS,VK), (IS,VL), (IS,VM), (IS,VN), (IS,VO), (IS,VP), (IS,VQ), (IS,VR), (IS,VS), (IS,VT), (IS,VU), (IS,VV), (IS,VW), (IS,VX), (IS,VY), (IS,VZ), (IS,WA), (IS,WB), (IS,WC), (IT,VA), (IT,VB), (IT,VC), (IT,VD), AVE), (IT,VF), (IT,VG), (IT,VH), (IT,VI), (IT,VJ), (IT,VK), (IT,VL), (IT,VM), (IT,VN), (IT,VO), (IT,VP), (IT,VQ), (IT,VR), (IT,VS), (IT,VT), (IT,VU), (IT,VV), (IT,VW), (IT,VX), (IT,VY), (IT,VZ), (IT,WA), (IT,WB), (IT,WC), (IU,VA), (IU,VB), (IU,VC), (IU,VD), (IU,VE), (IU,VF), (IU,VG), (IU,VH), (IU,VI), (IU,VJ), (IU,VK), (IU,VL), (IU,VM), (IU,VN), (U,VO), (U,VP), (IU,VQ), (IU,VR), (IU,VS), (IU,VT), (U,VU), (U,VV), (IU,VW), (IU,VX), (IU,VY), (IU,VZ), (IU,WA), (IU,WB), (IU,WC), (IV,VA), (IV,VB), (IV,VC), (IV,VD), (IV,VE), (IV,VF), (IV,VG), (IV,VH), (IR,VI), (IV,VJ), (IV,VK), (IV,VL), (IR,VM), (IV,VN), (IV,VO), (IV,VP), (IV,VQ), (IV,VR), (IV,VS), (IV,VT), (IV,VU), (IV,VV), (IV,VW), (IV,VX), (IV,VY), (IV,VZ), (IV,WA), (IV,WB), (IV,WC), (IW,VA), (IW,VB), (IW,VC), (IW,VD), (IW,VE), (IW,VF), (IW,VG), (IW,VH), (IW,VI), (IW,VJ), (IW,VK), (IW,VL), (IW,VM), (IW,VN), (IW,VO), (IW,VP), (IW,VQ), (IW,VR), (IW,VS), (IW,VT), (IW,VU), (IW,VV), (IW,VW), (IW,VX), (IW,VY), (IW,VZ), (IW,WA), (IW,WB), (IW,WC), (IX,VA), (IX,VB), (IX,VC), (IX,VD), (IX,VE), (IX,VF), (IX,VG), (IX,VH), (IX,VI), (IX,VJ), (IX,VK), (IX,VL), (IX,VM), (IX,VN), (IX,VO), (IX,VP), (IX,VQ), (IX,VR), (IX,VS), (IX,VT), (IX,VU), (IX,VV), (IX,VW), (IX,VX), (IX,VY), (IX,VZ), (IX,WA), (IX,WB), (IX,WC), (IY,VA), (IY,VB), (IY,VC), (IY,VD), (IY,VE), (IY,VF), (IY,VG), (IY,VH), (IY,VI), (IY,VJ), (IY,VK), (IY,VL), (IY,VM), (IY,VN), (IY,VO), (IY,VP), (IY,VQ), (IY,VR), (IY,VS), (IZ,VT), (IY,VU), (IY,VV), (IY,VW), (IY,VX), (IY,VY), (IY,VZ), (IY,WA), (IY,WB), (IZ,WC), (IZ,VA), (IZ,VB), (IZ,VC), (IZ,VD), (IZ,VE), (IZ,VF), (IZ,VG), (IZ,VH), (IZ,VK), (IZ,VM), (IZ,VN), (IZ,VO), (IZ,VP), (IZ,VQ), (IZ,VR), (IZ,VS), (IZ,VT), (IZ,VU), (IZ,VV), (IZ,VW), (IZ,VX), (IZ,VY), (IZ,VZ), (IZ,WA), (IZ,WB), (IZ,WC),
(JA,VA), (JA,VB), (JA,VC), (JA,VD), (JA,VE), (JA,VF), (JA,VG), (JA,VH), (JA,VI), (JA,VJ), (JA,VK), (JA,VL), (JA,VM), (JA,VN), (JA,VO), (JA,VP), (JA,VQ), (JA,VR), (JA,VS), (JA,VT), (JA,VU), (JA,VV), (JA,VW), (JA,VX), (JA,VY), (JA,VZ), (JA,WA), (JA,WB), (JA,WC), (JB,VA), (JB,VB), (JB,VC), (JB,VD), (JB,VE), (JB,VF), (JB,VG), (JB,VH), (JB,VI), (JB,VJ), (JB,VK), (JB,VL), (JB,VM), (JB,VN), (JB,VO), (JB,VP), (JB,VQ), (JB,VR), (JB,VS), (JB,VT), (JB,VU), (JB,VV), (JB,VW), (JB,VX), (JB,VY), (JB,VZ), (JB,WA), (JB,WB), (JB,WC), (JC,VA), (JC,VA), (JC,VB), (JC,VB), (JC,VC), (JC,VD), (JC,VE), (JC,VF), (JC,VG), (JC,VH), (JC,VI), (JC,VJ), (JC,VK), (JC,VL), (JC,VM), (JC,VN), (JC,VO), (JC,VP), (JC,VQ), (JC,VR), (JC,VS), (JC,VT), (JC,VU), (JC,VV), (JC,VW), (JC,VX), (JC,VY), (JC,VZ), (JC,WA), (JC,WB), (JC,WC), (JD,VC), (JD,VD), (JD,VE), (JD,VF), (JD,VG), (JD,VH), (JD,VI), (JD,VJ), (JD,VK), (JD,VL), (JD,VM), (JD,VN), (JD,VO), (JD,VP), (JD,VQ), (JD,VR), (JD,VS), (JD,VT), (JD,VU), (JD,VV), (JD,VW), (JD,VX), (JD,VY), (JD,VZ), (JD,WA), (JD,WB), (JD,WC), (JE,VA), (JE,VB), (JE,VC), (JE,VD), (JE,VE), (JE,VF), (JE,VG), (JE,VH), (JE,VI), (JE,VJ), (JE,VK), (JE,VL), (JE,VM), (JE,VN), (JE,VO), (JE,VP), (JE,VQ), (JE,VR), (JE,VS), (JE,VT), (JE,VU), (JE,VV), (JE,VW), (JE,VX), (JE,VY), (JE,VZ), (JE,WA), (JE,WB), (JE,WC), (JF,VA), (JF,VB), (JF,VC), (JF,VD), (JF,VE), (JF,VF), (JF,VG), (JF,VH), (JF,VI), (JF,VJ), (JF,VK), (JF,VL), (JF,VM), (JF,VN), (JF,VO), (JF,VP), (JF,VQ), (JF,VR), (JF,VS), (JF,VT), (JF,VU), (JF,VV), (JF,VW), (JF,VX), (JF,VY), (JF,VZ), (JF,WA), (JF,WB), (JF,WC), (JG,VA), (JG,VB), (JG,VC), (JG,VD), (JG,VE), (JG,VF), (JG,VG), (JG,VH), (JG,VI), (JG,VJ), (JG,VK), (JG,VL), (JG,VM), (JG,VN), (JG,VO), (JG,VP), (JG,VQ), (JG,VR), (JG,VS), (JG,VT), (JG,VU), (JG,VV), (JG,VW), (JG,VX), (JG,VY), (JG,VZ), (JG,WA), (JG,WB), (JG,WC), (JH,VA), (JH,VB), (JH,VC), (JH,VD), (JH,VE), (JH,VF), (JH,VG), (JH,VH), (JH,VI), (JH,VJ), (JH,VK), (JH,VL), (JH,VM), (JH,VN), (JH,VO), (JH,VP), (JH,VQ), (JH,VR), (JH,VS), (JH,VT), (JH,VU), (JH,VV), (JH,VW), (JH,VX), (JH,VY), (JH,VZ), (JH,WA), (JH,WB), (JH,WC), (JI,VA), (JI,VB), (JI,VC), (JI,VD), (JI,VE), (JI,VF), (JI,VG), (JI,VH), (JI,VI), (JI,VJ), (JI,VK), (JI,VL), (JI,VM), (JI,VN), (JI,VO), (JI,VP), (JI,VQ), (JI,VR), (JI,VS), (JI,VT), (JI,VU), (JI,VV), (JI,VW), (JI,VX), (JI,VY), (JI,VZ), (JI,WA), (JI,WB), (JI,WC), (JJ,VA), (JJ,VB), (JJ,VC), (JJ,VD), (JJ,VE), (JJ,VF), (JJ,VG), (JJ,VH), (JJ,VI), (JJ,VJ), (JJ,VK), (JJ,VL), (JJ,VM), (JJ,VN), (JJ,VO), (JJ,VP), (JJ,VQ), (JJ,VR), (JJ,VS), (JJ,VT), (JJ,VU), (JJ,VV), (JJ,VW), (JJ,VX), (JJ,VY), (JJ,VZ), (JJ,WA), (JJ,WB), (JJ,WC), (JK,VA), (JK,VB), (JK,VC), (JK,VD), (JK,VE), (JK,VF), (JK,VG), (JK,VH), (JK,VI), (JK,VJ), (JK,VK), (JK,VL), (JK,VM), (JK,VN), (JK,VO), (JK,VP), (JK,VQ), (JK,VR), (JK,VS), (JK,VT), (JK,VU), (JK,VV), (JK,VW), (JK,VX), (JK,VY), (JK,VZ), (JK,WA), (JK,WB), (JK,WC), (JL,VA), (JL,VB), (JL,VC), (JL,VD), (JF,VE), (JL,VF), (JL,VG), (JL,VH), (JL,VI), (JL,VJ), (JL,VK), (JL,VL), (JL,VM), (JL,VN), (JL,VO), (JL,VP), (JL,VQ), (JL,VR), (JL,VS), (JL,VT), (JL,VU), (JL,VV), (JL,VW), (JL,VX), (JL,VY), (JL,VZ), (JL,WA), (JL,WB), (JL,WC), (JM,VA), (JM,VB), (JM,VC), (JM,VD), (JM,VE), (JM,VF), (JM,VG), (JM,VH), (JM,VS), (JM,VJ), (JM,VK), (JM,VL), (JM,VM), (JM,VN), (JM,VO), (JM,VP), (JM,VQ), (JM,VR), (JM,VS), (JM,VT), (JM,VU), (JM,VV), (JM,VW), (JM,VX), (JM,VY), (JM,VZ), (JM,WA), (JM,WB), (JM,WC), (JN,VA), (JN,VB), (JN,VC), (JN,VD), (JN,VE), (JN,VF), (JN,VG), (JN,VH), (JN,VI), (JN,VJ), (JN,VK), (JN,VL), (JN,VM), (JN,VN), (JN,VO), (JN,VP), (JN,VQ), (JN,VR), (JN,VS), (JN,VT), (JN,VU), (JN,VV), (JN,VW), (JN,VX), (JN,VY), (JN,VZ), (JN,WA), (JN,WB), (JN,WC), (JO,VA), (JO,VB), (JO,VC), (JO,VD), (JO,VE), (JO,VF), (JO,VG), (JO,VH), (JO,VS), (JO,VJ), (JO,VK), (JO,VL), (JO,VM), (JO,VN), (JO,VO), (JO,VP), (JO,VQ), (JO,VR), (JO,VS), (JO,VT), (JO,VU), (JO,VV), (JO,VW), (JO,VX), (JO,VY), (JO,VZ), (JO,WA), (JO,WB), (JO,WC), (JP,VA), (JP,VB), (JP,VC), (JP,VD), (JP,VE), (JP,VF), (JP,VG), (JP,VH), (JP,VI), (JP,VJ), (JP,VK), (JP,VL), (JP,VM), (JP,VN), (JP,VO), (JP,VP), (JP,VQ), (JP,VR), (JP,VS), (JP,VT), (JP,VU), (JP,VV), (JP,VW), (JP,VX), (JP,VY), (JP,VZ), (JP,WA), (JP,WB), (JP,WC), (JQ,VA), (JQ,VB), (JQ,VC), (JQ,VD), (JQ,VE), (JQ,VF), (JQ,VG), (JQ,VH), (JQ,VI), (JQ,VJ), (JQ,VK), (JQ,VL), (JQ,VM), (JQ,VN), (JQ,VO), (JQ,VP), (JQ,VQ), (JQ,VR), (JQ,VS), (JQ,VT), (JQ,VU), (JQ,VV), (JQ,VW), (JQ,VX), (JQ,VY), (JQ,VZ), (JQ,WA), (JQ,WB), (JQ,WC), (JR,VA), (JR,VB), (JR,VC), (JR,VD), (JR,VE), (JR,VF), (JR,VG), (JR,VH), (JR,VI), (JR,VJ), (JR,VK), (JR,VL), (JR,VM), (JR,VN), (JR,VO), (JR,VP), (JR,VQ), (JR,VR), (JR,VS), (JR,VT), (JR,VU), (JR,VV), (JR,VW), (JR,VX), (JR,VY), (JR,VZ), (JR,WA), (JR,WB), (JR,WC), (JS,VA), (JS,VB), (JS,VC), (JS,VD), (JS,VE), (JS,VF), (JS,VG), (JS,VH), (JS,VI), (JS,VJ), (JS,VK), (JS,VL), (JS,VM), (JS,VN), (JS,VO), (JS,VP), (JS,VQ), (JS,VR), (JS,VS), (JS,VT), (JS,VU), (JS,VV), (JS,VW), (JS,VX), (JS,VY), (JS,VZ), (JS,WA), (JS,WB), (JS,WC), (JT,VA), (AVB), (QVC), (JT,VD), (JT,VE), (JT,VF), (JT,VG), (JT,VH), (JT,VI), (JT,VJ), (JT,VK), (JT,VL), (JT,VM), (JT,VN), (JT,VO), (JT,VP), (JT,VQ), (JT,VR), (JT,VS), (JT,VT), (JT,VU), (JT,VV), (GVW), (JT,VX), (JT,VY), (JT,VZ), (JT,WA), (JT,WB), (JT,WC), (JU,VA), (JU,VB), (JU,VC), (JU,VD), (JU,VE), (JU,VF), (JU,VG), (JU,VH), (JU,VI), (JU,VJ), (JU,VK), (JU,VL), (JU,VM), (JU,VN), (JU,VO), (JU,VP), (JU,VQ), (JU,VR), (JU,VS), (JU,VT), (JU,VU), (JU,VV), (JU,VW), (JU,VX), (JU,VY), (JU,VZ), (JU,WA), (JU,WB), (JU,WC), (JV,VA), (JV,VB), (JV,VC), (JV,VD), (JV,VE), (JV,VF), (JV,VG), (JV,VH), (JV,VI), (JV,VJ), (JV,VK), (JV,VL), (JV,VM), (JV,VN), (JV,VO), (JT,VP), (JV,VQ), (JV,VR), (JV,VS), (JV,VT), (JV,VU), (JV,VV), (JV,VW), (JV,VX), (JV,VY), (JV,VZ), (JW,WA), (JW,WB), (JW,WC), (JW,VA), (JW,VB), (JW,VC), (JW,VD), (JW,VE), (JW,VF), (JW,VG), (JW,VH), (JW,VI), (JW,VJ), (JW,VK), (JW,VL), (JW,VM), (JW,VN), (JW,VO), (JW,VP), (JW,VQ), (JW,VR), (JW,VS), (JW,VT), (JW,VU), (JW,VV), (JW,VW), (JW,VX), (JW,VY), (JW,VZ), (JW,WA), (JW,WB), (JW,WC), (JX,VA), (JX,VB), (JX,VC), (JX,VD), (JX,VE), (JX,VF), (JX,VG), (JX,VH), (JX,VI), (JX,VK), (JX,VL), (JX,VM), (JX,VN), (JX,VO), (JX,VP), (JX,VQ), (JX,VR), (JX,VS), (JX,VT), (JX,VU), (JX,VV), (JX,VW), (JX,VX), (JX,VY), (JX,VZ), (JX,WA), (JX,WB), (JX,WC), (JY,VA), (JY,VB), (JY,VC), (JY,VD), (JY,VE), (JY,VF), (JY,VG), (JY,VH), (JY,VI), (JY,VJ), (JY,VK), (JY,VL), (JY,VM), (JY,VN), (JY,VO), (JY,VP), (JY,VQ), (JY,VR), (JY,VS), (JY,VT), (JY,VU), (JY,VV), (JY,VW), (JY,VX), (JY,VY), (JY,VZ), (JY,WA), (JY,WB), (JY,WC), (JZ,VA), (JZ,VB), (JZ,VC), (JZ,VD), (JZ,VE), (JZ,VF), (JZ,VG), (JZ,VH), (JZ,VI), (JZ,VJ), (JZ,VK), (JZ,VL), (JZ,VM), (JZ,VN), (JZ,VO), (JZ,VP), (JZ,VQ), (JZ,VR), (JZ,VS), (JZ,VT), (JZ,VU), (JZ,VV), (JZ,VW), (JZ,VX), (JZ,VY), (JZ,VZ), (JZ,WA), (JZ,WB), (JZ,WC),
(KA,VA), (KA,VB), (KA,VC), (KA,VD), (KA,VE), (KA,VF), (KA,VG), (KA,VH), (KA,VI), (KA,VJ), (KA,VK), (KA,VL), (KA,VM), (KA,VN), (KA,VO), (KA,VP), (KA,VQ), (KA,VR), (KA,VS), (KA,VT), (KA,VU), (KA,VV), (KA,VW), (KA,VX), (KA,VY), (KA,VZ), (KA,WA), (KA,WB), (KA,WC), (KB,VA), (KB,VB), (KB,VC), (KB,VD), (KB,VE), (KB,VF), (KB,VG), (KB,VH), (KB,VI), (KB,VJ), (KB,VK), (KB,VL), (KB,VM), (KB,VN), (KB,VO), (KB,VP), (KB,VQ), (KB,VR), (KB,VS), (KB,VT), (KB,VU), (KB,VV), (KB,VW), (KB,VX), (KB,VY), (KB,VZ), (KB,WA), (KB,WB), (KB,WC), (KC,VA), (KC,VA), (KC,VB), (KC,VB), (KC,VC), (KC,VD), (KC,VE), (KC,VF), (KC,VG), (KC,VH), (KC,VI), (KC,VJ), (KC,VK), (KC,VL), (KC,VM), (KC,VN), (KC,VO), (KC,VP), (KC,VQ), (KC,VR), (KC,VS), (KC,VT), (KC,VU), (KC,VV), (KC,VW), (KC,VX), (KC,VY), (KC,VZ), (KC,WA), (KC,WB), (KC,WC), (KD,VC), (KD,VD), (KD,VE), (KD,VF), (KD,VG), (KD,VH), (KD,VI), (KD,VJ), (KC,VK), (KD,VL), (KD,VM), (KD,VN), (KD,VO), (KD,VP), (KC,VQ), (KD,VR), (KD,VS), (KD,VT), (KD,VU), (KD,VV), (KD,VW), (KD,VX), (KD,VY), (KD,VZ), (KA,WA), (KD,WB), (KD,WC), (KE,VA), (KE,VB), (KE,VC), (KE,VD), (KE,VE), (KE,VF), (KE,VG), (KE,VH), (KE,VI), (KE,VJ), (KE,VK), (KE,VL), (KE,VM), (KE,VN), (KE,VO), (KE,VP), (KC,VQ), (KE,VR), (KE,VS), (KE,VT), (KE,VU), (KE,VV), (KE,VW), (KE,VX), (KE,VY), (KE,VZ), (KE,WA), (KE,WB), (KE,WC), (KF,VA), (KF,VB), (KF,VC), (KF,VD), (KF,VE), (KC,VF), (KF,VG), (KF,VH), (KF,VI), (KA,VJ), (KF,VK), (KF,VL), (KF,VM), (KF,VN), (KF,VO), (KF,VP), (KF,VQ), (KF,VR), (KF,VS), (KF,VT), (KF,VU), (KF,VV), (KF,VW), (KF,VX), (KF,VY), (KF,VZ), (KF,WA), (KF,WB), (KF,WC), (KG,VA), (KG,VB), (KG,VC), (KG,VD), (KG,VE), (KG,VF), (KG,VG), (KG,VH), (KG,VI), (KG,VJ), (KG,VK), (KG,VL), (KG,VM), (KG,VN), (KG,VO), (KG,VP), (KG,VQ), (KG,VR), (KG,VS), (KG,VT), (KG,VU), (KG,VV), (KG,VW), (KG,VX), (KG,VY), (KG,VZ), (KG,WA), (KG,WB), (KG,WC), (KH,VA), (KH,VB), (KH,VC), (KH,VD), (KH,VE), (KH,VF), (KH,VG), (KH,VH), (KH,VI), (KH,VJ), (KH,VK), (KH,VL), (KH,VM), (KH,VN), (KH,VO), (KH,VP), (KH,VQ), (KH,VR), (KH,VS), (KH,VT), (KH,VU), (KH,VV), (KH,VW), (KH,VX), (KH,VY), (KH,VZ), (KH,WA), (KH,WB), (KH,WC), (KI,VA), (KI,VB), (KI,VC), (KI,VD), (KI,VE), (KI,VF), (KI,VG), (KI,VH), (KI,VI), (KI,VJ), (KI,VK), (KI,VL), (KI,VM), (KI,VN), (KI,VO), (KI,VP), (KI,VQ), (KI,VR), (KI,VS), (KI,VT), (KI,VU), (KI,VV), (KI,VW), (KI,VX), (KI,VY), (KI,VZ), (KI,WA), (KI,WB), (KI,WC), (KJ,VA), (KJ,VB), (KJ,VC), (KJ,VD), (KG,VE), (KJ,VF), (KJ,VG), (KJ,VH), (KJ,VI), (KJ,VJ), (KJ,VK), (KJ,VL), (KJ,VM), (KJ,VN), (KJ,VO), (KJ,VP), (KJ,VQ), (KJ,VR), (KJ,VS), (KJ,VT), (KJ,VU), (KJ,VV), (KJ,VW), (KJ,VX), (KJ,VY), (KJ,VZ), (KJ,WA), (KJ,WB), (KJ,WC), (KK,VA), (KK,VB), (KK,VC), (KK,VD), (KK,VE), (KK,VF), (KK,VG), (KK,VH), (KK,VI), (KK,VJ), (KK,VK), (KK,VL), (KK,VM), (KK,VN), (KK,VO), (KK,VP), (KK,VQ), (KK,VR), (KK,VS), (KK,VT), (KK,VU), (KK,VV), (KK,VW), (KK,VX), (KK,VY), (KK,VZ), (KK,WA), (KK,WB), (KK,WC), (KL,VA), (KL,VB), (KL,VC), (KL,VD), (KL,VE), (KL,VF), (KL,VG), (KL,VH), (KL,VI), (KL,VJ), (KL,VK), (KL,VL), (KL,VM), (KL,VN), (KL,VO), (KL,VP), (KL,VQ), (KL,VR), (KL,VS), (KL,VT), (KL,VU), (KL,VV), (KL,VW), (KL,VX), (KL,VY), (KL,VZ), (KL,WA), (KL,WB), (KL,WC), (KM,VA), (KH,VB), (KM,VC), (KM,VD), (KM,VE), (KM,VF), (KM,VG), (KM,VH), (KM,VI), (KM,VJ), (KM,VK), (KM,VL), (KM,VM), (KM,VN), (KM,VO), (KM,VP), (KM,VQ), (KM,VR), (KM,VS), (KM,VT), (KM,VU), (KM,VV), (KM,VW), (KM,VX), (KM,VY), (KM,VZ), (KM,WA), (KM,WB), (KM,WC), (KN,VA), (KN,VB), (KN,VC), (KN,VD), (KN,VE), (KN,VF), (KN,VG), (KN,VH), (KN,VI), (KN,VJ), (KN,VK), (KN,VL), (KN,VM), (KN,VN), (KN,VO), (KN,VP), (KN,VQ), (KN,VR), (KN,VS), (KN,VT), (KN,VU), (KN,VV), (KN,VW), (KN,VX), (KN,VY), (KN,VZ), (KN,WA), (KN,WB), (KN,WC), (KO,VA), (KO,VB), (KO,VC), (KO,VD), (KO,VE), (KO,VF), (KO,VG), (KO,VH), (KO,VI), (KO,VJ), (KO,VK), (KO,VL), (KO,VM), (KO,VN), (KO,VO), (KO,VP), (KO,VQ), (KO,VR), (KO,VS), (KO,VT), (KO,VU), (KO,VV), (KO,VW), (KO,VX), (KO,VY), (KO,VZ), (KO,WA), (KO,WB), (KO,WC), (KP,VA), (KP,VB), (KP,VC), (KP,VD), (KP,VE), (KP,VF), (KP,VG), (KP,VH), (KP,VI), (KP,VJ), (KP,VK), (KP,VL), (KP,VM), (KP,VN), (KP,VO), (KP,VP), (KP,VQ), (KP,VR), (KP,VS), (KP,VT), (KP,VU, (KP,VV), (KP,VW), (KP,VX), (KP,VY), (KP,VZ), (KP,WA), (KP,WB), (KP,WC), (KQ,VA), (KQ,VB), (KQ,VC), (KQ,VD), (KQ,VE), (KQ,VF), (KQ,VG), (KQ,VH), (KQ,VI), (KQ,VJ), (KQ,VK), (KQ,VL), (KQ,VM), (KQ,VN), (KQ,VO), (KQ,VP), (KQ,VQ), (KQ,VR), (KQ,VS), (KQ,VT), (KQ,VU), (KQ,VV), (KQ,VW), (KQ,VX), (KQ,VY), (KQ,VZ), (KQ,WA), (KQ,WB), (KQ,WC), (KR,VA), (KR,VB), (KR,VC), (KR,VD), (KR,VE), (KR,VF), (KR,VG), (KR,VH), (KR,VI), (KR,VJ), (KR,VK), (KR,VL), (KR,VM), (KR,VN), (KR,VO), (KR,VP), (KR,VQ), (KR,VR), (KR,VS), (KR,VT), (KR,VU), (KR,VV), (KR,VW), (KR,VX), (KR,VY), (KR,VZ), (KR,WA), (KN,WB), (KR,WC), (KS,VA), (KS,VB), (KS,VC), (KS,VD), (KS,VE), (KS,VF), (KS,VG), (KS,VH), (KS,VI), (KS,VJ), (KS,VK), (KS,VL), (KS,VM), (KS,VN), (KS,VO), (KS,VP), (KS,VQ), (KS,VR), (KS,VS), (KS,VT), (KS,VU), (KS,VV), (KS,VW), (KS,VX), (KS,VY), (KQ,VZ), (KS,WA), (KS,WB), (KS,WC), (KT,VA), (KT,VB), (KT,VC), (KT,VD), (KT,VE), (KT,VF), (KT,VG), (KT,VH), (KT,VI), (KT,VJ), (KT,VK), (KT,VL), (KT,VM), (KT,VN), (KT,VO), (KT,VP), (KT,VQ), (KT,VR), (KT,VS), (KT,VT), (KT,VU), (KT,VV), (KT,VW), (KT,VX), (KT,VY), (KT,VZ), (KT,WA), (KT,WB), (KT,WC), (KU,VA), (KU,VB), (KU,VC), (KU,VD), (KU,VE), (KU,VF), (KU,VG), (KU,VH), (KU,VI), (KU,VJ), (KU,VK), (KU,VL), (KU,VM), (KU,VN), (KU,VO), (KU,VP), (KU,VQ), (KU,VR), (KU,VS), (KU,VT), (KU,VU), (KU,VV), (KU,VW), (KU,VX), (KU,VY), (KU,VZ), (KU,WA), (KU,WB), (KU,WC), (KV,VA), (KV,VB), (KV,VC), (KV,VD), (KV,VE), (KV,VF), (KV,VG), (KV,VH), (KV,VI), (KV,VJ), (KV,VK), (KV,VL), (KV,VM), (KV,VN), (KV,VO), (KV,VP), (KV,VQ), (KV,VR), (KV,VS), (KV,VT), (KV,VU), (KV,VV), (KV,VW), (KV,VX), (KV,VY), (KV,VZ), (KV,WA), (KV,WB), (KV,WC), (KW,VA), (KW,VB), (KW,VC), (KW,VD), (KW,VE), (KW,VF), (KW,VG), (KW,VH), (KW,VI), (KW,VJ), (KW,VK), (KW,VL), (KW,VM), (KW,VN), (KW,VO), (KW,VP), (KW,VQ), (KW,VR), (KW,VS), (KW,VT), (KW,VU), (KW,VV), (KW,VW), (KW,VX), (KW,VY), (KW,VZ), (KW,WA), (KW,WB), (KW,WC), (KX,VA), (KX,VB), (KX,VC), (KX,VD), (KX,VE), (KX,VF), (KX,VG), (KX,VH), (KX,VI), (KX,VJ), (KX,VK), (KX,VL), (KX,VM), (KX,VN), (KX,VO), (KU,VP), (KU,VQ), (KX,VR), (KX,VS), (KX,VT), (KX,VU), (KX,VV), (KX,VW), (KU,VX), (KX,VY), (KX,VZ), (KU,WA), (KX,WB), (KX,WC), (KY,VA), (KY,VB), (KY,VC), (KY,VD), (KY,VE), (KY,VF), (KY,VG), (KY,VH), (KY,VI), (KY,VJ), (KY,VK), (KY,VL), (KY,VM), (KY,VN), (KY,VO), (KY,VP), (KY,VQ), (KY,VR), (KY,VS), (KY,VT), (KY,VU), (KY,VV), (KY,VW), (KY,VX), (KY,VY), (KY,VZ), (KY,WA), (KY,WB), (KY,WC), (KZ,VA), (KZ,VB), (KZ,VC), (KZ,VD), (KZ,VE), (KZ,VF), (KZ,VG), (KZ,VH), (KZ,VI), (KZ,VJ), (KZ,VK), (KZ,VL), (KZ,VM), (KZ,VN), (KZ,VO), (KZ,VP), (KZ,VQ), (KZ,VR), (KZ,VS), (KZ,VT), (KZ,VU), (KZ,VV), (KZ,VW), (KZ,VX), (KZ,VY), (KZ,VZ), (KZ,WA), (KZ,WB), (KZ,WC),
(LA,VA), (LH,VB), (LN,VC), (LN,VD), (LA,VE), (LA,VF), (LN,VG), (LA,VH), (LA,VI), (LA,VJ), (LA,VK), (LN,VL), (LN,VM), (LA,VN), (LA,VO), (LG,VP), (LG,VQ), (LA,VR), (LA,VS), (LG,VT), (LA,VU), (LA,VV), (LA,VW), (LA,VX), (LA,VY), (LA,VZ), (LA,WA), (LA,WB), (LL,WC), (LB,VA), (LH,VB), (LB,VC), (LN,VD), (LB,VE), (LB,VF), (LN,VG), (LB,VH), (LB,VI), (LB,VJ), (LB,VK), (LN,VL), (LN,VM), (LB,VN), (LB,VO), (LG,VP), (LB,VQ), (LB,VR), (LB,VS), (LG,VT), (LB,VU), (LB,VV), (LB,VW), (LB,VX), (LB,VY), (LB,VZ), (LB,WA), (LL,WB), (LL,WC), (LC,VA), (LC,VA), (LC,VB), (LC,VB), (LB,VC), (LC,VD), (LC,VE), (LC,VF), (LC,VG), (LC,VH), (LC,VI), (LC,VJ), (LC,VK), (LC,VL), (LC,VM), (LC,VN), (LC,VO), (LC,VP), (LB,VQ), (LC,VR), (LC,VS), (LC,VT), (LC,VU), (LC,VV), (LC,VW), (LC,VX), (LC,VY), (LC,VZ), (LC,WA), (LC,WB), (LC,WC), (LD,VC), (LD,VD), (LD,VE), (LD,VF), (LD,VG), (LD,VH), (LD,VI), (LD,VJ), (LD,VK), (LD,VL), (LD,VM), (LD,VN), (LD,VO), (LD,VP), (LD,VQ), (LD,VR), (LD,VS), (LD,VT), (LD,VU), (LD,VV), (LD,VW), (LD,VX), (LD,VY), (LD,VZ), (LD,WA), (LD,WB), (LD,WC), (LE,VA), (LH,VB), (LN,VC), (LE,VD), (LE,VE), (LE,VF), (LE,VG), (LE,VH), (LE,VI), (LE,VJ), (LE,VK), (LE,VL), (LE,VM), (LE,VN), (LE,VO), (LE,VP), (LE,VQ), (LE,VR), (LE,VS), (LE,VT), (LE,VU), (LE,VV), (LE,VW), (LE,VX), (LE,VY), (LE,VZ), (LE,WA), (LL,WB), (LL,WC), (LF,VA), (LF,VB), (LF,VC), (LF,VD), (LF,VE), (LF,VF), (LF,VG), (LF,VH), (LF,VI), (LF,VJ), (LF,VK), (LF,VL), (LF,VM), (LF,VN), (LF,VO), (LF,VP), (LF,VQ), (LF,VR), (LF,VS), (LF,VT), (LF,VU), (LF,VV), (LF,VW), (LF,VX), (LF,VY), (LF,VZ), (LF,WA), (LF,WB), (LF,WC), (LG,VA), (LG,VB), (LG,VC), (LG,VD), (LG,VE), (LG,VF), (LG,VG), (LG,VH), (LG,VI), (LG,VJ), (LG,VK), (LG,VL), (LG,VM), (LG,VN), (LG,VO), (LG,VP), (LG,VQ), (LG,VR), (LG,VS), (LG,VT), (LG,VU), (LG,VV), (LG,VW), (LG,VX), (LG,VY), (LG,VZ), (LG,WA), (LL,WB), (LL,WC), (LH,VA), (LH,VB), (LH,VC), (LH,VD), (LH,VE), (LH,VF), (LH,VG), (LH,VH), (LH,VI), (LH,VJ), (LH,VK), (LH,VL), (LH,VM), (LH,VN), (LH,VO), (LH,VP), (LH,VQ), (LH,VR), (LH,VS), (LH,VT), (LH,VU), (LH,VV), (LH,VW), (LH,VX), (LH,VY), (LH,VZ), (LH,WA), (LH,WB), (LH,WC), (LI,VA), (LI,VB), (LI,VC), (LI,VD), (LI,VE), (LI,VF), (LI,VG), (LI,VH), (LI,VI), (LI,VJ), (LI,VK), (LI,VL), (LI,VM), (LI,VN), (LI,VO), (LI,VP), (LI,VQ), (LI,VR), (LI,VS), (LI,VT), (LI,VU), (LI,VV), (LI,VW), (LI,VX), (LI,VY), (LI,VZ), (LI,WA), (LI,WB), (LI,WC), (LJ,VA), (LJ,VB), (LJ,VC), (LJ,VD), (LJ,VE), (LJ,VF), (LJ,VG), (LJ,VH), (LJ,VI), (LJ,VJ), (LJ,VK), (LJ,VL), (LJ,VM), (LJ,VN), (LJ,VO), (LJ,VP), (LJ,VQ), (LJ,VR), (LJ,VS), (LJ,VT), (LJ,VU), (LJ,VV), (LJ,VW), (LJ,VX), (LJ,VY), (LJ,VZ), (LJ,WA), (LJ,WB), (LJ,WC), (LK,VA), (LH,VB), (LN,VC), (LN,VD), (LK,VE), (LK,VF), (LN,VG), (LK,VH), (LK,VI), (LK,VJ), (LK,VK), (LN,VL), (LN,VM), (LK,VN), (LK,VO), (LG,VP), (LG,VQ), (LK,VR), (LK,VS), (LG,VT), (LK,VU), (LK,VV), (LK,VW), (LK,VX), (LK,VY), (LK,VZ), (LK,WA), (LL,WB), (LL,WC), (LL,VA), (LL,VB), (LL,WC), (LL,VD), (LL,VE), (LL,VF), (LL,VG), (LL,VH), (LL,VI), (LL,VJ), (LL,VK), (LL,VL), (LL,VM), (LL,VN), (LL,VO), (LL,VP), (LL,VQ), (LL,VR), (LL,VS), (LL,VT), (LL,VU), (LL,VV), (LL,VW), (LL,VX), (LL,VY), (LL,VZ), (LL,WA), (LL,WB), (LL,WC), (LM,VA), (LM,VB), (LM,VC), (LM,VD), (LM,VE), (LM,VF), (LM,VG), (LM,VH), (LM,VI), (LM,VJ), (LM,VK), (LM,VL), (LM,VM), (LM,VN), (LM,VO), (LM,VP), (LM,VQ), (LM,VR), (LM,VS), (LM,VT), (LM,VU), (LM,VV), (LM,VW), (LM,VX), (LM,VY), (LM,VZ), (LM,WA), (LM,WB), (LM,WC), (LN,VA), (LH,VB), (LN,VC), (LN,VD), (LN,VE), (LN,VF), (LN,VG), (LN,VH), (LN,VI), (LN,VJ), (LN,VK), (LN,VL), (LN,VM), (LN,VN), (LN,VO), (LG,VP), (LG,VQ), (LN,VR), (LN,VS), (LN,VT), (LN,VU), (LN,VV), (LN,VW), (LN,VX), (LN,VY), (LN,VZ), (LN,WA), (LN,WB), (LN,WC), (LO,VA), (LO,VB), (LO,VC), (LO,VD), (LO,VE), (LO,VF), (LO,VG), (LO,VH), (LO,VI), (LO,VJ), (LO,VK), (LO,VL), (LO,VM), (LO,VN), (LO,VO), (LO,VP), (LO,VQ), (LO,VR), (LO,VS), (LO,VT), (LO,VU), (LO,VV), (LO,VW), (LO,VX), (LO,VY), (LO,VZ), (LO,WA), (LO,WB), (LO,WC), (LP,VA), (LP,VB), (LP,VC), (LP,VD), (LP,VE), (LP,VF), (LP,VG), (LP,VH), (LP,VI), (LP,VJ), (LP,VK), (LP,VL), (LP,VM), (LP,VN), (LP,VO), (LP,VP), (LP,VQ), (LP,VR), (LP,VS), (LP,VT), (LP,VU), (LP,VV), (LP,VW), (LP,VX), (LP,VY), (LP,VZ), (LP,WA), (LP,WB), (LP,WC), (LQ,VA), (LQ,VB), (LQ,VC), (LQ,VD), (LQ,VE), (LQ,VF), (LQ,VG), (LQ,VH), (LQ,VI), (LQ,VJ), (LQ,VK), (LQ,VL), (LQ,VM), (LQ,VN), (LQ,VO), (LQ,VP), (LQ,VQ), (LQ,VR), (LQ,VS), (LQ,VT), (LQ,VU), (LQ,VV), (LQ,VW), (LQ,VX), (LQ,VY), (LQ,VZ), (LQ,WA), (LQ,WB), (LQ,WC), (LR,VA), (LH,VB), (LN,VC), (LN,VD), (LR,VE), (LR,VF), (LN,VG), (LR,VH), (LR,VI), (LR,VJ), (LR,VK), (LN,VL), (LR,VM), (LR,VN), (LR,VO), (LG,VP), (LG,VQ), (LR,VR), (LR,VS), (LG,VT), (LR,VU), (LR,VV), (LR,VW), (LR,VX), (LR,VY), (LR,VZ), (LR,WA), (LL,WB), (LL,WC), (LS,VA), (LS,VB), (LS,VC), (LS,VD), (LS,VE), (LS,VF), (LS,VG), (LS,VH), (LS,VI), (LS,VJ), (LS,VK), (LS,VL), (LS,VM), (LS,VN), (LS,VO), (LS,VP), (LS,VQ), (LS,VR), (LS,VS), (LS,VT), (LS,VU), (LP,VV), (LS,VW), (LS,VX), (LS,VY), (LS,VZ), (LS,WA), (LS,WB), (LS,WC), (LT,VA), (LT,VB), (LT,VC), (LT,VD), (LT,VE), (LT,VF), (LT,VG), (LT,VH), (LT,VI), (LT,VJ), (LT,VK), (LT,VL), (LT,VM), (LT,VN), (LT,VO), (LT,VP), (LT,VQ), (LT,VR), (LT,VS), (LT,VT), (LT,VU), (LT,VV), (LT,VW), (LT,VX), (LT,VY), (LT,VZ), (LT,WA), (LT,WB), (LT,WC), (LU,VA), (LU,VB), (LU,VC), (LU,VD), (LU,VE), (LU,VF), (LU,VG), (LU,VH), (LU,VI), (LU,VJ), (LU,VK), (LU,VL), (LU,VM), (LU,VN), (LU,VO), (LU,VP), (LU,VQ), (LU,VR), (LU,VS), (LU,VT), (LU,VU), (LU,VV), (LU,VW), (LU,VX), (LU,VY), (LU,VZ), (LU,WA), (LU,WB), (LU,WC), (LV,VA), (LV,VB), (LV,VC), (LV,VD), (LV,VE), (LP,VF), (LV,VG), (LV,VH), (LV,VI), (LV,VJ), (LV,VK), (LP,VL), (LV,VM), (LV,VN), (LV,VO), (LV,VP), (LV,VQ), (LV,VR), (LV,VS), (LV,VT), (LV,VU), (LV,VV), (LV,VW), (LV,VX), (LV,VY), (LV,VZ), (LV,WA), (LV,WB), (LV,WC), (LW,VA), (LW,VB), (LW,VC), (LW,VD), (LW,VE), (LW,VF), (LW,VG), (LW,VH), (LW,VI), (LW,VJ), (LW,VK), (LW,VL), (LW,VM), (LW,VN), (LW,VO), (LW,VP), (LW,VQ), (LW,VR), (LW,VS), (LW,VT), (LW,VU), (LW,VV), (LW,VW), (LW,VX), (LW,VY), (LW,VZ), (LW,WA), (LW,WB), (LW,WC), (LX,VA), (LX,VB), (LX,VC), (LX,VD), (LX,VE), (LX,VF), (LX,VG), (LX,VH), (LX,VI), (LX,VJ), (LX,VK), (LX,VL), (LX,VM), (LX,VN), (LX,VO), (LX,VP), (LX,VQ), (LX,VR), (LX,VS), (LX,VT), (LX,VU), (LX,VV), (LX,VW), (LX,VX), (LX,VY), (LW,VZ), (LX,WA), (LX,WB), (LX,WC), (LY,VA), (LY,VB), (LY,VC), (LY,VD), (LY,VE), (LY,VF), (LY,VG), (LY,VH), (LY,VI), (LY,VJ), (LY,VK), (LY,VL), (LY,VM), (LY,VN), (LY,VO), (LY,VP), (LY,VQ), (LY,VR), (LY,VS), (LY,VT), (LY,VU), (LY,VV), (LY,VW), (LY,VX), (LY,VY), (LY,VZ), (LY, WAX (LY,WB), (LY,WC), (LZ,VA), (LZ,VB), (LZ,VC), (LZ,VD), (LZ,VE), (LZ,VF), (LZ,VG), (LZ,VH), (LZ,VI), (LZ,VJ), (LZ,VK), (LZ,VL), (LZ,VM), (LZ,VN), (LZ,VO), (LZ,VP), (LZ,VQ), (LZ,VR), (LZ,VS), (LZ,VT), (LZ,VU), (LZ,VV), (LZ,VW), (LZ,VX), (LZ,VY), (LZ,VZ), (LZ,WA), (LZ,WB), (LZ,WC),
(MA,VA), (MA,VB), (MA,VC), (MA,VD), (MA,VE), (MA,VF), (MA,VG), (MG,VH), (MA,VI), (MA,VJ), (MG,VK), (MA,VL), (MA,VM), (MA,VN), (MA,VO), (MA,VP), (MA,VQ), (MA,VR), (MA,VS), (MA,VT), (MA,VU), (MA,VV), (MA,VW), (MA,VX), (MA,VY), (MA,VZ), (MA,WA), (MA,WB), (MA,WC), (MB,VA), (MB,VB), (MB,VC), (MB,VD), (MB,VE), (MB,VF), (MB,VG), (MB,VH), (MB,VI), (MB,VJ), (MB,VK), (MB,VL), (MB,VM), (MB,VN), (MB,VO), (MB,VP), (MB,VQ), (MB,VR), (MB,VS), (MB,VT), (MB,VU), (MB,VV), (MB,VW), (MB,VX), (MB,VY), (MB,VZ), (MB,WA), (MB,WB), (MB,WC), (MC,VA), (MC,VA), (MC,VB), (MC,VB), (MC,VC), (MC,VD), (MC,VE), (MC,VF), (MC,VG), (MC,VH), (MC,VI), (MC,VJ), (MC,VK), (MC,VL), (MC,VM), (MC,VN), (MC,VO), (MC,VP), (MC,VQ), (MC,VR), (MC,VS), (MC,VT), (MC,VU), (MC,VV), (MC,VW), (MC,VX), (MC,VY), (MC,VZ), (MC,WA), (MC,WB), (MC,WC), (MD,VC), (MD,VD), (MD,VE), (MD,VF), (MD,VG), (MD,VH), (MD,VI), (MD,VJ), (MD,VK), (MD,VL), (MD,VM), (MD,VN), (MD,VO), (MD,VP), (MD,VQ), (MD,VR), (MD,VS), (MD,VT), (MD,VU), (MD,VV), (MD,VW), (MD,VX), (MD,VY), (MD,VZ), (MD,WA), (MD,WB), (MD,WC), (ME,VA), (ME,VB), (ME,VC), (ME,VD), (ME,VE), (ME,VF), (ME,VG), (ME,VH), (ME,VI), (ME,VJ), (ME,VK), (ME,VL), (ME,VM), (ME,VN), (ME,VO), (ME,VP), (ME,VQ), (ME,VR), (ME,VS), (ME,VT), (ME,VU), (ME,VV), (ME,VW), (ME,VX), (ME,VY), (ME,VZ), (ME,WA), (ME,WB), (ME,WC), (MF,VA), (MF,VB), (MF,VC), (MF,VD), (MF,VE), (MF,VF), (MF,VG), (MF,VH), (MF,VI), (MF,VJ), (MF,VK), (MF,VL), (MF,VM), (MF,VN), (MF,VO), (MF,VP), (MF,VQ), (MF,VR), (MF,VS), (MF,VT), (MF,VU), (MF,VV), (MF,VW), (MF,VX), (MF,VY), (MF,VZ), (MF,WA), (MF,WB), (MF,WC), (MG,VA), (MG,VB), (MG,VC), (MG,VD), (MG,VE), (MG,VF), (MG,VG), (MG,VH), (MG,VI), (MG,VJ), (MG,VK), (MG,VL), (MG,VM), (MG,VN), (MG,VO), (MG,VP), (MG,VQ), (MG,VR), (MG,VS), (MG,VT), (MG,VU), (ME,VV), (MG,VW), (MG,VX), (MG,VY), (MG,VZ), (MG,WA), (MG,WB), (MG,WC), (MH,VA), (MH,VB), (MH,VC), (MH,VD), (MH,VE), (MH,VF), (MH,VG), (MH,VH), (MH,VI), (MH,VJ), (MH,VK), (MH,VL), (MH,VM), (MH,VN), (MH,VO), (MH,VP), (MH,VQ), (MH,VR), (MH,VS), (MH,VT), (MH,VU), (MH,VV), (MH,VW), (MH,VX), (MH,VY), (MH,VZ), (MH,WA), (MH,WB), (MH,WC), (MI,VA), (MI,VB), (MI,VC), (MI,VD), (MI,VE), (MI,VF), (MI,VG), (MI,VH), (MI,VI), (MI,VJ), (MI,VK), (MI,VL), (MI,VM), (MI,VN), (MI,VO), (MI,VP), (MI,VQ), (MI,VR), (MI,VS), (MI,VT), (MI,VU), (MI,VV), (MI,VW), (MI,VX), (MI,VY), (MI,VZ), (MJ,WA), (MI,WB), (MI,WC), (MJ,VA), (MJ,VB), (MJ,VC), (MJ,VD), (MJ,VE), (MI,VF), (MJ,VG), (MJ,VH), (MJ,VI), (MJ,VJ), (MJ,VK), (MJ,VM), (MJ,VN), (MJ,VO), (MJ,VP), (MJ,VQ), (MJ,VR), (MJ,VS), (MF,VT), (MJ,VU), (MJ,VV), (MJ,VW), (MJ,VX), (MF,VY), (MF,VZ), (MJ,WA), (MJ,WB), (MJ,WC), (MK,VA), (MK,VB), (MK,VC), (MK,VD), (MK,VE), (MK,VF), (MK,VG), (MK,VH), (MK,VI), (MK,VJ), (MK,VK), (MK,VL), (MK,VM), (MK,VN), (MK,VO), (MK,VP), (MK,VQ), (MK,VR), (MK,VS), (MK,VT), (MK,VU), (MK,VV), (MK,VW), (MK,VX), (MK,VY), (MK,VZ), (MK,WA), (MK,WB), (MK,WC), (ML,VA), (ML,VB), (ML,VC), (ML,VD), (ML,VE), (ML,VF), (ML,VG), (ML,VH), (ML,VI), (ML,VJ), (ML,VK), (ML,VL), (ML,VM), (ML,VN), (ML,VO), (ML,VP), (ML,VQ), (ML,VR), (ML,VS), (ML,VT), (ML,VU), (ML,VV), (ML,VW), (ML,VX), (ML,VY), (ML,VZ), (ML,WA), (ML,WB), (ML,WC), (MM,VA), (MM,VB), (MM,VC), (MM,VD), (MM,VE), (MM,VF), (MM,VG), (MM,VH), (MM,VI), (MM,VJ), (MM,VK), (MM,VL), (MM,VM), (MM,VN), (MM,VO), (MM,VP), (MM,VQ), (MM,VR), (MM,VS), (MM,VT), (MM,VU), (MM,VV), (MM,VW), (MM,VX), (MM,VY), (MM,VZ), (MM,WA), (MM,WB), (MM,WC), (MN,VA), (MN,VB), (MN,VC), (MN,VD), (MN,VE), (MN,VF), (MN,VG), (MN,VH), (MN,VI), (MN,VJ), (MN,VK), (MN,VL), (MN,VM), (MN,VN), (MN,VO), (MN,VP), (MN,VQ), (MN,VR), (MN,VS), (MN,VT), (MN,VU), (MN,VV), (MN,VW), (MN,VX), (MN,VY), (MN,VZ), (MN,WA), (MN,WB), (MN,WC)
As used herein, the “emesis, vomiting and/or constipation” includes nausea, emesis, vomiting and/or constipation which are induced by ingestion of a compound having the opioid receptor (particularly, opioid receptor) agonistic activity. Specifically, examples of the “compound having the opioid receptor agonistic activity” include morphine, oxycodone, fentanyl, methadone, codeine, dihydrocodeine, hydromorphone, levorphanol, meperidine, propoxyphene, dextropropoxyphen, tramadol, and a pharmaceutically acceptable salt, or a solvate thereof. Particularly, when the compound is morphine, oxycodone, or a pharmaceutically acceptable salt, or a solvate thereof, the present compound is particularly effective.
Influence of the present compound on emesis or vomiting can be confirmed, for example, by the following test.
At thirty minutes after ingestion of a diet, each test substance is administered to a ferret. The test compound is dissolved in 5% xylitol, and is administered at 5 mg/kg. At thirty minutes after administration of the test compound, 0.6 mg/kg of morphine was subcutaneously administered, and the vomiting symptom is observed visually until 30 minutes after administration of morphine.
For each of emesis (rhythmic constriction movement at an abdominal part) and vomiting (vomiting conduct of excreting a vomiting substance or a similar conduct), an appearance time, a latent time (time from morphine administration to initial appearance of vomiting symptom) and a sustaining time (time from initial vomiting to final vomiting) are collected.
In addition, influence of the present compound on constipation can be confirmed, for example, by the following test.
1) Preparation of Test Diet (Dye)
Using a 0.5 w/v % Evans Blue aqueous solution, a 2.5 w/v % carboxymethylcellulose salt solution is prepared, and this is used as a test diet.
2) Animal
For example, a Wistar male rat (6 to 7 week old) may be used. The animal is fasted from about 20 or more hours before test initiation, and water is given ad lib.
3) Test Compound and Medium
The test compound is dissolved in a solvent (DMAA/Solutol/5% meglumine=15/15/70).
DMAA: N,N-dimethylacetamide
Solutol (registered trademark) HS15
Meglumine: D(−)-N-methylglucamine
Morphine hydrochloride is dissolved in a physiological saline.
The test compound, the solvent and morphine are all administered at a liquid amount of 2 mL/kg.
4) Method
The test compound 0.03, 0.1, 0.3, 1 or 3 mg/kg (test compound administration group) or the solvent (solvent administration group) is subcutaneously administered, and amount of 3 mg/kg of morphine is subcutaneously administered to all groups after 75 minutes. As a control group, the solvent is subcutaneously administered, and a physiological saline is administered after 75 minutes.
The test diet 2 mL/rat is orally administered at 30 minutes after administration of morphine. At fifteen minutes after the test diet (at 120 minutes after administration of the test substance), the rats are isolated from esophagus to an ileocecal part near a stomach cardia part. A distance from pyloric part of the stomach to an ileocecal part (full length of small intestine) and a distance until a dye reaching front part (dye movement distance) are measured.
5) Data Processing
Transport rate (%)=(dye movement distance (cm))/full length of small intestine (cm))×100
M.P.E. (%)={(small intestine transport rate (%) of each individual of test compound administration group−average small intestine transport rate (%) of solvent administration group)/(average small intestine transport rate (%) of control group−average small intestine transport rate (%) of solvent administration group)}×100
An ED50 value is calculated by reverse estimation of regression a SAS program using % MPE and letting a value of a control group to be 100%.
The present compound has the opioid receptor (particularly, opioid 8 and μ receptors) antagonistic activity. Therefore, the present compound is effective in treating and/or preventing digestive tract passage disorder which occurs by a cause such as acute dyspepsia, acute alcoholism, food poisoning, cold, stomach ulcer, duodenum ulcer, stomach cancer, ileus, appendicitis, peritonitis, cholelithiasis, hepatitis, liver inflammation, encephalitis, meningitis, increased brain pressure, head trauma, motion sickness, vomiting of pregnancy, side effect due to chemotherapy, side effect due to radiation therapy, side effect due to anti-cancer agent, pressure-stenosis of digestive tract, and intestinal tract coalescence after operation, treating and/or preventing emesis and vomiting which occurs by a cause such as increase in brain pressure due to brain tumor-brain bleeding-meningitis-irradiation of brain with radiation, and treating and/or preventing acute constipation derived from a cause such as ileus, duodenum ulcer or appendicitis, relaxing constipation derived from a cause such as nervous disorder, low nutrient, general prostration, vitamin deficiency, anemia, sensitivity reduction or mechanical stimulation insufficiency, or convulsive constipation derived from a cause such as stress, in addition to emesis-vomiting-constipation induced by a compound having the opioid receptor agonistic activity.
Since the present compound has low brain transition, it exhibits the high alleviating effect on a side effect such as emesis, vomiting, constipation and the like induced by an opioid receptor agonistic activity almost without inhibiting the analgesic activity of a compound having the opioid receptor agonistic activity which is administered to the patient with a decease accompanying pain (e.g. cancerous pain (pain due to bone transition, nervous pressure, increased intracranial pressure, soft tissue infiltration, pain due to constipation or spasm of muscle, pain of internal organ, muscle, fascia, waist or shoulder joint periphery, chronic pain after operation), AIDS etc.). In addition, the present compound has pure antagonistic activity on an opioid receptor, and also has an advantage in safety point that the hERG channel inhibitory activity is low, there is no cardiac toxicity, and so on. Further, the present compound also has an advantageous characteristic in dynamics in a body such as high oral absorbability, high stability in human plasma, high bioavailability and the like, and is very effective as a medicament.
When the present compound is administered against emesis, vomiting, or constipation induced by a compound having the opioid receptor agonistic activity, the administration may be any of before, after or at the same time with administration of the compound having the opioid receptor agonistic activity. An administration interval between these two kinds of drugs is not particularly limited. For example, when the present compound is administered after administration of the compound having the opioid receptor agonistic activity, if the administration is immediately after to in about 3 days, preferably immediately after to in about 1 day from administration of the compound having the opioid receptor agonistic activity, the present compound works more effectively. In addition, when the present invention is administered before administration of the compound having the opioid receptor agonistic activity, if the administration is immediately before to before about 1 day, preferably immediately before to before about 12 hours from administration of the compound having the opioid receptor agonistic activity, the present compound works more effectively.
When the present compound is administered as an agent for treating and/or preventing emesis, vomiting and/or constipation, it may be used jointly with other agent for treating and/or preventing emesis, vomiting and/or constipation. For example, it is possible to administer the agent jointly with ondansetrone hydrochloride, adrenal cortical steroid (methylprednisolone, prednisolone, dexamethasone etc.), prochlorperazine, haloperidol, thymiperone, perphenazine, metoclopramide, domperidone, scopolamine, chlorpromazine hydrochloride, droperidol, stimulating laxative (sennoside, picosulfate sodium etc.), osmotic laxative (lactulose etc.), or salt laxative (magnesium oxide etc.).
Alternatively, a combination agent between the present compound and a compound having the opioid receptor agonistic activity, or a combination agent between the present compound and other agent for treating and/or preventing emesis, vomiting and/or constipation can be administered.
When the present compound is administered to a human, it can be administered orally as powders, granules, tablets, capsules, pills, solutions, or the like, or parenterally as injectables, suppositories, transdermal absorbable agents, absorbable agents, or the like. Oral agents are preferable.
In addition, the present compound can be formulated into pharmaceutical preparations by adding pharmaceutical additives such as excipients, binders, wetting agents, disintegrating agents, lubricants and the like, which are suitable for formulations and, an effective amount of the present compound.
The present compound may be formulated into medical mixtures in which a compound having the opioid receptor agonistic activity and/or other agent for treating and/or preventing emesis, vomiting and/or constipation and, if necessary, various pharmaceutical additives.
A dose is different depending on state of a disease, an administration route, and an age and a weight of a patient, and is usually 0.1 μg to 1 g/day, preferably 0.01 to 200 mg/day when orally administered to an adult, and is usually 0.1 μg to 10 g/day, preferably 0.1 to 2 g/day when parenterally administered.
Following Examples and Test Examples illustrate the present invention in more detail, but the present invention is not limited by these Examples.
Example 1 Production of Compound (I-4)
Figure USRE046375-20170425-C00132

wherein Bn indicates benzyl, Et indicates ethyl, and Pri indicates isopropyl.
(First step) 7-Ethoxycarbonylnaltrexone
To a suspension of 3-O-benzyl-7-ethoxycarbonylnaltrexone described in Non-Patent Literature 2 (11.16 g, 22.15 mmol) in ethyl acetate (50 mL) and methanol (50 mL) was added palladium hydroxide (Perlman's catalyst) (1.2 g), and the mixture was vigorously stirred for 2 hours under a hydrogen atmosphere. After filtration of the catalyst, the filtrate was concentrated, and the residue was crystallized from ethyl acetate and hexane to obtain 8.96 g (92%) of the title compound as colorless crystals.
NMR (300 MHz, CDCl3)
δ 0.14-0.17 (m, 2H), 0.55-0.58 (m, 2H), 0.86 (m, 1H), 1.23-1.29 (m, 3H), 1.67 (d, 1H, J=9.6 Hz), 2.02 (dd, 1H, J=1.2, 16.2 Hz), 2.20-2.79 (m, 8H), 3.08 (d, 1H, J=18.6 Hz), 3.24 (br, 1H), 4.12-4.20 (m, 2H), 4.96 (s, 1H), 5.17 (br, 1H), 6.59 (d, 1H, J=8.1 Hz), 6.72 (d, 1H, J=8.1 Hz), 12.12 (s, 1H).
Elemental analysis (C23H27NO6.0.2H2O)
(Calculated value) C, 66.24; H, 6.62; N, 3.36.
(Found value) C, 66.29; H, 6.50; N, 3.45.
(Second step) 7-Isopropylaminocarbonylnaltrexone
A solution of 7-ethoxycarbonylnaltrexone obtained in the first step (200 mg, 0.484 mmol), isopropylamine (0.412 mL, 4.84 mmol) and triethylamine (0.202 mL, 1.45 mmol) in 2-methoxyethanol (1.5 mL) was stirred at 180° C. for 45 minutes under microwave irradiation. After cooled to room temperature, 7 mL of 5 mol/L hydrochloric acid was added to the reaction mixture, and stirring was continued at 70° C. for 20 minutes. After the reaction solution was cooled, pH value was adjusted to 8.5 with aqueous ammonia, followed by extraction with ethyl acetate. The organic layer was washed with water, and dried, and the solvent was evaporated. The residue was purified by silica gel column chromatography (chloroform:methanol=99:1 to 94:6) to obtain 140 mg of the title compound at a yield of 68%.
NMR (300 MHz, d6-DMSO)
δ 0.12-0.15 (m, 2H), 0.44-0.53 (m, 2H), 0.83 (m, 1H), 1.02 (d, 3H, J=6.6 Hz), 1.08 (d, 3H, J=6.6 Hz), 1.41 (d, 1H, J=11.4 Hz), 1.85 (d, 1H, J=15.6 Hz), 2.04-2.62 (m, 8H), 3.04 (d, 1H, J=18.6 Hz), 3.24 (m, 1H), 3.96 (m, 1H), 4.71 (s, 1H), 4.74 (s, 1H), 6.51 (d, 1H, J=8.4 Hz), 6.56 (d, 1H, J=8.4 Hz), 7.40 (br d, 1H, J=7.2 Hz), 9.16 (s, 1H), 14.50 (s, 1H).
Elemental analysis (C24H30N2O5.0.2H2O)
(Calculated value) C, 67.02; H, 7.12; N, 6.51
(Found value) C, 67.02; H, 7.20; N, 6.49.
Example 2 Preparation of Compound (I-44)
Figure USRE046375-20170425-C00133

wherein Bn indicates benzyl, Me indicates methyl, Et indicates ethyl, and Pri indicates isopropyl.
(First step) 3-O-Benzyl-7-ethoxycarbonyl-6-O-methylnaltrexone
To a solution of 3-O-benzyl-7-ethoxycarbonylnaltrexone described in Non-Patent Literature 2 (504 mg, 1 mmol) in tetrahydrofuran (10 mL) were successively added 1,1′-azodicarbonylpiperidine (379 mg, 1.5 mmol), tri-n-butylphosphine (370 μL, 1.5 mmol) and methanol (41 μl, 1 mmol), and the mixture was stirred at room temperature for 7 hours. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate) to obtain the title compound (421 mg, 81%) as colorless oil.
1H NMR (CDCl3, δ ppm): 0.10-0.20 (m, 2H), 0.50-0.65 (m, 2H), 0.88 (m, 1H), 1.26 (t, J=6.6 Hz, 3H), 1.67 (d, J=11.4 Hz, 1H), 2.15-2.80 (m, 8H), 3.00-3.30 (m, 2H), 3.93 (s, 3H), 4.05-4.20 (m, 2H), 4.86 (br s, 1H), 5.15 (s, 2H), 5.18 (br s, 1H), 6.57 (d, J=8.1 Hz, 1H), 6.72 (d, J=8.1 Hz, 1H), 7.28-7.45 (m, 5H)
(Second step) 3-O-Benzyl-7-isopropylaminocarbonyl-6-O-methylnaltrexone
To a mixed solution of 3-O-benzyl-7-ethoxycarbonyl-6-O-methylnaltrexone obtained in the first step (145 mg, 0.28 mmol) in methanol (6 mL) and dioxane (2 mL) was added a 50% potassium hydroxide aqueous solution (2 mL), and the mixture was stirred at 50° C. for 30 minutes. The reaction solution was cooled to room temperature, and adjusted to pH=4 with 0.5M an aqueous citric acid solution, followed by extraction with ethyl acetate. The organic layer was successively washed with water, brinebrine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The resulting crystalline residue, 3-O-benzyl-7-carboxy-6-O-methylnaltrexone was used in the next reaction without purification. To a solution of the above residue in dimethylformamide (3 mL) were successively added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (40 mg, 0.2 mmol), 1-hydroxybenzotriazole (27 mg, 0.2 mmol) and isopropylamine (16 μL, 0.182 mmol), and the mixture was stirred at room temperature for 15 hours. The reaction solution was poured into water and this was extracted with ethyl acetate, and the organic layer was washed with water, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=9/1) to obtain the title compound (39 mg, 44%) as a colorless foam.
1H NMR (CDCl3, δ ppm): 0.10-0.20 (m, 2H), 0.50-0.65 (m, 2H), 0.88 (m, 1H), 1.13 (d, J=2.1 Hz, 3H), 1.15 (d, J=1.8 Hz, 3H), 1.58 (d, J=11.4 Hz, 1H), 2.08-2.80 (m, 8H), 2.99-3.30 (m, 2H), 3.94 (s, 3H), 4.06 (m, 1H), 4.83 (br s, 1H), 5.14 (d, J=2.4 Hz, 2H), 5.23 (br s, 1H), 6.56 (d, J=8.4 Hz, 1H), 6.72 (d, J=8.4 Hz, 1H), 7.28-7.45 (m, 6H)
(Third step) 7-Isopropylaminocarbonyl-6-O-methylnaltrexone
To a solution of 3-O-benzyl-7-isopropylaminocarbonyl-6-O-methylnaltrexone obtained in the second step (33 mg, 0.073 mmol) in tetrahydrofuran (5 mL) was added palladium hydroxide (33 mg), and the mixture was stirred for 1 hour under a hydrogen atmosphere. The reaction solution was filtered with Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=9/1) to obtain the title compound (13 mg, 41%) as a colorless foam.
1H NMR (CDCl3, δ ppm): 0.10-0.15 (m, 2H), 0.50-0.70 (m, 2H), 0.85 (m, 1H), 1.12 (d, J=0.9 Hz, 3H), 1.14 (d, J=0.9 Hz, 3H), 1.66 (d, J=11.4 Hz, 1H), 2.06-2.80 (m, 8H), 3.00-3.30 (m, 2H), 3.92 (s, 3H), 4.05 (M, 1H), 4.80 (br s, 1H), 5.26 (br s, 1H), 6.56 (d, J=8.1 Hz, 1H), 6.69 (d, J=8.1 Hz, 1H), 7.36 (d, J=7.8 Hz, 1H)
Example 3
Figure USRE046375-20170425-C00134

wherein Bn indicates benzyl, Me indicates methyl, and Et indicates ethyl.
(First Step)
A solution of compound (1) (28.7 g, 57.0 mmol) in tetrahydrofuran (250 mL) was cooled to −10° C. and to the solution were 1,1′-azodicarbonylpiperidine (21.6 g, 85.5 mol), tri-n-butylphosphine (21.4 mL, 85.5 mmol) and benzyl alcohol (6.50 mL, 62.7 mmol) successively added, and the mixture was stirred at room temperature for 6 hours and 45 minutes. The reaction solution was filtered and the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform→chloroform/methanol=50/1) to obtain quantitatively the objective compound (2) (33.8 g) as a pale yellow oil.
1H NMR (CDCl3, δ ppm): 0.10-0.20 (m, 2H), 0.50-0.65 (m, 2H), 0.88 (m, 1H), 0.94 (t, J=7.2 Hz, 3H), 1.20-3.60 (m, 11H), 4.14 (q, J=7.2 Hz, 2H), 5.10-5.35 (m, 5H), 6.58 (d, J=8.1 Hz, 1H), 6.74 (d, J=8.1 Hz, 1H), 7.15-7.50 (m, 10H)
(Second Step)
To a mixed solution of compound (2) obtained in the first step (33.8 g, 57.0 mmol) in methanol (130 mL) and dioxane (43 mL) was added a 4N-potassium hydroxide aqueous solution (43 mL), and the mixture was stirred at 50° C. for 14 hours and 35 minutes. The reaction solution was cooled to room temperature, and concentrated under reduced pressure, and the residue was adjusted to pH=3 to 4 with ice-water and 2N-hydrochloric acid, followed by extraction with a mixed solution of ethyl acetate and tetrahydrofuran. The organic layer was successively washed with water, and brine, dried with anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was converted into a powder with ether to obtain the objective compound (3) (24.8 g, 77%) as a colorless powder.
1H NMR (DMSO-d6, δ ppm): 0.20-0.40 (m, 2H), 0.50-0.65 (m, 2H), 0.95 (m, 1H), 1.30-3.60 (m, 11H), 5.00-5.25 (m, 5H), 5.39 (s, 1H), 6.68 (d, J=8.1 Hz, 1H), 6.88 (d, J=8.1 Hz, 1H), 7.27-7.52 (m, 10H)
(Third Step)
To a solution of compound (3) obtained in the second step (350 mg, 0.619 mmol) in tetrahydrofuran (4 mL) were successively added 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (142 mg, 0.743 mmol), 1-hydroxybenzotriazole (100 mg, 0.743 mmoL), dimethylglycine methyl ester hydrochloride (114 mg, 0.743 mmol) and N-methylmorpholine (82 μL, 0.743 mmol), and the mixture was stirred at room temperature overnight. The reaction solution was poured into ice-water and a saturated sodium bicarbonate aqueous solution, followed by extracted with ethyl acetate, and the organic layer was washed with brine, dried with anhydrous sodium sulfate, and concentrated under the reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=50/1) to obtain the objective compound (4) (300 mg, 73%) as a pale yellow foam.
1H NMR (CDCl3, δ ppm): 0.08-0.20 (m, 2H), 0.50-0.60 (m, 2H), 0.87 (m, 1H), 1.13 (s, 3H), 1.22 (s, 3H), 1.55-2.80 (m, 11H), 3.62 (s, 3H), 4.85 (br s, 1H), 5.13-5.40 (m, 5H), 6.58 (d, J=8.4 Hz, 1H), 6.76 (d, J=8.4 Hz, 1H), 7.26-7.48 (m, 10H), 7.94 (s, 1H)
(Fourth Step)
To a solution of compound (4) obtained in the third step (290 mg, 0.436 mmol) in methanol (4 mL) was added palladium hydroxide (60 mg), followed by stirring for 3 hours under a hydrogen atmosphere. The reaction solution was filtered with Celite, and the filtrate was concentrated under reduced pressure. The residue was crystallized with hexane/ethyl acetate to obtain the objective compound (I-49) (181 mg, 86%) as colorless crystals.
1H NMR (DMSO-d6, δ ppm): 0.10-0.20 (m, 2H), 0.40-0.57 (m, 2H), 0.84 (m, 1H), 1.33 (s, 3H), 1.37 (s, 3H), 1.40-3.40 (m, 11H), 3.55 (s, 3H), 4.72 (s, 1H), 4.77 (br s, 1H), 6.52 (d, J=8.1 Hz, 1H), 6.57 (d, J=8.1 Hz, 1H), 7.68 (br s, 1H), 9.18 (br s, 1H), 13.78 (br s, 1H)
According to the same procedure, other compounds (I) can be synthesized. Structural formulas and physical constants are shown below.
In Tables, Me indicates methyl, Et indicates ethyl, Pri indicates isopropyl, and Ph indicates phenyl.
In addition, in Tables,
Figure USRE046375-20170425-C00135
TABLE 9
Compound
No. Chemical structure NMR (1H-NMR (d6-DMSO) δ)
I-1
Figure USRE046375-20170425-C00136
0.10-0.25 (m, 2H), 0.50-0.60 (m, 2H), 1.87 (m, 1H), 1.13 (t, J = 7.2 Hz, 3H), 1.68 (d, J = 11.4 Hz, 1H), 2.20-2.80 (m, 7H), 3.00-3.35 (m, 5H), 4.94 (s, 1H), 5.40 (m, 1H), 6.57 (d, J = 8.1 Hz, 1H), 6.72 (d, J= 8.1 Hz, 1H), 14.20 8br s, 1H)
I-2
Figure USRE046375-20170425-C00137
0.10-0.20 (m, 2H), 0.40-0.60 (m, 2H), 0.85 (m, 1H), 1.41 (d, J = 11.4 Hz, 1H), 1.90-3.40 (m, 14H), 4.71 (s, 1H), 4.73 (br s, 1H), 6.50 (d, J = 8.1 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 7.77 (br s, 1H)
I-3
Figure USRE046375-20170425-C00138
(CDCl3) 0.10-0.25 (m, 2H), 0.50-0.62 (m, 2H), 0.81-0.98 (m, 4H), 1.24- 1.74 (m, 6H), 2.21-2.77 (m, 7H), 3.05-3.30 (m, 5H), 4.93 (s, 1H), 5.40 (br t, 1H), 6.57 (d, J = 8.7 Hz, 1H), 14.21 (s, 1H).
I-4
Figure USRE046375-20170425-C00139
0.12-0.15 (m, 2H), 0.44-0.53 (m, 2H), 0.83 (m, 1H), 1.02 (d, 3H, J = 6.6 Hz), 1.08 (d, 3H, J = 6.6 Hz), 1.41 (d, 1H, J = 11.4 Hz), 1.85 (d, 1H, J = 15.6 Hz), 2.04-2.62 (m, 8H), 3.04 (d, 1H, J = 18.6 Hz), 3.24 (m, 1H), 3.96 (m, 1H), 4.71 (s, 1H), 4.74 (s, 1H), 6.51 (d, 1H, J = 8.4 Hz), 6.56 (d, 1H, J = 8.4 Hz), 7.40 (br d, 1H, J = 7.2 Hz), 9.16 (s, 1H), 14.50 (s,
I-5
Figure USRE046375-20170425-C00140
0.10-0.25 (m, 2H), 0.50-0.62 (m, 2H), 0.85 (m, 1H), 1.40-1.60 (m, 4H), 1.83-3.20 (m, 11H), 4.41 (br s, 1H), 4.72 (s, 1H), 4.74 (s, 1H), 6.51 (d, J = 8.7 Hz), 6.56 (d, J = 8.7 Hz, 1H), 7.70 (s, 1H), 9.15 (br s, 1H), 14.42 (s, 1H).
I-6
Figure USRE046375-20170425-C00141
0.10-0.25 (m, 2H), 0.50-0.62 (m, 2H), 0.85 (m, 1H), 1.42 (d, J = 11.7 Hz, 1H), 1.83-2.64 (m, 10H), 2.10 (s, 6H), 3.00-3.18 (m, 3H), 4.72 (s, 1H), 4.74 (s, 1H), 6.51 (d, J = 8.7 Hz), 6.56 (d, J = 8.7 Hz, 1H), 7.65 (s, 1H), 9.10 (br s, 1H).
I-7
Figure USRE046375-20170425-C00142
0.10-0.25 (m, 2H), 0.50-0.60 (m, 2H), 1.90 (m, 1H), 1.57 (dd, J = 2.4, 12.6 Hz, 2H), 1.85-2.80 (m, 10H), 3.00-3.25 (m, 3H), 3.35-3.60 (m, 3H), 4.20 (m, 1H), 4.76 (br s, 1H), 5.85 (br s, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 8.1 Hz, 1H)
TABLE 10
Compound
No. Chemical structure NMR (1H-NMR (d6-DMSO)δ)
I-8 
Figure USRE046375-20170425-C00143
0.10-0.20 (m, 2H), 0.45-0.68 (m, 2H), 1.88 (m, 1H), 1.35 (d, J = 11.4 Hz, 1H), 1.65-2.20 (m, 4H), 2.30-3.60 (m, 13H), 4.29 (dd, J = 4.8, 12.6 Hz, 1H), 5.08 (s, 1H), 5.23 (br s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 9.25 (br s, 1H)
I-9 
Figure USRE046375-20170425-C00144
(CDCl3) 0.10-0.25 (m, 2H), 0.50-0.62 (m, 2H), 0.85 (m, 1H), 1.62-2.77 (m, 6H), 3.07 (d, J = 18.6 Hz, 1H), 3.23 (d, J = 7.2 Hz, 1H), 4.42 (d, J = 5.4 Hz, 2H), 4.93 (s, 1H), 5.66 (br s, 1H), 6.55 (d, J = 8.7 Hz), 6.72 (d, J = 8.7 Hz, 1H), 7.22-7.39 (m, 5H), 14.15 (s, 1H).
I-10
Figure USRE046375-20170425-C00145
0.10-0.24 (m, 2H), 0.45-0.60 (m, 2H), 0.89 (m, 1H), 1.45 (d, J = 11.1 Hz, 1H), 1.70-3.40 (m, 10H), 4.78 (s, 1H), 4.82 (s, 1H), 6.54 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 7.05 (m, 1H), 7.29 (t, J = 7.8 Hz, 2H), 7.51 (d, J = 8.7 Hz, 2H), 9.14 (s, 1H), 9.24 (br s, 1H), 13.90 (br s, 1H)
I-11
Figure USRE046375-20170425-C00146
0.10-0.22 (m, 2H), 0.44-0.58 (m, 2H), 0.89 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.75-3.40 (m, 10H), 4.78 (s, 1H), 4.83 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J= 8.1 Hz, 1H),7.13 (t, J = 8.7 Hz, 2H), 7.48-7.56 (m, 2H), 9.17 (s, 1H), 9.27 (br s, 1H), 13.90 (br (s, 1H)
I-12
Figure USRE046375-20170425-C00147
0.10-0.18 (m, 2H), 0.52-0.60 (m, 2H), 0.80-0.98 (m, 2H), 0.98-3.21 (m, 26H), 4.41 (br, s, 1H), 4.70 (d, J = 12.3 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.65 (d, J= 8.1 Hz, 1H)
I-13
Figure USRE046375-20170425-C00148
0.10-0.25 (m, 2H), 0.50-0.60 (m, 2H), 0.87 (m, 1H), 1.58 (d, J = 111.7 Hz, 1H), 2.05-2.50 (m, 6H), 2.55-2.90 (m, 5H), 3.00-3.30 (m, 2H), 4.42 (s, 1H), 4.81-4.87 (m, 2H), 5.55 (br s, 1H), 6.60 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 7.20- 7.40 (m, 5H)
I-14
Figure USRE046375-20170425-C00149
0.10-0.22 (m, 2H), 0.45-0.60 (m, 2H), 0.90 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 2.10-3.40 (m, 10H), 3.78 (s, 3H), 4.96 (s, 1H), 6.36 (br s, 1H), 6.59 (d, J = 8.1 Hz, 1H), 6.73 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 9.0 Hz, 2H), 6.98 (br s, 1H), 7.29 (d, J = 9.0 Hz, 2H), 14.00 (br s, 1H)
TABLE 11
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-15
Figure USRE046375-20170425-C00150
0.05-0.20 (m, 2H), 0.45-0.60 (m, 2H),0.88(m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 2.00-3.35 (m, 10H), 3.78 (s, 3H), 4.34 (d, J = 5.1 Hz, 2H),4.91 (s, 1H), 5.61 (br s, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 8.1 Hz, 1H), 6.85 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 14.13 (brs, 1H)
I-16
Figure USRE046375-20170425-C00151
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.90 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.77 (s, 1H), 4.84 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.30-7.38 (m, 2H), 7.53-7.60 (m, 2H), 9.17 (s, 1H), 9.28 (br s, 1H), 13.80 (br s, 1H)
I-17
Figure USRE046375-20170425-C00152
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.89 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 13H), 4.77 (s, 1H), 4.82 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 9.17 (s, 1H), 9.27 (br s, 1), 13.90 (br s, 1H)
I-18
Figure USRE046375-20170425-C00153
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.89 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.85-3.40 (m, 10H), 3.80 (s, 3H), 4.81 (br s, 2H), 6.52 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.87 (m, 1H), 6.98-7.10 (m, 2H), 7.82 (m, 1H), 9.19 (s, 1H), 9.70 (br s, 1H), 12.90 (br s, 1H)
I-19
Figure USRE046375-20170425-C00154
I-20
Figure USRE046375-20170425-C00155
0.12-0.14 (d, J = 4.5 Hz, 2H), 0.46-0.52 (t, J = 8.3 Hz, 2H), 0.71-0.85 (m, 4H), 0.98-1.06 (dd, J = 6.8, 17.3 Hz, 4H), 1.35-1.45 (m, 4H), 1.82-1.92 (m, 2H), 2.44-2.61 (m), 3.04 (d, J = 18.9 Hz, 1H), 3.19-3.24 (m, 1H), 3.71-3.82 ( m, 1H), 4.71-4.76 (m, 2H), 6.50-6.57 (dd, J = 8.1, 14.4 Hz, 2H), 7.31-7.38 (m, 1H), 9.15 (br s, 1H), 14.52 (br s, 1H)
I-21
Figure USRE046375-20170425-C00156
0.12-0.14 (d, J = 4.2 Hz, 2H), 0.49 (t, J = 8.1 Hz, 2H), 0.69-0.86 (m, 6H), 1.32-1.47 (m, 5H), 1.88 (d, J = 15.3 Hz, 1H), 2.06-2.30 (m, 4H), 2.45-2.61 (m), 3.04 (d, J = 18.0 Hz, 1H), 3.19-3.24 (m, 1H), 4.71-4.75 (m, 2H), 6.05-6.58 (dd, J = 8.8, 14.4 Hz, 2H), 7.24 (d, J = 7.8 Hz, 1H), 9.15 (br s, 1H), 14.55 (br s, 1H)
TABLE 12
NMR
Compound No. Chemical structure (1H-NMR (d6-DMS O) δ)
I-22
Figure USRE046375-20170425-C00157
0.12-0.14 (d, J = 4.5 Hz, 2H), 0.49 (t, J = 8.1 Hz, 2H), 0.85 (m, 1H), 1.06 (m, 1H), 1.16-1.28 (m, 4H), 1.39-1.43 (d, J = 11.4 Hz, 1H), 1.54-1.70 (m, 6H), 1.84-1.89 (d, J = 15.6 Hz, 1H), 2.08-2.60 (m, 6H), 3.00-3.07 (d, J = 18.6 Hz, 1H), 3.17-3.24 (m, 1H), 3.60 (br s, 1H), 4.71-4.76 (m, 2H), 6.49-6.57 (dd, J = 8.1, 14.7 Hz, 2H), 7.37 (d, J = 9.0 Hz, 1H), 9.13 (br s, 1H), 14.47 (br s, 1H)
I-23
Figure USRE046375-20170425-C00158
0.12-0.14 (d, J = 4.5 Hz, 2H), 0.49 (t, J = 7.8 Hz, 2H), 0.83-0.92 (m, 4H), 1.19-1.70 (m, 9H), 1.83-1.93 (m, 1H), 2.06-2.61 (m, 9H), 3.01-3.07 (d, J = 18.3 Hz, 1H), 3.18-3.20 (d, J = 4.2 Hz, 1H), 3.67 (m, 1H), 4.71-4.76 (m, 2H), 6.52-6.55 (dd, J = 8.1, 14.4 Hz, 2H), 9.13 (br s, 1H), 14.48 (br s, 1H)
I-24
Figure USRE046375-20170425-C00159
0.12-0.14 (d, J = 4.5 Hz, 2H), 0.49 (t, J = 8.0 Hz, 2H), 0.83-0.87 (m, 1H), 1.34-1.55 (m, 12H), 1.84-1.89 (d, J = 15.6 Hz, 1H), 2.09-2.60 (m, 9H), 3.00-3.07 (d, J = 18.3 Hz, 1H), 3.17-3.19 (d, J = 6.0 Hz, 1H), 3.78-3.81 (m, 1H), 4.71-4.76 (m, 2H), 6.49-6.57 (dd, J = 8.1, 14.7 Hz, 2H), 7.39 (d, J = 8.1 Hz, 1H), 9.13 (br s, 1H), 14.46 (br s, 1H)
I-25
Figure USRE046375-20170425-C00160
0.13-0.14 (d, J = 4.5 Hz, 2H), 0.49 (t, J = 7.8 Hz, 2H), 0.85 (m, 1H), 1.39-1.43 (d, J = 11.1 Hz, 1H), 1.56-1.64 (m, 2H), 1.85-2.32 (m, 12H), 2.43-2.61 (m), 3.01-3.07 (d, J = 18.3 Hz, 1H), 3.18-3.20 (d, J = 6.0 Hz, 1H), 4.16-4.27 (m, 1H), 4.72-4.73 (m, 2H), 6.50-6.57 (dd, J = 8.1, 18.9 Hz, 2H), 7.77 (d, J = 7.5 Hz, 1H), 9.12 (br s, 1H), 14.41 (br s, 1H)
I-26
Figure USRE046375-20170425-C00161
0.16-0.19 (m, 2H), 0.48-0.57 (m, 2H), 0.88 (m, 1H), 1.46 (d, J = 11.2 Hz, 1H), 1.92 (d, J = 15.6 Hz, 1H), 2.04-2.66 (m, 6H), 3.08 (d, J = 18.8 Hz, 1H), 3.17-3.40 (m, 6H), 3.24 (s, 3H), 4.77 (s, 1H), 6.55 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 7.76 (br t, 1H), 9.15 (s, 1H), 14.33 (s, 1H).
I-27
Figure USRE046375-20170425-C00162
0.16-0.19 (m, 2H), 0.48-0..57 (m, 2H), 0.90 (m, 1H), 1.10 (t, J = 6.8 Hz, 3H), 1.46 (d, J = 11.2 Hz, 1H), 1.92 (d, J = 15.6 Hz, 1H), 2.04-2.66 (m, 6H), 3.08 (d, J = 18.8 Hz, 1H), 3.17-3.46 (m, 8H)? 4.77 (s, 1H), 6.55 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 7.77 (br, 1H), 9.15 (s, 1H), 14.32 (s, 1H).
I-28
Figure USRE046375-20170425-C00163
0.16-0.17 (m, 2H), 0.50-0.63 (m, 2H), 0.89 (m, 1H), 1.46 (d, J = 12.0 Hz, 1H), 1.92 (d, J = 15.2 Hz, 1H), 2.06 (s, 3H), 2.06-2.70 (m, 6H), 3.08 (d, J = 18.4 Hz, 1H), 3.20-3.32 (m, 6H), 4.77 (s, 1H), 6.55 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 7.76 (brs, 1H), 9.16 (s, 1H), 14.31 (s, 1H).
TABLE 13
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-29
Figure USRE046375-20170425-C00164
0.17-0.18 (m, 2H), 0.51-0.57 (m, 2H), 0.90 (m, 1H), 1.46 (d, J = 11.6 Hz, 1H), 1.93 (d, J = 16.0 Hz, 1H), 2.11-2.78 (m, 6H), 3.08 (d, J = 18.4 Hz, 1H), 3.21 (d, J = 6.0 Hz, 1H), 3.27-3.32 (m, 5H), 4.77 (s, 1H), 6.56 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 7.19-7.32 (m, 5H), 7.86 (br s, 1H), 9.16 (s, 1H), 14.38 (s, 1H).
I-30
Figure USRE046375-20170425-C00165
0.16-0.19 (m, 2H), 0.48-0.57 (m, 2H), 0.88 (m, 1H), 1.46, (d, J = 11.2 Hz, 1H), 1.94 (d, J = 15.6 Hz, 1H), 2.11-2.71 (m, 6H), 3.08 (d, J = 18.8 Hz, 1H), 3.49-3.51 (m, 2H), 3.96-4.4.05 (m, 2H), 4.79 (s, 1H), 6.56 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 8.0 Hz, 1H), 6.94-6.97 (m, 3H), 7.27-7.34 (m, 2H), 7.94 (br, 1H), 9.17 (s, 1H), 14.28 (s, 1H).
I-31
Figure USRE046375-20170425-C00166
0.10-0.28 (m, 2H), 0.44-0.65 (m, 2H), 0.94 (m, 1H), 1.50 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.72 (br s, 1H), 4.86 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.54-7.80 (m, 4H), 9.16 (s, 1H), 9.32 (s, 1H), 13.90 (br s, 1H)
I-32
Figure USRE046375-20170425-C00167
0.10-0.25 (m, 2H), 0.42-0.62 (m, 2H), 0.90 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.75 (br s, 1H), 4.84 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.41-7.54 (m, 4H), 9.17 (s, 1H), 9.28 (s, 1H), 13.85 (br s, 1H)
I-33
Figure USRE046375-20170425-C00168
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.90 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.77 (s, 1H), 4.81 (s, 1H), 5.98 (s, 2H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.82-6.95 (m, 2H), 7.15 (d, J = 1.8 Hz, 1H), 9.16 (s, 1H), 9.26 (s, 1H), 13.98 (br s, 1H)
I-34
Figure USRE046375-20170425-C00169
0.20-0.40 (m, 2H), 0.45-0.65 (m, 2H), 0.90 (m, 1H), 1.50 (m, 1H), 1.70-3.40 (m, 10H), 4.65 (br s, 1H), 4.88 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 7.60-7.80 (m, 4H), 9.17 (s, 1H ), 9.30 (s, 1H), 14.00 (br s, 1H)
I-35
Figure USRE046375-20170425-C00170
0.10-0.20 (m, 2H), 0.50-0.82 (m, 2H), 0.88 (m, 1H), 1.65 (d, J = 10.8 Hz, 1H), 2.00-3.80 (m, 14H), 3.78 (s, 3H), 4.93 (s, 1H), 5.46 (br s, 1H), 6.57 (d, J = 8.1 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 6.82 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 8.4 Hz, 2H), 14.17 (br s, 1H)
TABLE 14
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-36
Figure USRE046375-20170425-C00171
0.10-0.25 (m, 2H), 0.43-0.63 (m, 2H), 0.88 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 3.71 (s, 3H), 4.77 (s, 1H), 4.82 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.64 (m, 1H), 7.00-7.25 (m, 3H), 9.17 (s, 1H), 9.27 (s, 1H), 13.90 (br s, 1H)
I-37
Figure USRE046375-20170425-C00172
0.12-0.14 (d, J = 4.5 Hz, 2H), 0.49 (t, J = 8.1 Hz, 2H), 0.85 (m, 1H), 1.06 (m, 1H), 1.39-1.62 (m, 18H), 1.84-1.89 (d, J = 15.6 Hz, 1H), 2.08-2.34 (m, 5H), 2.43-2.54 (m), 2.58-2.60 (d, J = 6.9 Hz, 1H), 3.00-3.07 (d, J = 18.6 Hz, 1H), 3.18-3.20 (d, J = 6 Hz, 1H), 3.87 (br s, 1H), 4.71-4.76 (m, 2H), 6.49-6.57 (dd, J = 8.1, 14.7 Hz, 2H), 7.38 (d, J = 7.8 Hz, 1H), 9.13 (br s, 1H), 14.47 (br s, 1H)
I-38
Figure USRE046375-20170425-C00173
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.89 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 13H), 4.78 (s, 1H), 4.82 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 9.17 (s, 1H), 9.27 (s, 1H), 14.00 (br s, 1H)
I-39
Figure USRE046375-20170425-C00174
0.10-0.20 (m, 2H), 0.40-0.60 (m, 2H), 0.87 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 16H), 4.76 (s, 1H), 4.80 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 6.65 (d, J = 9.0 Hz, 2H), 7.29 (d, J = 9.0 Hz, 2H), 9.10 (br s, 2H), 14.20 (br s, 1H)
I-40
Figure USRE046375-20170425-C00175
0.10-0.30 (m, 2H), 0.45-0.65 (m, 2H), 0.90 (m, 1H), 1.48 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.77 (s, 1H), 4.85 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.25-7.35 (m, 2H), 7.64 (d, J = 9.0 Hz, 2H), 9.18 (s, 1H), 9.29 (s, 1H), 13.90 (br s,
TABLE 15
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-41
Figure USRE046375-20170425-C00176
0.20-0.40 (m, 2H), 0.45-0.70 (m, 2H), 0.96 (m, 1H), 1.50 (m, 1H), 1.70-3.40 (m, 13H), 4.67 (br s, 1H), 4.88 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 7.76 (s, 4H), 9.18 (s, 1H), 9.31 (s, 1H), 14.00 (br s, 1H)
I-42
Figure USRE046375-20170425-C00177
0.18 (br, s, 2H), 0.42-0.63 (m, 3H), 0.80-0.97 (m, 2H), 1.20-3.43 (m, 24H), 4.92 (s, 1H), 5.89 (br, s, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.71 (d, J = 7.8 Hz, 1H), 14.13 (br, s, 1H)
I-43
Figure USRE046375-20170425-C00178
0.12-0.19 (m, 2H), 0.41-0.58 (m, 2H), 0.74 (d, J = 3.3 Hz, 6H), 1.43 (m, 1H), 1.88-3.41 4.65-4.80 (m, 2H), 6.50-6.62 (m, 2H), 7.51 (br, s, 1H), 9.13 (s, 1H), 14.23 (br, s, 1H)
I-44
Figure USRE046375-20170425-C00179
0.10-0.15 (m, 2H), 0.50-0.70 (m, 2H), 0.85 (m, 1H), 1.12 (d, J = 0.9 Hz, 3H), 1.14 (d, J = 0.9 Hz, 3H), 1.66 (d, J = 11.4 Hz, 1H), 2.06-2.80 (m, 8H), 3.00-3.30 (m, 2H), 3.92 (s, 3H), 4.05 (m, 1H), 4.80 (br s, 1H), 5.26 (br s, 1H), 6.56 (d, J = 8.1 Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 7.36 (d, J = 7.8 Hz, 1H)
I-45
Figure USRE046375-20170425-C00180
TABLE 16
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-46
Figure USRE046375-20170425-C00181
0.15-0.35 (m, 2H), 0.45-0.70 (m, 2H), 0.92 (m, 1H), 1.50 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.72 (br s, 1H), 4.86 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.54-7.74 (m, 4H), 9.16 (s, 1H), 9.27 (s, 1H), 14.00 (br s, 1H)
I-47
Figure USRE046375-20170425-C00182
0.10-0.20 (m, 2H), 0.40-0.60 (m, 2H), 0.86 (m, 1H), 1.42 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 3.61 (s, 3H), 3.82 (d, J = 5.7 Hz, 2H), 4.77 (s, 2H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 8.21 (br t, J = 5.7 Hz, 1H), 9.17 (s, 1H), 13.87 (br s, 1H)
I-48
Figure USRE046375-20170425-C00183
0.10-0.20 (m, 2H), 0.50-0.65 (m, 2H), 0.89 (m, 1H), 0.90 (d, J = 4.5 Hz, 3H), 0.94 (d, J = 4.5 Hz, 3H), 1.45 (s, 9H), 1.66 (d, J = 10.8 Hz, 1H), 2.10-3.40 (m, 11H), 4.43 (dd, J = 4.5, 8.1 Hz, 1H), 4.94 (s, 1H), 6.00 (d, J = 8.1 Hz, 1H), 6.58 (d,
I-49
Figure USRE046375-20170425-C00184
0.10-0.30 (m, 2H), 0.45-0.70 (m, 2H), 0.90 (m, 1H), 1.34 (s, 3H), 1.38 (s, 3H), 1.50-3.40 (m, 11H), 3.56 (s, 3H), 4.77 (br s, 2H), 6.58 (br s, 2H), 7.69 (br s, 1H), 9.20 (br s, 1H), 13.76 (br s, 1H)
I-50
Figure USRE046375-20170425-C00185
0.10-0.20 (m, 2H), 0.40-0.60 (m, 2H), 0.88 (m, 1H), 1.44 (d, J = 11.7 Hz, 1H), 1.90-3.40 (m, 10H), 3.68 (d, J = 4.5 Hz, 2H), 4.77 (s, 1H), 6.52 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 8.00 (br, t, J = 4.5 hz, 1H), 9.18 (br s, 1H), 14.00 (br s, 1H)
TABLE 17
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-51
Figure USRE046375-20170425-C00186
0.30-0.50 (m, 2H), 0.55-0.75 (m, 2H), 0.89 (d, J = 3.3 Hz, 3H), 0.91 (d, J = 3.3 Hz, 3H), 1.04 (m, 1H), 1.65 (d, J = 13.5 Hz, 1H), 2.00-3.92 (m, 11H), 4.10 (t, J = 6.6 Hz, 1H), 4.95 (s, 1H), 6.64 (d, J = 8.1 Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 7.53 (d, J = 7.8 Hz, 9.43 (s, 1H) 13.66 (br s, 1H)
I-52
Figure USRE046375-20170425-C00187
0.10-0.25 (m, 2H), 0.45-0.60 (m, 2H), 0.89 (m, 1H), 1.34 (s, 3H), 1.36 (s, 3H), 1.46 (d, J = 9.6 Hz, 1H), 1.90-3.40 (m, 10H), 4.75 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 7.68 (s, 1H), 9.21 (br s, 1H), 14.11 (br s, 1H)
I-53
Figure USRE046375-20170425-C00188
0.13-0.14 (m, 2H), 0.47-0.49 (m, 2H), 0.88 (m, 1H), 1.30 (m, 1H), 1.63-2.10 (m, 6H), 2.30-2.70 (m, 4H), 2.96-3.58 (m, 6H), 4.06-4.23 (m, 3H), 5.04 (s, 1H), 5.23 (br, 1H), 6.54 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 8.08 (br, 1H), 9.23 (br, 1H) ..
I-54
Figure USRE046375-20170425-C00189
0.13-0.14 (m, 2H), 0.47-0.49 (m, 2H), 0.88 (m, 1H), 1.30 (d, J = 12.0 Hz, 1H), 1.63-2.12 (m, 6H), 2.28-2.70 (m, 4H), 2.97-3.53 (m, 6H), 4.06-4.23 (m, 3H), 5.06 (s, 1H), 5.22 (br, 1H), 6.54 (d, J = 8.0 Hz, 1H), 6.58 (d, J = 8.0 Hz, 1H), 8.13 (d, J = 6.4 Hz, 1H), 8.32 (s, 1H), 9.23 (br, 1H), 10.97 (s, 1H).
TABLE 18
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-55
Figure USRE046375-20170425-C00190
0.10-0.25 (m, 2H), 0.40-0.60 (m, 2H), 0.90 (m, 1H), 1.45 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.42 (s, 2H), 4.77 (s, 1H), 5.12 (s, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 7.23 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 9.20 (s, 1H), 9.28 (s, 1H), 14.00 (br s, 1H)
I-56
Figure USRE046375-20170425-C00191
0.10-0.40 (m, 2H), 0.45-0.70 (m, 2H), 0.92 (m, 1H), 1.29 (t, J = 7.2 Hz, 3H), 1.49 (d, J = 9.0 Hz, 1H), 1.70-3.40 (m, 10H), 4.26 (q, J = 7.2 Hz, 2H), 4.72 (br s, 1H), 4.86 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.59 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 9.0 Hz, 2H), 7.90 (d, J = 9.0 Hz, 2H), 9.18 (s, 1H), 9.29 (s, 1H)
I-57
Figure USRE046375-20170425-C00192
0.25-0.40 (m, 2H), 0.50-0.70 (m, 2H), 1.00 (m, 1H), 1.56 (d, J = 10.8 Hz, 1H), 1.70-3.40 (m, 10H), 4.87 (s, 1H), 4.92 (s, 1H), 6.59 (d, J = 8.1 Hz, 1H), 6.64 (d, J = 8.1 Hz, 1H), 7.68 (d, J = 8.4 Hz, 2H), 7.86 (d, J = 8.4 Hz, 2H), 9.33 (br s, 2H)
I-58
Figure USRE046375-20170425-C00193
0.08-0.20 (m, 2H), 0.43-0.57 (m, 2H), 0.88 (m, 1H), 1.22-3.40 (m, 11H), 4.76 (s, 1H), 4.84 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 6.62-6.81 (m, 3H), 7.06-7.16 (m, 2H), 7.73 (s, 1H), 9.16 (s, 1H), 9.61 (s, 1H), 13.80 (br s, 1H)
I-59
Figure USRE046375-20170425-C00194
0.08-0.10 (m, 2H), 0.38-0.58 (m, 2H), 0.86 (m, 1H), 1.22-3.40 (m, 17H), 4.71 (s, 2H), 6.51 (d, J = 8.1 Hz, 2H), 6.56 (d, J = 8.1 Hz, 1H), 8.58 (s, 1H), 9.15 (s, 1H), 14.30 (br s, 1H)
TABLE 19
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-60
Figure USRE046375-20170425-C00195
0.10-0.20 (m, 2H), 0.45-0.55 (m, 2H), 0.88 (m, 1H), 1.81 (t, J = 7.2 Hz, 3H), 1.20-3.75 (m, 20H), 4.07 (q, J = 7.2 Hz, 2H), 5.13 (s, 1H), 5.21 (br s, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.57 (d, J = 8.4 Hz, 1H), 9.21b (br s, 1H)
I-61
Figure USRE046375-20170425-C00196
0.11-0.39 (m, 2H), 0.53-0.70 (m, 2H), 0.95 (m, 1H), 1.10-1.20 (m, 3H), 1.66-1.73 (m, 1H), 1.82-3.99 (m, 24H), 4.90 (s, 1H), 6.32 (br, s, 1H), 6.56 (d, J = 8.4 Hz, 1H), 6.68-6.73 (m, 1H), 14.03 (br, s, 1H)
I-62
Figure USRE046375-20170425-C00197
0.10-0.18 (m, 2H), 0.42-0.56 (m, 2H), 0.85 (m, 1H), 1.03 (d, J = 6.9 Hz, 3H), 1.41 (m, 1H), 1.88 (d, J = 15.6 Hz, 1H), 2.04-2.31 (m, 4H), 2.42 2.62 (m, 6H), 3.04 (d, J = 18.0 Hz, 1H), 3.17-3.35 (m, 7H), 3.87 (m, 1H), 4.64 (t, J = 5.7 Hz, 1H), 4.72 (s, 1H), 6.50-6.57 (m, 2H), 7.27 (d, J = 8.1 Hz, 1H), 9.13 (s, 1H), 14.45 (s, 1H)
I-63
Figure USRE046375-20170425-C00198
0.13 (d, J = 4.2 Hz, 2H), 0.43-0.55 (m, 2H), 0.85 (m, 1H), 0.98 (d, J = 6.9 Hz, 3H), 1.41 (d, J = 10.8 Hz, 1H), 1.89 (d, J = 15.9 Hz, 1H), 2.04-2.32 (m, 4H), 2.43-2.63 (m, 3H), 3.04 (d, J = 18.3 Hz, 1H), 3.19-3.40 (m, 11H), 3.86 (m, 1H), 4.72 (s, 1H), 6.50-6.58 (m, 2H), 7.24 (m, 1H), 9.14 (s, 1H), 14.41 (br, s, 1H)
TABLE 20
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-64
Figure USRE046375-20170425-C00199
0.13 (d, J = 4.8 Hz, 2H), 0.43-0.55 (m, 2H), 0.85 (m, 1H), 1.41 (d, J = 12.3 Hz, 1H), 1.92 (d, J = 16.2 Hz, 1H), 2.06-2.32 (m, 4H), 2.43-2.61 (m, 3H), 3.04 (d, J = 18.3 Hz, 1H), 3.20 (d, J = 6.6 Hz, 1H), 3.33-3.44 (m, 4H), 3.82 (m, 1H), 4.59 (t, J = 5.7 Hz, 1H), 4.68 (t, J = 5.7 Hz, 1H), 4.73 (s, 2H), 6.50-6.59 (m, 2H), 7.14 (br, s, 1H), 9.14 (s, 1H), 14.33 (br, s, 1H)
I-65
Figure USRE046375-20170425-C00200
0.17-0.18 (m, 2H), 0.51-0.53 (m, 2H), 0.92 (m, 1H), 1.34 (m, 1H), 1.35 (br s, 9H), 1.71-3.49 (m, 14H), 3.95-4.20 (m, 3H), 5.10 (br, 1H), 5.26 (br, 1H), 6.57 (d, J = 8.4 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 7.10 (br, 1H), 8.35 (s, 1H), 9.24 (s, 1H).
I-66
Figure USRE046375-20170425-C00201
0.41 (m, 1H), 0.50 (m, 1H), 0.60 (m, 1H), 0.69 (m, 1H), 1.08 (m, 1H), 1.56 (m, 1H), 1.76-4.29 (m, 17H), 5.19 (s, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.71 (d, J = 8.0 Hz, 1H), 8.14 (br, 1H), 8.20 (br, 1H), 8.98 (br, 1H).
I-67
Figure USRE046375-20170425-C00202
0.41 (m, 1H), 0.50 (m, 1H), 0.59 (m, 1H), 0.69 (m, 1H), 1.09 (m, 1H), 1.30-4.29 (m, 18H), 5.19 (s, 1H), 5.75 (br, 1H), 6.66 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 8.21 (br, 1H), 8.26 (br, 1H), 8.99 (br, 1H).
TABLE 21
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-68
Figure USRE046375-20170425-C00203
0.17-0.18 (m, 2H), 0.51-0.53 (m, 2H), 0.92 (m, 1H), 1.34 (m, 1H), 1.43 (br s, 9H), 1.71-2.03 (m, 5H), 2.18-2.74 (m, 4H), 2.92-3.69 (m, 5H), 3.95-4.20 (m, 2H), 5.07 (s, 1H), 5.26 (br, 1H), 6.57 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 7.20 (br, 1H), 9.25 (s, 1H).
I-69
Figure USRE046375-20170425-C00204
0.10-0.26 (m, 2H), 0.42-0.60 (m, 2H), 0.90 (m, 1H), 1.47 (d, J = 10.5 Hz, 1H), 1.90-3.40 (m, 10H), 3.84 (s, 3H), 4.81 (br s, 1H), 6.52 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.80 (br s, 1H), 8.08 (br s, 1H), 9.18 (br s, 1H), 11.60 (br s, 1H)
I-70
Figure USRE046375-20170425-C00205
0.10-0.20 (m, 2H), 0.40-0.55 (m, 2H), 0.88 (m, 1H), 1.30-4.35 (m, 20H), 5.13 (s, 1H), 6.52 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 9.20 (br s, 1H)
I-71
Figure USRE046375-20170425-C00206
0.25-0.45 (m, 2H), 0.45-0.70 (m, 2H), 0.97 (m, 1H), 1.64 (d, J = 11.1 Hz, 1H), 2.00-3.40 (m, 10H), 4.07 (br s, 1H), 4.97 (s, 1H), 6.63 (d, J = 8.1 Hz, 1H), 6.68 (d, J = 8.1 Hz, 1H), 7.44 (d, J = 5.4 Hz, 1H), 7.80 (d, J = 5.4 Hz, 1H), 9.44 (br s, 1H), 13.40 (br s, 1H)
I-72
Figure USRE046375-20170425-C00207
0.14 (d, J = 4.5 Hz, 2H), 0.40-0.58 (m, 2H), 0.79-0.92 (m, 13H), 1.25 (br, s, 1H), 1.41 (m, 1H), 1.907 (s, 1H), 2.11-2.64 (m, 8H), 3.03 (m, 1H), 3.21-3.77 (m, 4H), 4.53 (br, s, 1H), 4.72-4.80 (m, 2H), 6.50-6.58 (m, 2H), 6.95-7.22 (m, 2H), 9.13 (s,
TABLE 22
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-73
Figure USRE046375-20170425-C00208
0.14 (d, J = 4.5 Hz, 2H), 0.40-0.58 (m, 3H), 0.74-1.01 (m, 10H), 1.25-1.61 (m, 4H), 1.88 (m, 1H), 2.06-2.62 (m, 8H), 3.03 (m, 1H), 3.21 (d, J = 6.0 Hz, 1H), 3.45 (t, J = 5.4 Hz, 2H), 3.68 (m, 1H), 4.57 (m, 1H), 4.72 (s, 1H), 4.76 (br, s, 1H), 6.51-6.58 (m, 2H), 7.14-7.27 (m, 2H), 9.15 (s, 1H), 14.44 (s, 1H)
I-74
Figure USRE046375-20170425-C00209
0.16-0.18 (m, 2H), 0.52 (br d, J = 7.6 Hz, 2H), 0.92 (m, 1H), 1.35 (d, J = 11.2 Hz, 1H), 1.72-3.48 (m, 16H), 4.11-4.29 (m, 3H), 4.73-5.25 (m, 2H), 6.57 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 9.23 (s, 1H), 11.16 (s, 1H).
I-75
Figure USRE046375-20170425-C00210
0.14-0.15 (m, 2H), 0.43-0.57 (m, 2H), 0.87 (m, 1H), 1.44 (d, J = 11.2 Hz, 1H), 1.97 (d, J = 15.6 Hz, 1H), 2.08-3.22 (m, 10H), 4.15-4.48 (m, 2H), 4.76 (s, 1H), 6.55 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 7.23-7.29 (m, 2H), 7.75 (m, 1H), 8.48-8.54 (m, 2H).
I-76
Figure USRE046375-20170425-C00211
0.16-0.17 (m, 2H), 0.50-0.56 (m, 2H), 0.89 (m, 1H), 1.43 (br d, 1H), 1.97 (d, J = 15.6 Hz, 1H), 2.11-3.21 (m, 10H), 4.30-4.46 (m, 2H), 4.77 (s, 1H), 6.56 (d, J = 8.0 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 7.29 (s, 2H), 7.44 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 8.42 (br, 1H), 9.17 (br, 1H), 14.19 (s, 1H).
TABLE 23
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-77
Figure USRE046375-20170425-C00212
0.10-0.25 (m, 2H), 0.44-0.60 (m, 2H), 0.88 (m, 1H), 1.45 (d, J = 11.1 Hz, 1H), 1.70-3.40 (m, 13H), 4.78 (s, 1H), 4.81 (s, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 9.0 Hz, 2H), 7.48 (d, J = 9.0 Hz, 2H), 9.15 (s, 1H), 9.25 (s, 1H), 9.88 (s, 1H), 14.00 (br s, 1H)
I-78
Figure USRE046375-20170425-C00213
0.10-0.25 (m, 2H), 0.44-0.60 (m, 2H), 0.89 (m, 1H), 1.17 (t, J = 7.2 Hz, 3H), 1.45 (d, J = 11.4 Hz, 1H), 1.70-3.40 (m, 10H), 3.60 (s, 2H), 4.06 (q, J = 7.2 Hz, 2H), 4.78 (s, 1H), 4.83 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.17 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 8.7 Hz, 2H), 9.16 (s, 1H), 9.26 (s, 1H), 13.95 (br s, 1H)
I-79
Figure USRE046375-20170425-C00214
0.12-0.30 (m, 2H), 0.44-0.62 (m, 2H), 0.90 (m, 1H), 1.48 (d, J = 11.4 Hz, 1H), 1.70-3.40 (m, 10H), 3.51 (s, 2H), 4.81 (s, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.60 (d, J = 8.1 Hz, 11-1), 7.17 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 9.20 (s, 1H), 9.40 (br s, 1H), 14.00 (br s, 1H)
I-80
Figure USRE046375-20170425-C00215
0.10-0.17 (m, 2H), 0.46-0.52 (m, 2H), 0.86 (m, 1H), 1.41 (d, J = 13.2 Hz, 1H), 1.87 (m, 1H), 2.09-2.64 (m, 8H), 3.00-3.50 (m, 15H), 4.57 (m, 1H), 4.73 (br, s, 2H), 6.50-6.57 (m, 2H), 7.73 (br, s, 1H), 9.14 (s, 1H), 14.38 (br, s,
I-81
Figure USRE046375-20170425-C00216
0.30-0.50 (m, 2H), 0.50-0.70 (m, 2H), 1.05 (m, 1H), 1.50-3.40 (m, 11H), 4.58 (s, 1H), 5.39 (s, 1H), 6.52 (d, J = 6.0 Hz, 1H), 6.59 (d, J = 6.0 Hz, 1H), 6.84 (br s, 1H), 7.26 (m, 1H), 7.38 (m, 1H), 9.15
TABLE 24
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-82
Figure USRE046375-20170425-C00217
1H-NMR (CDCl3 + CD3OD) d: 0.17 (brs, 2 H), 0.59 (brs, 2 H), 0.89 (brs, 1 H), 1.71 (d, J = 10.8 Hz, 1 H), 2.17 (d.d, J = 17.1 & 1.8 Hz, 1 H), 2.22- 2.57 (m, 4 H), 2.60-2.84 (m, 3 H), 3.06 (d, J = 15.6 Hz, 1 H), 3.24 (brs, 1 H), 4.07 (s, 3 H), 5.31 (s, 1 H), 6.56 (d, J = 8.4 Hz, 1 H), 6.67 (d, J = 8.4 Hz, 1 H), 7.02-7.10 (m, 1 H), 7.26-7.32 (m, 2 H), 7.39 (d.d, J = 8.4 & 0.9 Hz, 2 H), 9.61 (s, 1 H).
I-83
Figure USRE046375-20170425-C00218
1H-NMR (CDCI3 +30 CD30D) d: 0.15 (brs, 2 H), 0.58 (brs, 2 H), 0.88 (brs, 1 H), 1.49 (t, J = 6.9 Hz, 3 H), 1.68 (d, J = 9.9 Hz, 1 H), 2.15 (d.d, J = 17.1 & 1.5 Hz, 1 H),2.28 (brs, 2 H), 2.39 (brs, 2 H), 2.60-2.80 (m, 3 H), 3.06 (d, J = 18.3 Hz, 1 H), 3.26 (brs, 1 H), 4.29 (q, J = 6.9 Hz, 1 H), 4.48 (q, J = 6.9 Hz, 1 H), 5.27 (s, 1 H), 6.56 (d, J = 7.8 Hz, 1 H), 6.66 (d, J = 7.8 Hz, 1 H), 7.03-7.09 (m, 1 H), 7.26-7.31 (m, 2 H), 7.50 (d.d, J = 8.7 & 0.9 Hz, 2 H).
I-84
Figure USRE046375-20170425-C00219
1H-NMR (CDCl3 + CD3OD) d: 0.16 (brs, 2 H), 0.57 (brs, 2 H), 0.86 (brs, 1 H), 1.13 (d, J = 6.6 Hz, 3 H), 1.14 (d, J = 6.6 Hz, 3 H), 1.39 (t, J = 6.9 Hz, 3 H), 1.66 (d, J = 9.0 Hz, 1 H), 2.08 (d.d, J = 17.1 & 1.5 Hz, 1 H), 2.21 (brs, 2 H), 2.38 (brs, 2 H), 2.58-2.77 (m, 3 H), 3.03 (d, J = 18.6 Hz, 1 H), 3.21 (brs, 1 H), 4.03 (quint, J = 6.6 Hz, 1 H), 4.20 (q, J = 6.9 Hz, 1 H), 4.40 (q, J = 6.9 Hz, 1 H), 5.19 (s, 1 H), 6.54 (d, J = 8.1 Hz, 1 H), 6.65 (d, J = 8.1 Hz, 1 H), 7.50 (d, J = 7.5 Hz, 1 H).
TABLE 25
NMR
Compound No. Chemical structure (1H-NMR (d6-DMSO) δ)
I-85
Figure USRE046375-20170425-C00220
1H-NMR (CDCl3 + CD3OD) d: 0.14(brs, 2 H), 0.56 (brs, 2 H), 0.86 (brs, 1 H), 1.14 (d, J = 6.6 Hz, 3 H), 1.15 (d, J = 6.6 Hz, 3 H), 1.32 (d, J = 4.8 Hz, 1 H), 1.34 (d, J = 4.8 Hz, 3 H), 1.64 (d, J = 9.9 Hz, 1 H), 2.10 (d.d, J = 17.1 & 1.5 Hz, 1 H), 2.27 (brs, 2 H), 2.39 (brs, 2 H), 2.55-2.77 (m, 3 H), 3.04 (d, J = 18.3 Hz, 1 H), 3.22 (brs, 1 H), 4.03 (quint, J = 6.6 Hz, 1 H), 4.81 (quint, J = 6.0 Hz, 1 H), 5.10 (s, 1 H), 6.54 (d, J = 8.4 Hz, 1 H), 6.67 (d, J = 8.4 Hz, 1 H), 7.76 (d, J = 6.9 Hz, 1 H).
I-86
Figure USRE046375-20170425-C00221
1H-NMR (CDCl3 + CD3OD) d: 0.16 (brs, 2 H), 0.568 (brs, 2 H), 0.87 (brs, 1 H), 1.67 (d, J = 9.9 Hz, 1 H), 2.14 (d.d, J = 18.3 & 1.2 Hz, 1 H), 2.27 (brs, 2 H), 2.41 (brs, 2 H), 3.05 (d, J = 18.6 Hz, 1 H), 3.25 (brd, J = 4.5 Hz, 1 H), 3.92 (s, 1 H), 4.46 (d, J = 5.7 Hz, 2 H), 5.23 (s, 1 H), 6.54 (d, J = 8.1 Hz, 1 H), 6.64 (d, J = 8.1 Hz, 1 H), 7.20-7.36 (m, 5 H), 8.03 (brt, J = 5.7 Hz, 1 H).
I-87
Figure USRE046375-20170425-C00222
1H-NMR (CDCl3 + CD3OD) d: 0.26 (brs, 2 H), 0.63 (brs, 2 H), 0.94 (brs, 1 H), 1.72 (brd, J = 9.0 Hz, 1 H), 2.09-2.93 (m, 8 H), 3.15 (d, J = 18.9 Hz, 1 H), 4.97 (s, 1 H), 6.61 (d, J = 8.1 Hz, 1 H), 6.70 (d, J = 8.1 Hz, 1 H), 7.04-7.08 (m, 1 H), 7.69-7.75 (m, 1 H), 8.13 (d, J = 14.0 Hz, 2 H), 8.23 (d, J = 3.9 Hz, 1 H).
TABLE 26
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-89
Figure USRE046375-20170425-C00223
m/z 462 [M + H]+ 0.94 min
I-90
Figure USRE046375-20170425-C00224
m/z 511 [M + H]+ 0.63 min
I-91
Figure USRE046375-20170425-C00225
m/z 500 [M + H]+ 0.44 min
I-92
Figure USRE046375-20170425-C00226
m/z 462 [M + H]+ 0.44 min
I-93
Figure USRE046375-20170425-C00227
m/z 487 [M + H]+ 0.50 min
TABLE 27
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-94
Figure USRE046375-20170425-C00228
m/z 540 [M + H]+ 1.07 min
I-95
Figure USRE046375-20170425-C00229
m/z 537 [M + H]+ 1.12 min
I-96
Figure USRE046375-20170425-C00230
m/z 581 [M + H]+ 1.15 min
I-97
Figure USRE046375-20170425-C00231
m/z 512 [M + H]+ 0.50 min
I-98
Figure USRE046375-20170425-C00232
m/z 531 [M + H]+ 0.50 min
TABLE 28
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-99 
Figure USRE046375-20170425-C00233
m/z 537 [M + H]+ 1.17 min
I-100
Figure USRE046375-20170425-C00234
m/z 581 [M + H]+ 1.15 min
I-101
Figure USRE046375-20170425-C00235
m/z 581 [M + H]+ 1.03 min
I-102
Figure USRE046375-20170425-C00236
m/z 538 [M + H]+ 0.85 min
I-103
Figure USRE046375-20170425-C00237
m/z 540 [M + H]+ 1.05 min
TABLE 29
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
1-104
Figure USRE046375-20170425-C00238
m/z 581 [M + H]+ 1.12 min
1-105
Figure USRE046375-20170425-C00239
m/z 538 [M + H]+ 0.90 min
1-106
Figure USRE046375-20170425-C00240
m/z 537 [M + H]+ 1.05 min
1-107
Figure USRE046375-20170425-C00241
m/z 581 [M + H]+ 1.09 min
TABLE 30
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-108
Figure USRE046375-20170425-C00242
m/z 581 [M + H]+ 1.03 min
I-109
Figure USRE046375-20170425-C00243
m/z 488 [M + H]+ 0.50 min
I-110
Figure USRE046375-20170425-C00244
m/z 518 [M + H]+ 0.50 min
I-111
Figure USRE046375-20170425-C00245
m/z 518 [M + H]+ 0.56 min
I-112
Figure USRE046375-20170425-C00246
m/z 519 [M + H]+ 0.50 min
TABLE 31
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-113
Figure USRE046375-20170425-C00247
m/z 511 [M + H]+ 0.50 min
I-114
Figure USRE046375-20170425-C00248
m/z 486 [M + H]+ 0.57 min
I-115
Figure USRE046375-20170425-C00249
m/z 462 [M + H]+ 0.44 min
I-116
Figure USRE046375-20170425-C00250
m/z 497 [M + H]+ 0.63 min
I-117
Figure USRE046375-20170425-C00251
m/z 513 [M + H]+ 0.69 min
TABLE 32
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-118
Figure USRE046375-20170425-C00252
m/z 493 [M + H]+ 1.06 min
I-119
Figure USRE046375-20170425-C00253
m/z 469 [M + H]+ 0.44 min
I-120
Figure USRE046375-20170425-C00254
m/z 538 [M + H]+ 0.94 min
I-121
Figure USRE046375-20170425-C00255
m/z 559 [M + H]+ 0.69 min
I-122
Figure USRE046375-20170425-C00256
m/z 559 [M + H]+ 0.69 min
TABLE 33
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-123
Figure USRE046375-20170425-C00257
m/z 555 [M + H]+ 0.56 min
I-124
Figure USRE046375-20170425-C00258
m/z 543 [M + H]+ 0.63 min
I-125
Figure USRE046375-20170425-C00259
m/z 425 [M + H]+ 0.50 min
I-126
Figure USRE046375-20170425-C00260
m/z 525 [M + H]+ 0.56 min
I-127
Figure USRE046375-20170425-C00261
(CDCl3 + CD3OD) d: 0.10-0.21 (m, 2 H), 0.48-0.63 (m, 2 H), 0.78-0.94 (m, 1 H), 1.67 (d, J = 9.6 Hz, 1 H), 2.10-2.50 (m, 6 H), 2.57-2.80 (m, 2 H), 3.06 (d, J = 18.6 Hz, 1 H), 3.27 (brs, 1 H), 5.10 (d, J = 1.7 Hz, 1 H), 6.31-6.40 (m, 1 H), 6.53 (d, J = 8.1 Hz, 1 H), 6.65 (d, J = 8.1 Hz, 1 H), 7.02-7.12 (m, 1 H), 7.22- 7.34 (m, 2 H),7.44-7.56 (m, 2 H).
TABLE 34
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-128
Figure USRE046375-20170425-C00262
m/z 553 [M + H]+ 0.94 min
I-129
Figure USRE046375-20170425-C00263
m/z 559 [M + H]+ 0.63 min
I-130
Figure USRE046375-20170425-C00264
m/z 529 [M + H]+ 0.75 min
I-131
Figure USRE046375-20170425-C00265
m/z 497 [M + H]+ 0.63 min
I-132
Figure USRE046375-20170425-C00266
m/z 529 [M + H]+ 0.88 min
TABLE 35
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-133
Figure USRE046375-20170425-C00267
m/z 511 [M + H]+ 0.97 min 0.12-0.16 (m, 2 H), 0.46-0.52 (m, 2 H), 0.86 (m, 1 H), 1.42 (d, J = 10.5 Hz, 1 H), 1.86 (d, J = 15.6 Hz, 1 H), 2.06-2.65 (m, 15 H), 3.05 (d, J = 18.3 Hz, 1 H), 3.26 (d, J = 5.9 Hz, 1 H), 3.55 (s, 3 H), 4.73 (s, 1 H), 6.52 (d, J = 8.1 Hz, 1 H), 6.58 (d, J = 8.1 Hz, 1 H), 7.76 (brs, 1 H), 9.31 (brs, 1 H), 13.8 (brs, 1 H)
I-134
Figure USRE046375-20170425-C00268
m/z 498 [M + H]+ 0.96 min 0.13-0.16 (m, 2 H), 0.48-0.54 (m, 2 H), 0.87 (m, 1 H), 1.43 (d, J = 10.5 Hz, 1 H), 1.86 (d, J = 15.6 Hz, 1 H), 2.06-2.67 (m, 15 H), 3.06 (d, J = 18.6 Hz, 1 H), 3.27 (d, J = 6.0 Hz, 1 H), 4.73 (s, 1 H), 6.53 (d, J = 8.1 Hz, 1 H), 6.58 (d, J = 8.1 Hz, 1 H), 7.72 (brs, 1 H), 9.20 (brs, 1 H), 14.1 (brs, 1 H)
I-135
Figure USRE046375-20170425-C00269
m/z 483 [M + H]+ 0.87 min 0.12-0.14 (m, 2 H), 0.46-0.51 (m, 2 H), 0.85 (m, 1 H), 1.06-1.09 (m, 2 H), 1.35-1.36 (m, 2 H), 1.41 (d, J= 11.7 Hz, 1 H), 1.86 (d, J = 15.6 Hz, 1 H), 2.17-2.61 (m, 7 H), 3.03 (d, J = 18.3 Hz, 1 H), 3.17 (d, J = 6.0 Hz, 1 H), 3.56 (s, 3 H), 4.74 (s, 1 H), 4.77 (brs, 1 H), 6.51 (d, J = 8.1 Hz, 1 H), 6.56 (d, J = 8.1 Hz, 1 H), 9.17 (brs, 1 H), 14.1 (brs, 1 H)
I-136
Figure USRE046375-20170425-C00270
m/z 469 [M + H]+ 0.89 min 0.12-0.16 (m, 2 H), 0.43-0.51 (m, 2 H), 0.85 (m, 1 H), 1.06-1.12 (m, 2 H), 1.35-1.36 (m, 2 H), 1.42 (d, J= 11.7 Hz, 1 H), 1.86 (d, J = 15.6 Hz, 1 H), 2.06-2.63 (m, 7 H), 3.02 (d, J = 18.3 Hz, 1 H), 3.13 (d, J = 5.4 Hz, 1 H), 4.76 (s, 1 H), 4.77 (brs, 1 H), 6.52 (d, J = 8.1 Hz, 1 H), 6.56 (d, J = 8.1 Hz, 1 H), 9.18 (brs, 1 H), 14.1 (brs, 1 H)
TABLE 36
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-137
Figure USRE046375-20170425-C00271
m/z 539 [M + H]+ 0.50 min
I-138
Figure USRE046375-20170425-C00272
m/z 466 [M + H]+ 0.57 min
I-139
Figure USRE046375-20170425-C00273
m/z 486 [M + H]+ 0.44 min
I-140
Figure USRE046375-20170425-C00274
m/z 520 [M + H]+ 0.56 min
I-141
Figure USRE046375-20170425-C00275
m/z 510 [M + H]+ 0.75 min
TABLE 37
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-142
Figure USRE046375-20170425-C00276
m/z 521 [M + H]+ 0.50 min
I-143
Figure USRE046375-20170425-C00277
m/z 553 [M + H]+ 0.88 min
I-144
Figure USRE046375-20170425-C00278
m/z 494 [M + H]+ 0.57 min
I-145
Figure USRE046375-20170425-C00279
m/z 469 [M + H]+ 0.83 min
I-146
Figure USRE046375-20170425-C00280
m/z 467 [M + H]+ 1.01 min
TABLE 38
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-147
Figure USRE046375-20170425-C00281
m/z 467 [M + H]+ 1.00 min
I-148
Figure USRE046375-20170425-C00282
m/z 559 [M + H]+ 1.16 min**
I-149
Figure USRE046375-20170425-C00283
m/z 598 [M + H]+ 1.34 min**
I-150
Figure USRE046375-20170425-C00284
m/z 514 [M + H]+ 0.50 min
I-151
Figure USRE046375-20170425-C00285
m/z 538 [M + H]+ 0.63 min
TABLE 39
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-152
Figure USRE046375-20170425-C00286
m/z 494 [M + H]+ 0.56 min
I-153
Figure USRE046375-20170425-C00287
m/z 465 [M + H]+ 0.90 min
I-154
Figure USRE046375-20170425-C00288
m/z 465 [M + H]+ 0.96 min
I-155
Figure USRE046375-20170425-C00289
m/z 544 [M + H]+ 1.00 min
I-156
Figure USRE046375-20170425-C00290
m/z 483 [M + H]+ 0.35 min
TABLE 40
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO)δ)
I-157
Figure USRE046375-20170425-C00291
m/z 510 [M + H]+ 0.96 min 0.11-0.14 (m, 2H), 0.46-0.50 (m, 2H), 0.83 (m, 1H), 0.87 (t, J = 7.2 Hz, 1H), 0.99 (d, J = 4.2 Hz, 3H), 1.01 (d, J = 4.2 Hz, 3H), 1.08- 1.43 (m, 5H), 1.95 (d, J = 17.1 Hz, 1H), 2.11- 2.65 (m, 7H), 2.96-3.16 (m, 4H), 3.78 (q, J = 7.5 Hz, 1H), 4.78 (brs, 1H), 5.21 (s, 1H), 6.49 (d, J= 8.1 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 7.41 (t, J = 5.1 Hz, 1H), 7.50 (d, J = 7.8 Hz, 12H), 9.02 (brs, 1H)
I-158
Figure USRE046375-20170425-C00292
m/z 496 [M + H]+ 0.93 min 0.11-0.13 (m, 2H), 0.46-0.50 (m, 2H), 0.85 (m, 1H), 1.01 (d, J = 4.1 Hz, 3H), 1.02 (d, J = 4.2 Hz, 3H), 1.07 (d, J = 4.0 Hz, 3H), 1.09 (d, J = 4.0 Hz, 3H), 1.40 (d, J = 11.1 Hz, 1H), 1.95 (d, J = 17.1 Hz, 1H), 2.09-2.63 (m, 7H), 2.98 (d, J = 18.1 Hz, 1H), 3.13 (d, J = 5.4 Hz, 1H), 3.82 (q, J = 6.6 Hz, 1H), 3.88 (q, J = 6.9 Hz, 1H), 5.24 (brs, 1H), 5.76 (s, 1H), 6.50 (d, J = 7.5 Hz, 1H), 6.55 (d, J = 7.5 Hz, 1H), 7.20 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 6.9 Hz, 1H), 9.01 (brs, 1H)
I-159
Figure USRE046375-20170425-C00293
m/z 536 [M + H]+ 0.95 min 0.11-0.13 (m, 2H), 0.46-0.50 (m, 2H), 0.83 (m, 1H), 0.99 (d, J = 3.0 Hz, 3H), 1.01 (d, J = 3.0 Hz, 3H), 1.15-1.38 (m, 6H), 1.40 (d, J = 11.1 Hz, 1H), 1.52-1.80 (m, 4H), 1.97 (d, J = 17.1 Hz, 1H), 2.09-2.65 (m, 7H), 2.98 (d, J = 18.6 Hz, 1H), 3.13 (d, J = 5.7 Hz, 1H), 3.58 (m, 1H), 3.79 (q, J = 6.9 Hz, 1H), 5.23 (s, 1H), 6.50 (d, J = 7.8 Hz, 1H), 6.55 (d, J = 7.8 Hz, 1H), 7.17 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 9.00 (brs, 1H)
TABLE 41
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO)δ)
I-160
Figure USRE046375-20170425-C00294
m/z 522 [M + H]+ 1.04 min 0.12-0.13 (m, 2H), 0.46-0.51 (m, 2H), 0.85 (m, 1H), 0.99 (d, J = 3.3 Hz, 3H), 1.01 (d, J = 3.3 Hz, 3H), 1.15-1.49 (m, 7H), 1.91 (d, J = 16.5 Hz, 1H), 2.08-2.65 (m, 7H), 2.98 (d, J = 17.5 Hz, 1H), 3.12 (d, J = 5.7 Hz, 1H), 3.16-3.34 (m, 4H), 3.79 (q, J = 6.9 Hz, 1H), 4.76 (brs, 1H), 5.01 (s, 1H), 6.54 (d, J = 7.8 Hz, 1H), 6.58 (d, J = 7.8 Hz, 1H), 7.19 (d, J = 7.5 Hz, 1H), 9.01 (brs, 1H)
I-161
Figure USRE046375-20170425-C00295
m/z 524 [M + H]+ 0.92 min 0.12-0.14 (m, 2H), 0.46-0.51 (m, 2H), 0.86 (m, 1H), 0.99 (d, J = 3.3 Hz, 3H), 1.01 (d, J = 3.3 Hz, 3H), 1.41 (d, J = 11.1 Hz, 1H), 1.95 (d, J = 17.1 Hz, 1H), 2.08-2.67 (m, 11H), 2.98 (d, J = 17.5 Hz, 1H), 3.12 (d, J = 5.7 Hz, 1H), 3.49-3.60 (m, 4H), 3.82 (q, J = 6.9 Hz, 1H), 4.78 (brs, 1H), 5.01 (s, 1H), 6.54 (d, J = 8.1 Hz, 1H), 6.58 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 7.8 Hz, 1H), 9.13 (brs, 1H)
I-162
Figure USRE046375-20170425-C00296
m/z 530 [M + H]+ 0.94 min 0.13-0.14 (m, 2H), 0.47-0.51 (m, 2H), 0.83 (m, 1H), 0.84 (d, J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 1.44 (d, J = 10.5 Hz, 1H), 2.02 (d, J = 16.8 Hz, 1H), 2.11-2.65 (m, 7H), 3.03 (d, J = 18.6 Hz, 1H), 3.17 (d, J = 5.7 Hz, 1H), 3.58 (m, 1H), 3.74 (q, J = 6.3 Hz, 1H), 4.86 (brs, 1H), 5.39 (s, 1H), 6.52 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 7.03 (t, J = 7.2 Hz, 1H), 7.26 (t, J = 7.8 Hz, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 8.1 Hz, 2H), 9.01 (brs, 1H), 9.70 (brs, 1H)
TABLE 42
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-163
Figure USRE046375-20170425-C00297
m/z 445 [M + H]+ 0.83 min
I-164
Figure USRE046375-20170425-C00298
0.14-0.22 (m, 2H), 0.48-0.61 (m, 2H), 0.91 (m, 1H), 1.12 (d, J = 6.6 Hz, 6H), 1.53-1.66 (m, 1H), 2.15-2.22 (m, 2H), 2.23- 2.30 (m, 2H), 2.35-2.49 (m, 2H), 2.70 (d.d, J = 18.9 & 6.6 Hz, 2H), 3.13 (d, J = 18.9 Hz, 1H), 3.27 (d, J = 6.6 Hz, 1H), 3.98 (quintet, J = 6.6 Hz, 1H), 4.99-5.04 (m, 1H), 6.32-6.36 (m, 1H), 6.53 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H).
I-165
Figure USRE046375-20170425-C00299
m/z 543 [M + H]+ 0.63 min
I-166
Figure USRE046375-20170425-C00300
m/z 446 [M + H]+ 0.94 min
TABLE 43
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-167
Figure USRE046375-20170425-C00301
(CD3OD) d: 0.12-0.22 (m, 2H), 0.48-0.63 (m, 2H), 0.82- 1.00 (m, 1H), 1.63 (d, J = 8.1 Hz, 1H), 2.10-2.50 (m, 7H), 2.72 (d.d, J = 18.6 & 6.6 Hz, 2H), 3.15 (d, J = 18.6 Hz, 1H), 5.10 (brs, 1H), 6.50-6.65 (m, 3H), 7.67 (d.d, J = 4.8 & 1.5 Hz, 1H), 8.36 (d.d, J = 4.8 & 1.5 Hz, 1H).
I-168
Figure USRE046375-20170425-C00302
m/z 582 [M + H]+ 0.90 min
I-169
Figure USRE046375-20170425-C00303
m/z 541 [M + H]+ 1.15 min
I-170
Figure USRE046375-20170425-C00304
m/z 480 [M + H]+ 0.37 min
I-171
Figure USRE046375-20170425-C00305
m/z 509 [M + H]+ 0.75 min
TABLE 44
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-172
Figure USRE046375-20170425-C00306
m/z 505 [M + H]+ 0.97 min 0.11-0.13 (m, 2H), 0.46-0.50 (m, 2H), 0.84 (m, 1H), 0.98 (d, J = 3.1 Hz, 3H), 1.01 (d, J = 3.1 Hz, 3H), 1.37 (d, J = 10.8 Hz, 1H), 2.08 (d, J = 17.4 Hz, 1H), 2.11-2.24 (m, 2H), 2.35 (d, J = 6.6 Hz, 1H), 2.51-2.63 (m, 2H), 3.01 (d, J = 18.3 Hz, 1H), 3.13 (d, J = 5.7 Hz, 1H), 3.54 (s, 3H), 3.86 (q, J = 7.2 Hz, 1H),4.79 (brs, 1H), 4.98 (brs, 1H), 5.76 (s, 1H), 6.54 (d, J = 7.8 Hz, 1H), 6.59 (d, J = 7.8 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1H), 9.16 (brs, 1H)
I-173
Figure USRE046375-20170425-C00307
m/z 426 [M + H]+ 0.90 min 0.12-0.14 (m, 2H), 0.46-0.52 (m, 2H), 0.85 (m, 1H), 0.97 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 10.2 Hz, 1H), 1.86 (d, J = 15.0 Hz, 1H), 2.02 (d, J = 15.0 Hz, 1H), 2.10-2.17 (m, 2H), 2.28 (dd, J = 6.9, 6.9 Hz, 1H), 2.43 (dd, J = 6.9, 8.4 Hz, 1H), 2.54-2.62 (m, 2H), 3.01 (d, J = 18.3 Hz, 1H), 3.17 (d, J = 5.7 Hz, 1H), 3.58 (m, 1H), 3.88 (q, J = 7.2 Hz, 1H), 4.62 (brs, 1H), 4.68 (s, 1H), 6.47 (d, J = 8.1 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 6.94 (brs, 1H), 9.06 (brs, 1H)
I-174
Figure USRE046375-20170425-C00308
(CD3OD) d: 0.10-0.25 (m, 2H), 0.48-0.63 (m, 2H), 0.83- 1.00 (m, 1H), 1.55 (d, J = 8.1 Hz, 1H), 2.01 (d, J = 15.6 Hz, 1H), 2.22-2.57 (m, 6H), 2.70 (d.d, J = 18.3 & 7.2 Hz, 2H), 3.12 (d, J = 18.3 Hz, 1H), 4.67 (s, 1H), 6.44-6.62 (m, 3H), 7.54 (d.d, J = 9.6 & 3.6 Hz, 1H), 8.00 (d, J = 3.6 Hz, 1H).
TABLE 45
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-175
Figure USRE046375-20170425-C00309
m/z 458 [M + H]+ 0.86 min
I-176
Figure USRE046375-20170425-C00310
ESI: m/z 458 [M + H]+
I-177
Figure USRE046375-20170425-C00311
m/z 460 [M + H]+ 1.20 min 0.13-0.17 (m, 2H), 0.47-0.50 (m, 2H), 0.87 (m, 1H), 1.41 (d, J = 10.5 Hz, 1H), 2.07 (d, J = 15.0 Hz, 1H), 2.10-2.25 (m, 2H), 2.32 (dd, J = 5.7, 6.9 Hz, 1H), 2.45 (dd, J = 5.7, 6.0 Hz, 1H), 2.63 (dt, J = 6.3, 11.7, 2H), 3.05 (d, J = 18.3 Hz, 1H), 3.19 (d, J = 6.0 Hz, 1H), 4.67 (brs, 1H), 4.75 (s, 1H), 6.51 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 6.96 (t, J = 7.5 Hz, 1H), 7.21 (t, J = 8.4 Hz, 1H), 7.25 (d, J = 3.6 Hz, 2H), 7.52 (d, J = 7.5 Hz, 2H), 8.38 (brs, 1H), 9.07 (brs, 1H)
TABLE 46
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-178
Figure USRE046375-20170425-C00312
m/z 636 [M + H]+ 1.11 min 0.11-0.13 (m, 2H), 0.46-0.51 (m, 2H), 0.86 (m, 1H), 0.95 (d, J = 6.6 Hz, 6H), 1.46 (d, J = 11.1 Hz, 1H), 1.87 (d, J = 18.0 Hz, 1H), 2.11-2.63 (m, 7H), 2.25 (s, 3H), 3.03 (d, J = 17.4 Hz, 1H), 3.18 (brs, 1H), 3.84 (q, 3 = 7.2 Hz, 1H), 4.71 (brs, 1H), 5.45 (brs, 1H), 6.50 (brs, 1H), 6.57 (brs, 1H), 7.61-8.19 (m, 4H), 9.03 (brs, 1H), 10.7 (brs, 1H), 12.7 (brs, 1H)
I-179
Figure USRE046375-20170425-C00313
m/z 581 [M + H]+ 1.06 min 0.11-0.13 (m, 2H), 0.46-0.51 (m, 2H), 0.86 (m, 1H), 0.95 (d, J = 6.6 Hz, 6H), 1.46 (d, J = 11.1 Hz, 1H), 1.87 (d, J = 18.0 Hz, 1H), 2.09 (s, 3H), 2.11-2.63 (m, 7H), 3.03 (d, J = 17.4 Hz, 1H), 3.18 (brs, 1H), 3.84 (q, J = 7.2 Hz, 1H), 4.69 (brs, 1H), 5.45 (brs, 1H), 6.48 (d, J = 7.2 Hz, 1H), 6.55 (d, J = 7.2 Hz, 1H), 7.33 (brd, J = 5.4 Hz, 2H), 7.54 (brs, 1H), 7.74 (d, J = 7.5 Hz, 2H), 9.11 (brs, 1H), 12.3 (brs, 1H)
TABLE 47
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-180
Figure USRE046375-20170425-C00314
m/z 597 [M + H]+ 1.03 min 0.11-0.13 (m, 2H), 0.46-0.51 (m, 2H), 0.85 (m, 1H), 0.95 (d, J = 6.6 Hz, 6H), 1.46 (d, J = 9.9 Hz, 1H), 1.87 (d, J = 17.4 Hz, 1H), 2.11-2.62 (m, 7H), 3.01 (d, J = 17.7 Hz, 1H), 3.15 (d, J = 4.6 Hz, 1H), 3.82 (s, 3H), 3.83 (q, J = 5.4 Hz, 1H), 4.67 (brs, 1H), 5.44 (s, 1H), 6.49 (d, J = 8.1 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H), 7.52 (brd, J = 9.3 Hz, 1H), 7.79 (d, J = 8.4 Hz, 2H), 9.12 (brs, 1H), 12.2 (brs, 1H)
I-181
Figure USRE046375-20170425-C00315
m/z 502 [M + H]+ 0.35 min
I-182
Figure USRE046375-20170425-C00316
m/z 553 [M + H]+ 0.68 min
I-183
Figure USRE046375-20170425-C00317
m/z 539 [M + H]+ FAB-MS
TABLE 48
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-184
Figure USRE046375-20170425-C00318
m/z 458 [M + H]+ 0.97 min
I-185
Figure USRE046375-20170425-C00319
m/z 519 [M + H]+ 0.43 min
I-186
Figure USRE046375-20170425-C00320
m/z 519 [M + H]+ 1.67 min**
I-187
Figure USRE046375-20170425-C00321
m/z 539 [M + H]+ 0.50 min
TABLE 49
NMR
Compound No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-188
Figure USRE046375-20170425-C00322
m/z 505 [M + H]+ 0.35 min
I-189
Figure USRE046375-20170425-C00323
m/z 505 [M + H]+ 0.42 min
I-190
Figure USRE046375-20170425-C00324
m/z 597 [M + H]+ 0.77 min
I-191
Figure USRE046375-20170425-C00325
m/z 523 [M + H]+ 1.20 min
I-192
Figure USRE046375-20170425-C00326
m/z 546 [M + H]+ 1.00 min
TABLE 50
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-193
Figure USRE046375-20170425-C00327
m/z 580 [M + H]+ 1.09 min
I-194
Figure USRE046375-20170425-C00328
m/z 474 [M + H]+ 0.88 min
I-195
Figure USRE046375-20170425-C00329
m/z 458 [M + H]+ 1.08 min
I-196
Figure USRE046375-20170425-C00330
0.12-0.16 (m, 2H), 0.46-0.55 (m, 2H), 0.88 (m, 1H), 1.43 (d, J = 12.4 Hz, 1H), 1.65- 2.65 (m, 12H), 2.97-3.70 (m, 6H), 3.59 (s, 3H), 4.74 (s, 1H), 6.55 (d, J = 8.0 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 7.68 (brs, 1H), 9.16 (brs, 1H), 13.6 (brs, 1H)
TABLE 51
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-197
Figure USRE046375-20170425-C00331
0.20-0.40 (m, 2H), 0.46-0.65 (m, 2H), 0.97 (m, 1H), 1.54 (d, J = 6.8 Hz, 1H), 1.80-2.10 (m, 3H), 2.31-3.69 (m, 15H), 4.83 (s 1H), 6.59 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 8.0 Hz, 1H), 7.56 (brs, 1H), 9.29 (brs, 1H), 13.6 (brs, 1H)
I-198
Figure USRE046375-20170425-C00332
m/z 533 [M + H]+ 0.95 min 0.11-0.13 (m, 2H), 0.46-0.52 (m, 2H), 0.86 (m, 1H), 1.03 (d, J = 6.3 Hz, 3H), 1.08 (d, J = 6.3 Hz, 3H), 1.46 (brd, J = 8.4 Hz, 1H), 1.94 (d, J = 17.7 Hz, 1H), 2.71-2.60 (m, 7H), 2.81 (s, 6H), 3.04 (d, J = 17.1 Hz, 1H), 3.18 (brs, 1H), 3.95 (q, J = 5.4 Hz, 1H), 4.77 (brs, 1H), 5.45 (s, 1H), 6.51 (d, J = 7.5 Hz, 1H), 6.57 (d, J = 7.5 Hz, 1H), 7.64 (brs, 1H), 9.14 (brs, 1H), 12.2 (brs, 1H)
I-199
Figure USRE046375-20170425-C00333
m/z 497 [M + H]+ 0.97 min 0.13-0.15 (m, 2H), 0.48-0.52 (m, 2H), 0.86 (m, 1H), 1.41 (d, J = 11.4 Hz, 1H), 1.85 (t, J = 7.8 Hz, 2H), 1.93 (d, J = 16.5 Hz, 1H), 2.07-2.62 (m, 11H), 3.05 (d, J = 18.3 Hz, 1H), 3.21 (d, J = 6.0 Hz, 1H), 3.59 (s, 3H), 4.72 (s, 1H), 4.77 (brs, 1H), 6.53 (d, J = 8.1 Hz, 1H), 6.57 (d, J = 8.1 Hz, 1H), 8.26 (brs, 1H), 9.15 (brs, 1H), 14.1 (brs, 1H)
I-200
Figure USRE046375-20170425-C00334
m/z 553 [M + H]+ 0.47 min
TABLE 52
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-201
Figure USRE046375-20170425-C00335
m/z 601 [M + H]+ 1.01 min
I-202
Figure USRE046375-20170425-C00336
m/z 563 [M + H]+ 0.58 min
I-203
Figure USRE046375-20170425-C00337
m/z 583 [M + H]+ 0.54 min
I-204
Figure USRE046375-20170425-C00338
m/z 539 [M + H]+ 0.33 min
I-205
Figure USRE046375-20170425-C00339
m/z 573 [M + H]+ 0.62 min
TABLE 53
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-206
Figure USRE046375-20170425-C00340
m/z 535 [M + H]+ 0.41 min
I-207
Figure USRE046375-20170425-C00341
m/z 484 [M + H]+ 0.32 min
I-208
Figure USRE046375-20170425-C00342
m/z 507 [M + H]+ 1.05 min
I-209
Figure USRE046375-20170425-C00343
m/z 518 [M + H]+ 1.14 min**
I-210
Figure USRE046375-20170425-C00344
m/z 495 [M + H]+ 1.64 min**
TABLE 54
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-211
Figure USRE046375-20170425-C00345
m/z 503 [M + H]+ 1.33 min**
I-212
Figure USRE046375-20170425-C00346
m/z 512 [M + H]+ 1.67 min**
I-213
Figure USRE046375-20170425-C00347
m/z 500 [M + H]+ 1.41 min**
I-214
Figure USRE046375-20170425-C00348
m/z 536 [M + H]+ 1.69 min**
TABLE 55
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-215
Figure USRE046375-20170425-C00349
m/z 485 [M + H]+ 1.60 min**
I-216
Figure USRE046375-20170425-C00350
m/z 565 [M + H]+ 1.82 min**
I-217
Figure USRE046375-20170425-C00351
m/z 548 [M + H]+ 1.17 min**
I-218
Figure USRE046375-20170425-C00352
m/z 512 [M + H]+ 0.95 min**
I-219
Figure USRE046375-20170425-C00353
m/z 512 [M + H]+ 1.66 min**
I-220
Figure USRE046375-20170425-C00354
m/z 525 [M + H]+ 1.60 min**
I-221
Figure USRE046375-20170425-C00355
m/z 521 [M + H]+ 1.35 min**
TABLE 56
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-222
Figure USRE046375-20170425-C00356
m/z 509 [M + H]+ 1.57 min**
I-223
Figure USRE046375-20170425-C00357
m/z 479 [M + H]+ 1.50 min**
I-224
Figure USRE046375-20170425-C00358
m/z 555 [M + H]+ 1.76 min**
I-225
Figure USRE046375-20170425-C00359
m/z 519 [M + H]+ 1.67 min**
I-226
Figure USRE046375-20170425-C00360
m/z 505 [M + H]+ 1.53 min**
I-227
Figure USRE046375-20170425-C00361
m/z 505 [M + H]+ 1.64 min**
I-228
Figure USRE046375-20170425-C00362
m/z 503 [M + H]+ 1.38 min**
TABLE 57
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-229
Figure USRE046375-20170425-C00363
m/z 626 [M + H]+ 1.74 min**
Figure USRE046375-20170425-C00364
m/z 521 [M + H]+ 1.56 min**
I-231
Figure USRE046375-20170425-C00365
m/z 500 [M + H]+ 1.40 min**
I-232
Figure USRE046375-20170425-C00366
m/z 630 [M + H]+ 1.72 min**
I-233
Figure USRE046375-20170425-C00367
m/z 501 [M + H]+ 1.25 min**
I-234
Figure USRE046375-20170425-C00368
m/z 505 [M + H]+ 1.46 min**
I-235
Figure USRE046375-20170425-C00369
m/z 515 [M + H]+ 1.56 min**
TABLE 58
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-236
Figure USRE046375-20170425-C00370
m/z 565 [M + H]+ 1.77 min**
I-237
Figure USRE046375-20170425-C00371
m/z 501 [M + H]+ 1.17 min**
I-238
Figure USRE046375-20170425-C00372
m/z 548 [M + H]+ 1.29 min**
I-239
Figure USRE046375-20170425-C00373
m/z 518 [M + H]+ 1.21 min**
I-240
Figure USRE046375-20170425-C00374
m/z 542 [M + H]+ 1.31 min**
I-241
Figure USRE046375-20170425-C00375
m/z 520 [M + H]+ 1.50 min**
I-242
Figure USRE046375-20170425-C00376
TABLE 59
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-243
Figure USRE046375-20170425-C00377
m/z 493 [M + H]+ 1.05 min
I-244
Figure USRE046375-20170425-C00378
m/z 601 [M + H]+ 1.02 min 0.11-0.13 (m, 2H), 0.48-0.51 (m, 2H), 0.87 (m, 1 H), 0.95 (d, J = 6.6 Hz, 6H), 1.48 (d, J = 11.1 Hz, 1H), 1.88 (d, J = 18.0 Hz, 1H), 2.10 (s, 3H), 2.18-2.57 (m, 7H), 3.04 (d, J = 16.8 Hz, 1H), 3.19 (brs, 1H), 3.78 (q, J = 6.9 Hz, 1H), 4.68 (brs, 1H), 5.43 (brs, 1H), 6.49 (d, J = 6.6 Hz, 1H), 6.51 (d, J = 6.6 Hz, 1H), 7.35-7.37 (m, 2H), 7.54 (brs, 1H), 7.85 (d, J = 6.9 Hz, 2H), 9.09 (brs, 1H), 12.4 (brs, 1H)
I-245
Figure USRE046375-20170425-C00379
m/z 601 [M + H]+ 0.76 min
I-246
Figure USRE046375-20170425-C00380
m/z 505 [M + H]+ 1.38 min**
I-247
Figure USRE046375-20170425-C00381
m/z 521 [M + H]+ 1.58 min**
TABLE 60
Compound NMR
No. Chemical structure LC/MS*1 (1H-NMR (d6-DMSO) δ)
I-248
Figure USRE046375-20170425-C00382
m/z 493 [M + H]+ 1.69 min**
I-249
Figure USRE046375-20170425-C00383
m/z 479 [M + H]+ 1.55 min**
I-250
Figure USRE046375-20170425-C00384
m/z 519 [M + H]+ 1.74 min**
I-251
Figure USRE046375-20170425-C00385
m/z 512 [M + H]+ 0.38 min
I-252
Figure USRE046375-20170425-C00386
0.10-0.15 (m, 2H), 0.34-0.38 (m, 2H), 0.73 (m, 1H), 1.26 (d, J = 9.6 Hz, 1H), 1.93-2.54 (m, 10H), 2.94 (d, J = 18.4 Hz, 1H), 3.10 (d, J = 6.0 Hz, 1H), 3.67 (s, 3H), 3.72 (s, 3H), 4.58 (s, 1H), 4.84 (s, 1H), 6.42 (d, J = 8.0 Hz, 2H), 6.48 (d, J = 8.0 Hz, 2H), 6.61 (d, J = 9.3 Hz, 2H), 6.69 (d, J = 9.2 Hz, 2H), 7.56 (dd, J = 2.8, 8.8 Hz, 1H), 7.66 (dd, J = 2.8, 8.8 Hz, 1H), 8.00 (d, J = 2.4 Hz, 1H), 8.08 (d, J = 2.0 Hz, 1H), 8.76 (s, 1H), 8.97 (s, 1H), 10.78 (s, 1H).
TABLE 61
Com-
pound
No. Chemical structure
I-253
Figure USRE046375-20170425-C00387
I-254
Figure USRE046375-20170425-C00388
I-255
Figure USRE046375-20170425-C00389
I-256
Figure USRE046375-20170425-C00390
I-257
Figure USRE046375-20170425-C00391
TABLE 62
Com-
pound
No. Chemical structure
I-258
Figure USRE046375-20170425-C00392
I-259
Figure USRE046375-20170425-C00393
I-260
Figure USRE046375-20170425-C00394
I-261
Figure USRE046375-20170425-C00395
I-262
Figure USRE046375-20170425-C00396
TABLE 63
Com-
pound
No. Chemical structure
I-253
Figure USRE046375-20170425-C00397
I-254
Figure USRE046375-20170425-C00398
I-255
Figure USRE046375-20170425-C00399
TABLE 64
Com-
pound
No. Chemical structure
I-266
Figure USRE046375-20170425-C00400
m/z 457.91 [M + H]+ 0.97 min
I-267
Figure USRE046375-20170425-C00401
m/z 457.91 [M + H]+ 0.62 min
I-268
Figure USRE046375-20170425-C00402
m/z 457.91 [M + H]+ 0.87 min
I-269
Figure USRE046375-20170425-C00403
m/z 473.91 [M + H]+ 0.69
I-270
Figure USRE046375-20170425-C00404
m/z 457.91 [M + H]+ 0.97 min
TABLE 65
Compound
No. Chemical Structure LC/MS*1
I-271
Figure USRE046375-20170425-C00405
m/z 520 [M + H]+ 1.63 min**
I-272
Figure USRE046375-20170425-C00406
m/z 513 [M + H]+ 0.45 min
I-273
Figure USRE046375-20170425-C00407
m/z 513 [M + H]+ 0.38 min
I-274
Figure USRE046375-20170425-C00408
m/z 499 [M + H]+ 0.38 min
I-275
Figure USRE046375-20170425-C00409
m/z 548 [M + H]+ 0.38 min
TABLE 66
Compound
No. Chemical Structure LC/MS*1
I-276
Figure USRE046375-20170425-C00410
m/z 559 [M + H]+ 0.53 min
I-277
Figure USRE046375-20170425-C00411
m/z 610 [M + H]+ 0.46 min
I-278
Figure USRE046375-20170425-C00412
m/z 545 [M + H]+ 0.38 min
I-279
Figure USRE046375-20170425-C00413
m/z 495 [M + H]+ 0.31 mm
I-280
Figure USRE046375-20170425-C00414
m/z 545 [M + H]+ 0.97 min
TABLE 67
Compound No. Chemical Structure LC/MS*1
I-281
Figure USRE046375-20170425-C00415
m/z 531 [M + H]+ 0.92 min
I-282
Figure USRE046375-20170425-C00416
m/z 455 [M + H]+ 0.87 min
I-283
Figure USRE046375-20170425-C00417
m/z 469 [M + H]+ 0.94 min
I-284
Figure USRE046375-20170425-C00418
m/z 571 [M + H]+ 0.68 min
I-285
Figure USRE046375-20170425-C00419
m/z 509 [M + H]+ 0.32 min
TABLE 68
Compound No. Chemical Structure LC/MS*1
I-286
Figure USRE046375-20170425-C00420
m/z 471 [M + H]+ 0.32 min
I-287
Figure USRE046375-20170425-C00421
m/z 455 [M + H]+ 0.90 min
I-288
Figure USRE046375-20170425-C00422
m/z 501 [M + H]+ 0.32 min
I-289
Figure USRE046375-20170425-C00423
m/z 584 [M + H]+ 0.46 min
(LC/MS conditions of measurement)*1:
Column: Chromolith Flash ROD RP-18e.
25 × 4.6 mm I.D.
Flow Rate: 2 ml/min
UV Detector: 280 nm
Solvent System:
[A] = H2O_0.05% HCOOH
[B] = MeOH_0.05% HCOOH
Gradient:
0 min; 90% [A]_10% [B]
0.2 min; 90% [A]_10% [B]
1.0 min; 10% [A]_90% [B]
1.80 min; 10% [A]_90% [B]
Proviso, values with symbol ** follow below conditions of measurement
Column: Phenomenex Luna 5 μ C18(2) 100A, size 50 × 4.60 mm
Gradient: 10%-100% Acetonitrile linear during 3.0 min at 3.0 mL/min
Test Example 1 Binding Assay of Opioid δ Receptor
1) Method of Preparing Membrane Specimen for Binding Assay
A rat cerebrum (Slc: SD) which had been stored at −80° C. was used. To a cerebrum which had been weighed was added a 20-fold amount of ice-cooled 10 mM Tris-HCl buffer (pH 7.0), and the mixture was homogenized (25000 rpm, 30 seconds) with Histocolon (NITI-ON), and centrifuged at 36600×g for 20 minutes. To the resulting pellet was added 15 ml of the same buffer, and the mixture was treated with Histocolon similarly, and centrifuged. This washing work was performed two times. After centrifugation, to the resulting pellet was added 15 mL of a 50 mM Tris-HCl buffer (pH 7.4), and this was treated with Histocolon, and finally resuspended in a 10-fold amount of the same buffer, which was used as a crude membrane fraction (Life Sci. 48, 111-116, 1991). The prepared membrane specimen was frozen and stored at −80° C., and at an assay, the specimen was rapidly thawed, and diluted to about 900 μg/mL with a 50 mM Tris-HCl buffer (pH 7.4) after the centrifugation and Histocolon treatment, and was used in an experiment. For measuring a protein concentration of the membrane specimen, Micro BCA Protein Assay Kit (PIERCE) was used.
2) Method of δ Receptor Binding Assay and Data Analysis
To a solution of 10 μl of the test compound diluted at 10-fold stage was added 10 μl of final 3 nM [3H]-DADLE (51.5 Ci/mmol: PerkinElmer) as a ligand. Into a tube was placed 480 μl of a rat cerebrum membrane fraction to which 100 mM choline chloride, 3 mM MnCl2 and 100 nM DAMGO had been added, and this was incubated at 25° C. for 2 hours. After incubation, this was suction-filtered with a Whatman GF/C filter which had been pre-treated with 0.5% polyethyleneimine, and washed with 2.5 mL of an ice-cooled 10 mM Tris-HCl buffer (pH7.4) four times. After washing, the filter was transferred to a mini vial for liquid scintillation counter, 5 mL of a scintillator (Cleasol I) was added, this was allowed to stand overnight, and the radioactivity was measured for 3 minutes with a liquid scintillation counter Tri-Carb 2200CA (PACKARD). DMSO was used for total binding (Total bound: TB) for data analysis, and 20 μM levallorphan was used for non-specific binding (Non-specific bound: NB), and a Ki value of the test compound was calculated using a KD value (2.93 nM) obtained in advance by Scatchard plot analysis.
Results are shown in Table 69.
TABLE 69
test compound Ki (nM)
I-3 8.76
I-4 7.38
I-7 7.4
I-10 19.92
I-13 5.02
I-30 5.34
I-39 41.8
I-49 3.99
I-92 5.23
I-118 27.65
I-133 9.85
I-135 9.76
I-145 13.87
I-188 3.01
I-199 12.77
I-208 13.28
I-229 5.9
I-240 11.5
I-243 5.2
I-244 0.56
I-267 41.46
I-283 3.73
I-284 0.91
I-285 5.77
I-286 2.46
I-288 5.36
I-289 0.47
From the above results, it is seen that compound (I) has an affinity for an opioid δ receptor.
Test Example 2 Binding Assay to Opioid μ Receptor
1) Method of Preparing Membrane Specimen for Binding Assay
A rat cerebrum (Slc: SD) which had been stored at −80° C. was used. To a cerebrum which had been weighed was added a 20-fold amount of ice-cooled 10 mM Tris-HCl buffer (pH 7.0), the mixture was homogenized (25000 rpm, 30 seconds) with Histocolon (NITI-ON), and centrifuged at 36600×g for 20 minutes. To the resulting pellet was added 15 ml of the same buffer, and the mixture was treated with Histocolon similarly, and centrifuged. This washing work was performed two times. After centrifugation, to the resulting pellet was added 15 mL of a 50 mM Tris-HCl buffer (pH 7.4), this was treated with Histocolon, and this was finally resuspended in a 10-fold amount of the same buffer, which was used as a crude membrane fraction (Life Sci. 48, 111-116, 1991). The prepared membrane specimen was frozen and stored at −80° C., and at a test, the specimen was rapidly thawed, and diluted to about 900 μg/mL with a 50 mM Tris-HCl buffer (pH 7.4) after the centrifugation and Histocolon treatment, and was used in an experiment. For measuring a protein concentration of the membrane specimen, Micro BCA Protein Assay Kit (PIERCE) was used.
2) Method of μ Receptor Binding Assay and Data Analysis
To a solution of 10 μl of the test compound diluted at 10-fold stage diluted test compound was added 10 μl of final 2 nM [3H]-DAMGO (51.5 Ci/mmol: PerkinElmer) as a ligand, further, 4800 of a rat cerebrum membrane fraction was placed into a tube, and this was incubated at 25° C. for 2 hours. After incubation, this was suction-filtered with a Whatman GF/C filter which had been pre-treated with 0.5% polyethyleneimine, and washed with 2.5 mL of an ice-cooled 10 mM Tris-HCl buffer (pH 7.4) four times. After washing, the filter was transferred to a mini vial for liquid scintillation counter, 5 mL of a scintillator (Cleasol I) was added, and this was allowed to stand overnight, and the radioactivity was measured for 3 minutes with a liquid scintillation counter Tri-Carb 2200CA (PACKARD). DMSO was used for total binding (Total bound: TB) for data analysis, and 20 μM levallorphan was used for non-specific binding (Non-specific bound: NB), and a Ki value of the test compound was calculated using a KD value (1.72 nM) obtained in advance by Scatchard plot analysis (Anal. Biochem. 107(1), 220-239, 1980).
Results are shown in Table 70.
TABLE 70
test compound Ki (nM)
I-4 5.18
I-10 4.05
I-39 0.33
I-49 16.49
I-118 2.29
I-122 2.7
I-123 1.68
I-124 3.9
I-133 4.99
I-135 1.58
I-138 15.53
I-145 28.09
I-188 17.27
I-199 9.45
I-208 5.89
I-229 1.3
I-240 6.85
I-243 5.28
I-244 11.02
I-267 0.84
I-283 20.14
I-284 1.13
I-285 7.29
I-286 13.98
I-288 14.38
I-289 12.95
Test Example 3 Mouse Carbon Powder Transport Assay
1) Preparation of Test Diet (Carbon Powder)
Using a 10 w/v % arabic gum aqueous solution, a 5 w/v % active carbon solution was prepared, which was used as a test diet.
2) Animal
A ddY line male mouse (5 to 6 weeks old) was used. The mouse was fasted from about 20 or more hours before assay initiation, and water was given ad lib.
3) Test Compound and Medium
The test compound was dissolved in a solvent (DMAA/Solutol/5% meglumine=15/15/70).
DMAA: N,N-dimethylacetamide
Solutol: Solutol (registered trademark) HS15
Meglumine: D(−)-N-methylglucamine
Morphine hydrochloride was dissolved in a physiological saline. The test compound, the above solvent and morphine were all administered at a liquid amount of 10 mL/kg.
4) Assay Method
The test compound 3 mg/kg (test compound administration group) or the solvent (solvent administration group) were subcutaneously administered and, after 15 minutes, amount of 3 mg/kg of morphine was administered to all groups. As a control group, the solvent was subcutaneously administered and, after 15 minutes, a physiological saline was administered.
The test diet 10 mL/kg was orally administered at 15 minutes after administration of morphine. At thirty minutes after administration of the test diet (60 minutes after administration of the test substance), all mice were isolated from esophagus to an ileocecal part near a stomach cardia part. A distance from pyloric part of the stomach to an ileocecal part (full length of small intestine) and a distance until a carbon powder reaching front part (carbon powder movement distance) were measured. The antagonistic activity on the carbon powder transport of inhibitory activity by morphine was calculated as MPE (%) using the following equation. Results are shown in Table 71.
Transport rate (%)=(carbon powder movement distance)/full length of small intestine (cm))×100
M.P.E. (%)={(small intestine transport rate (%) of each individual of test compound administration group−average small intestine transport rate (%) of solvent administration group)/(average small intestine transport rate (%) of control group−average small intestine transport rate (%) of solvent administration group)}×100
TABLE 71
test compound M.P.E. (%)
I-39 52
I-49 80
I-118 55.6
I-122 31.5
I-123 44.1
I-124 46.6
I-133 106.9
I-135 59.7
I-138 55.8
I-145 60.2
I-188 74.6
I-199 62.8
I-208 81.2
I-229 39.7
I-240 36.3
I-243 52.6
I-244 71.6
I-267 60
I-283 63.7
I-284 79.6
I-285 82.5
I-286 70.6
I-288 101.3
I-289 67
Formulation Example 1
A granule containing the following ingredients is prepared.
Ingredient
Compound represented by formula (I) 10 mg
Lactose 700 mg
Corn starch 274 mg
HPC-L 16 mg
1000 mg
The compound represented by the formula (I) and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed with a V-type mixer. To a mixed powder is added a HPC-L (lower viscosity hydroxypropylcellulose) aqueous solution, the materials are kneaded, granulated (extrusion granulation, pore diameter 0.5 to 1 mm), and dried. The resulting dry granule is passed through a sieve using a vibration sieve (12/60 mesh) to obtain a granule.
Formulation Example 2
A granule for filling into a capsule containing the following ingredients is prepared.
Ingredient
Compound represented by formula (I) 15 mg
Lactose 90 mg
Corn starch 42 mg
HPC-L 3 mg
150 mg
The compound represented by the formula (I) and lactose are passed through a 60 mesh sieve. Corn starch is passed through a 120 mesh sieve. These are mixed, to a mixed powder is added a HPC-L solution, the materials are kneaded, granulated, and dried. The resulting dry granule is size-adjusted, 150 mg of which is filled into a No. 4 hard gelatin capsule.
Formulation Example 3
A tablet containing the following ingredients is prepared.
Ingredient
Compound represented by the formula (I) 10 mg
Lactose 90 mg
Microcrystalline cellulose 30 mg
CMC-Na 15 mg
Magnesium stearate 5 mg
150 mg
The compound represented by the formula (I), lactose, microcrystallinecellulose, CMC-NA (carboxymethylcellulose sodium salt) are passed through a 60 mesh sieve, and mixed. Into a mixed powder is mixed magnesium stearate to obtain a mixed powder for tabletting. The present mixed powder is compressed to obtain 150 mg of a tablet.
Formulation Example 4
The following ingredients are warmed, mixed, and sterilized to obtain an injectable.
Ingredient
Compound represented by the formula (I) 3 mg
Nonionic surfactant 15 mg
Purified water for injection 1 ml
INDUSTRIAL APPLICABILITY
The present invention is useful as an agent for alleviating a side effect such as emesis, vomiting and/or constipation.

Claims (37)

The invention claimed is:
1. A compound represented by the formula (I):
Figure USRE046375-20170425-C00424
wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkylsulfonyl, optionally substituted acyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted aryl, an optionally substituted heterocyclic group, optionally substituted arylsulfonyl, or R1 and R2 are taken together with the nitrogen atom to which they are attached to form optionally substituted heterocycle;
R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy, mercapto, optionally substituted lower alkylthio, optionally substituted amino, optionally substituted carbamoyl, optionally substituted acyl, optionally substituted acyloxy, optionally substituted aryl, or an optionally substituted heterocyclic group; or
the group represented by the formula:
Figure USRE046375-20170425-C00425
wherein ring A and ring B are each independently optionally substituted nitrogen-containing heterocycle optionally containing additional nitrogen atom, oxygen atom, and/or sulfur atom in the ring;
a broken line indicates the presence or the absence of a bond;
when a broken line indicates the presence of a bond, p is 0;
when a broken line indicates the absence of a bond, p is 1;
Ra is hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, or optionally substituted lower alkynyl;
and Rb is hydrogen or oxo;
R4 is hydrogen or lower alkyl; and
R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl,
or a pharmaceutically acceptable salt, or a solvate thereof.
2. The compound according to claim 1, wherein R3 is hydroxy,
or a pharmaceutically acceptable salt, or a solvate thereof.
3. The compound according to claim 1, wherein R3 is optionally substituted amino, or a pharmaceutically acceptable salt, or a solvate thereof.
4. The compound in claim 1, wherein R1 is hydrogen or lower alkyl, R2 is optionally substituted lower alkyl, optionally substituted phenyl, optionally substituted cycloalkyl, or an optionally substituted heterocyclic group, and R5 is cyclopropylmethyl, or a pharmaceutically acceptable salt or a solvate thereof.
5. A pharmaceutical composition containing a compound in any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof.
6. A composition having an opioid receptor antagonistic activity containing a compound in any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof.
7. A composition for treating and/or preventing emesis, vomiting and/or constipation containing a compound in any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof.
8. A composition for alleviating, treating, and/or preventing a side effect induced by a compound having opioid receptor agonistic activity containing a compound in any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof.
9. A composition for alleviating, treating and/or preventing a side effect according to claim 8, wherein the side effect is emesis, vomiting and/or constipation.
10. A composition for alleviating, treating and/or preventing a side effect according to claim 9, wherein the compound having the opioid receptor agonistic activity is morphine, oxycodone, or a pharmaceutically acceptable salt, or a solvate thereof.
11. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation, comprising administering the compound in any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof.
12. An analgesic composition containing
a compound having an opioid receptor agonistic activity,
and an effective amount of compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, or a solvate thereof, for alleviating and/or preventing a side effect induced by administration of the compound having an opioid receptor agonistic activity.
13. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation, comprising administering a compound, or a pharmaceutically acceptable salt, or a solvate thereof, wherein the compound is represented by the formula (I):
Figure USRE046375-20170425-C00426
wherein
R1 is hydrogen;
R2 is selected from lower alkyl optionally substituted with lower alkoxy, lower alkoxycarbonyl, or a heterocyclic group optionally substituted with lower alkyl or phenyl; phenyl optionally substituted with lower alkyl, lower alkoxy, halogen, or cyano lower alkyl; cycloalkyl optionally substituted with lower alkoxycarbonyl or lower alkoxy lower alkyl; or a heterocyclic group optionally substituted with lower alkoxy or oxo;
R3 is hydroxyl;
R4 is hydrogen; and
R5 is cyclopropylmethyl;
or a pharmaceutically acceptable salt, or a solvate thereof.
14. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation, comprising administering a compound, or a pharmaceutically acceptable salt, or a solvate thereof, wherein the compound is represented by the formula (I):
Figure USRE046375-20170425-C00427
wherein
R1 is hydrogen;
R2 is lower alkyl optionally substituted with lower alkoxy or with a heterocyclic group that is optionally substituted with aryl; phenyl optionally substituted with lower alkyl or with lower alkoxy; cycloalkyl substituted with lower alkylcarbonyl; or a heterocyclic group substituted with lower alkoxy or with aryl;
R3 is hydroxyl;
R4 is hydrogen; and
R5 is cyclopropylmethyl;
or a pharmaceutically acceptable salt, or solvate thereof.
15. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation, comprising administering
Figure USRE046375-20170425-C00428
Figure USRE046375-20170425-C00429
Figure USRE046375-20170425-C00430
Figure USRE046375-20170425-C00431
or a pharmaceutically acceptable salt, or a solvate thereof.
16. The method according to claim 15, wherein the administered compound, or a pharmaceutically acceptable salt, or solvate thereof, is
Figure USRE046375-20170425-C00432
Figure USRE046375-20170425-C00433
or a pharmaceutically acceptable salt, or a solvate thereof.
17. The compound according to claim 1 which is a pharmaceutically acceptable solvate of
Figure USRE046375-20170425-C00434
18. The compound according to claim 17 wherein the pharmaceutically acceptable solvate is a hydrate.
19. The pharmaceutical composition according to claim 5 containing a pharmaceutically acceptable solvate of
Figure USRE046375-20170425-C00435
20. The pharmaceutical composition according to claim 19 in the form of a tablet.
21. The analgesic composition according to claim 12 wherein the compound for alleviating and/or preventing a side effect induced by administering of the compound having an opioid receptor agonistic activity is a pharmaceutically acceptable solvate of
Figure USRE046375-20170425-C00436
22. The analgesic composition according to claim 21 wherein the compound having an opioid receptor agonistic activity is morphine, oxycodone, or a pharmaceutically acceptable salt thereof.
23. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation comprising administering a compound of the formula
Figure USRE046375-20170425-C00437
or pharmaceutically acceptable salt thereof.
24. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation comprising administering a compound of the formula
Figure USRE046375-20170425-C00438
25. A method according to claim 23 wherein the compound administered is the p-toluene sulfonic acid salt of
Figure USRE046375-20170425-C00439
26. A method for alleviating, treating and/or preventing emesis, vomiting and/or constipation comprising administering a pharmaceutically acceptable solvate of a compound of the formula
Figure USRE046375-20170425-C00440
27. The method according to claim 23 wherein the compound is administered orally in the form of a tablet.
28. The method according to claim 25 wherein the compound is administered orally in the form of a tablet.
29. A method for treating opioid-induced constipation comprising administering a compound of the formula
Figure USRE046375-20170425-C00441
or a pharmaceutically acceptable salt or solvate thereof.
30. A method for treating opioid-induced constipation comprising administering a compound of the formula
Figure USRE046375-20170425-C00442
31. The method according to claim 29 wherein the compound administered is the p-toluene sulfonic acid salt of
Figure USRE046375-20170425-C00443
32. The method according to claim 31 wherein the compound is administered orally in the form of a tablet.
33. The method according to claim 29 wherein the compound is administered in a dose of 0.01 mg to 200 mg/day.
34. The method according to claim 31 wherein the compound is administered in a dose of 0.01 mg to 200 mg/day.
35. The composition of claim 19 further comprising a compound having opioid receptor agonistic activity.
36. The composition of claim 35 wherein the compound having opioid receptor agonistic activity is morphine, oxycodone, or a pharmaceutically acceptable salt thereof.
37. The method of claim 25 wherein the compound is administered in a dose of 0.01 mg to 200 mg/day.
US15/064,538 2005-05-25 2016-03-08 6,7-unsaturated-7-carbamoyl substituted morphinan derivative Active 2026-10-05 USRE46375E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/064,538 USRE46375E1 (en) 2005-05-25 2016-03-08 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP2005151864 2005-05-25
JP2005-151864 2005-05-25
JP2006065762 2006-03-10
JP2006-065762 2006-03-10
PCT/JP2006/310231 WO2006126529A1 (en) 2005-05-25 2006-05-23 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
WOPCT/JP2006/310231 2006-05-23
PCT/JP2006/310454 WO2006126637A1 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US11/920,851 US8084460B2 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US13/308,483 US8536192B2 (en) 2005-05-25 2011-11-30 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US15/064,538 USRE46375E1 (en) 2005-05-25 2016-03-08 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13/308,483 Reissue US8536192B2 (en) 2005-05-25 2011-11-30 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Publications (1)

Publication Number Publication Date
USRE46375E1 true USRE46375E1 (en) 2017-04-25

Family

ID=37451954

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/064,511 Active 2031-02-24 USRE46365E1 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US11/920,851 Ceased US8084460B2 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US13/308,483 Ceased US8536192B2 (en) 2005-05-25 2011-11-30 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US15/064,538 Active 2026-10-05 USRE46375E1 (en) 2005-05-25 2016-03-08 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/064,511 Active 2031-02-24 USRE46365E1 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US11/920,851 Ceased US8084460B2 (en) 2005-05-25 2006-05-25 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US13/308,483 Ceased US8536192B2 (en) 2005-05-25 2011-11-30 6,7-unsaturated-7-carbamoyl substituted morphinan derivative

Country Status (19)

Country Link
US (4) USRE46365E1 (en)
EP (1) EP1889848B8 (en)
JP (1) JP4323547B2 (en)
KR (1) KR100912782B1 (en)
CN (1) CN101228172B (en)
AU (1) AU2006250390B2 (en)
BR (1) BRPI0610343B8 (en)
CA (1) CA2609733C (en)
DK (1) DK1889848T3 (en)
ES (1) ES2525215T3 (en)
FR (1) FR19C1042I2 (en)
HU (1) HUS1900034I1 (en)
MX (1) MX2007014588A (en)
NL (1) NL300996I2 (en)
PL (1) PL1889848T3 (en)
PT (1) PT1889848E (en)
RU (1) RU2403255C2 (en)
TW (1) TWI311056B (en)
WO (2) WO2006126529A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126529A1 (en) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
JP5252391B2 (en) * 2008-02-21 2013-07-31 学校法人北里研究所 Morphinane derivative having oxabicyclo [2.2.2] octane and pharmaceutical use thereof
CA2734333A1 (en) * 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
CN104958298A (en) * 2009-09-18 2015-10-07 阿得罗公司 Use of an opioid receptor antagonist for the treatment or prevention of gastrointestinal tract disorders
KR20130072221A (en) * 2010-05-13 2013-07-01 주식회사 녹십자 (+)-3-hydroxymorphinan-based polycycle derivatives as neuroprotectants
SI2639234T1 (en) 2010-11-12 2019-10-30 Shionogi & Co Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
DK2851075T3 (en) * 2012-05-14 2022-01-31 Shionogi & Co PREPARATION CONTAINING 6,7-UNSaturated -7-CARBAMOYL MORPHININE DERIVATIVE
CA3048360C (en) 2016-12-26 2021-06-29 Shionogi & Co., Ltd. Production method for formulation having improved content uniformity
CN112312910A (en) 2018-04-12 2021-02-02 莫菲克医疗股份有限公司 Human integrin alpha 4 beta 7 antagonists
KR102201609B1 (en) 2019-04-19 2021-01-12 연성정밀화학(주) Process for Preparing Naldemedine
CA3154269A1 (en) 2019-10-16 2021-04-22 Matthew G. Bursavich Inhibiting human integrin .alpha.4.beta.7
WO2021100728A1 (en) 2019-11-20 2021-05-27 塩野義製薬株式会社 6,7-unsaturated-7-carbamoyl morphinan derivative-containing solid formulation
CN111905111B (en) * 2020-09-16 2023-03-31 地奥集团成都药业股份有限公司 Method for evaluating curative effect of compound glutamine composition on diarrhea-predominant irritable bowel syndrome

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5615290A (en) 1979-07-11 1981-02-14 Miles Lab 77 and 7788substituted 4*55alphaaepoxymorphinann 66one compound
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
JPS588067A (en) 1981-06-29 1983-01-18 エスアイエスエイ・フア−マシユ−チカル・ラボラトリ−ス・インコ−ポレ−テツド 17-cyclopropylmethyl-3-hydroxy-14-methoxy-7 alpha-methyl-morphinan-6-one
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
WO1995013071A2 (en) 1993-11-08 1995-05-18 Regents Of The University Of Minnesota Treatment of immunoregulatory disorders
WO1997025331A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
US6177438B1 (en) 1993-07-23 2001-01-23 Toray Industries, Inc. Morphinan derivatives and pharmaceutical use thereof
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
WO2001085150A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
WO2002036573A2 (en) 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2002042309A1 (en) 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and use thereof in medicines
WO2004005294A2 (en) 2002-07-03 2004-01-15 Alcasynn Pharmaceuticals Gmbh Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof
WO2004007503A1 (en) 2002-07-11 2004-01-22 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
WO2004026819A2 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
US20050038061A1 (en) 2001-12-17 2005-02-17 Johannes Schutz 6-Aminomorphinane derivatives, method for production and use thereof
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
WO2005117589A1 (en) 2004-05-28 2005-12-15 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
WO2006034039A2 (en) 2004-09-17 2006-03-30 Adolor Corporation Substituted morphinans and methods of their use
WO2006126637A1 (en) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US9108975B2 (en) 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7142420B2 (en) 2004-09-20 2006-11-28 Qualcomm, Incorporated Devices and methods for controlling relative movement between layers of an electronic device

Patent Citations (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
JPS5615290A (en) 1979-07-11 1981-02-14 Miles Lab 77 and 7788substituted 4*55alphaaepoxymorphinann 66one compound
US4275205A (en) 1980-05-05 1981-06-23 Miles Laboratories, Inc. 7,7-Ditosyloxymethyl-4,5α-epoxy-morphinan-6-ols
US4347361A (en) 1980-12-10 1982-08-31 Sisa, Incorporated 4,5α-Epoxy-3-hydroxy or methoxy-7-(1-hydroxy-alkyl or 1-oxoalkyl)morphinan-6-one compounds
JPS588067A (en) 1981-06-29 1983-01-18 エスアイエスエイ・フア−マシユ−チカル・ラボラトリ−ス・インコ−ポレ−テツド 17-cyclopropylmethyl-3-hydroxy-14-methoxy-7 alpha-methyl-morphinan-6-one
US4370333A (en) 1981-06-29 1983-01-25 Sisa, Incorporated 17-Cyclopropylmethyl-3-hydroxy-14-methoxy 7α-methyl-morphinan-6-one and therapeutic method of treating pain with it
US4443605A (en) 1982-07-30 1984-04-17 Miles Laboratories, Inc. 7β-Arylalkyl-6α, 7 α-oxymethylene-3-methoxy or 3-hydroxy-4, 5α-epoxy-17 methyl or 17-cycloalkyl-methyl morphinans
US4440932A (en) 1982-09-09 1984-04-03 Miles Laboratories, Inc. 7β-Arylalkyl-7α-methyl-6-oxo or 6α-hydroxy-3-methoxy or 3-hydroxy-4,5α-epoxy-17-methyl or 17-cycloalkyl-methylmorphinans
US6177438B1 (en) 1993-07-23 2001-01-23 Toray Industries, Inc. Morphinan derivatives and pharmaceutical use thereof
WO1995013071A2 (en) 1993-11-08 1995-05-18 Regents Of The University Of Minnesota Treatment of immunoregulatory disorders
WO1997025331A1 (en) 1996-01-10 1997-07-17 Smithkline Beecham S.P.A. Heterocycle-condensed morphinoid derivatives (ii)
JP2000503019A (en) 1996-01-10 2000-03-14 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Heterocyclic fused morphinoid derivative (II)
WO2001002375A1 (en) 1999-07-01 2001-01-11 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
JP2003528819A (en) 1999-11-29 2003-09-30 アドラー コーポレーション Novel methods and compositions for opioids and their antagonists
WO2001037785A2 (en) 1999-11-29 2001-05-31 Adolor Corporation Novel methods and compositions involving opioids and antagonists thereof
WO2001085257A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist compositions and dosage forms
WO2001085150A2 (en) 2000-05-05 2001-11-15 Pain Therapeutics, Inc. Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists
JP2004501094A (en) 2000-05-05 2004-01-15 ペイン・セラピューティクス・インコーポレイテッド Novel compositions and methods for enhancing the efficacy of opioid agonists or reducing the deleterious side effects of opioid agonists
JP2004522706A (en) 2000-10-31 2004-07-29 レンセラール ポリテクニック インスティチュート 8-carboxamide-2,6-methano-3-benzazocine
WO2002036573A2 (en) 2000-10-31 2002-05-10 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
WO2002042309A1 (en) 2000-11-22 2002-05-30 Toray Industries, Inc. Indole derivatives and use thereof in medicines
US20040019071A1 (en) 2000-11-22 2004-01-29 Satoshi Sakami Indole derivatives and use thereof in medicines
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
US20050038061A1 (en) 2001-12-17 2005-02-17 Johannes Schutz 6-Aminomorphinane derivatives, method for production and use thereof
WO2004005294A2 (en) 2002-07-03 2004-01-15 Alcasynn Pharmaceuticals Gmbh Morphinan derivatives the quaternary ammonium salts thereof substituted in position 14, method for production and use thereof
WO2004007503A1 (en) 2002-07-11 2004-01-22 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
US20060052409A1 (en) 2002-07-11 2006-03-09 Koji Kawai Therapeutic or preventive agent for nausea/vomiting
EP1522542A1 (en) 2002-07-11 2005-04-13 Toray Industries, Inc. Therapeutic or preventive agent for nausea/vomiting
WO2004026819A2 (en) 2002-09-18 2004-04-01 The Curators Of The University Of Missouri OPIATE ANALOGS SELECTIVE FOR THE delta-OPIOID RECEPTOR
JP2006502190A (en) 2002-09-18 2006-01-19 ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ Opiate analogs selective for delta-opioid receptors
US20040122230A1 (en) * 2002-09-18 2004-06-24 The Curators Of The University Of Missouri Opiate analogs selective for the delta -opioid receptor
US20040157784A1 (en) 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
WO2005105093A2 (en) 2003-08-26 2005-11-10 Duke University METHOD OF ARRESTING THE SIDE EFFECTS OF µ-OPIOID RECEPTOR AGONISTS DURING THEIR ADMINISTRATION
WO2005117589A1 (en) 2004-05-28 2005-12-15 Human Biomolecular Research Institute Synthesis of metabolically stable analgesics, pain medications and other agents
WO2006034039A2 (en) 2004-09-17 2006-03-30 Adolor Corporation Substituted morphinans and methods of their use
WO2006126637A1 (en) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
EP1889848A1 (en) 2005-05-25 2008-02-20 Shionogi Co., Ltd. 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US20090203723A1 (en) 2005-05-25 2009-08-13 Masanao Inagaki 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US9108975B2 (en) 2010-11-12 2015-08-18 Shionogi & Co., Ltd. Crystal of 6,7-unsaturated-7-carbamoyl morphinan derivative and method for producing the same

Non-Patent Citations (70)

* Cited by examiner, † Cited by third party
Title
"Persistently Low Natural Killer Cell Activity," Life Science, 48(2): 111-116 (1991).
Amendement and Response to Office Action, filed Jun. 29, 2011, for U.S. Appl. No. 11/920,851 (45 pages).
Amendment and Response to Office Action, filed Jun. 29, 2011, for U.S. Appl. No. 11/920,851 (45 pages).
Ananthan et al., "Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans," J. Med. Chem., 42: 3527-3538 (1999).
Ananthan et al.; "Synthesis, Opioid Receptor Binding, and Biological Activities of Naltrexone-Derived Pyrido- and Pyrimidomorphinans," J. Med. Chem., 42: 3527-3538 (1999).
B. D. Anderson et al., "Preparation of Water-Soluble Compounds Through Salt Formation", C. G. Wermuth editors, The Practice of Medicinal Chemistry, vol. 2 (Technomic Inc.), pp. 739-741, 750-753, 831-833, (1996).
Boche et al.; "Electrophilic Amination of Acyl Anion Equivalents: Mild Oxidation of Aldehydes to Amides Via 0-(Trimehylsilyl)Aldehyde Cyanohydrin Anions," Tetrahedron Letters, 23(32): 3255-3256 (1982).
Boche et al.; "Electrophilic Amination of Acyl Anion Equivalents: Mild Oxidation of Aldehydes to Amides Via 0-(Trimethylsilyl)Aldehyde Cyanohydrin Anions," Tetrahedron Letters, 23(32): 3255-3256 (1982).
Brandt; "A Uniform Molecular Model of δ Opioid Agonist and Antagonist Pharmacophore Conformations," J. Computer-Aided Molecular Design, 12: 615-621 (1998).
Brandt; "A Uniform Molecular Model δ Opioid Agonist and Antagonist Pharmacophore Conformations," J. Computer-Aided Molecular Design, 12: 615-621 (1998).
Caira, Mino R., Crystalline Polymorphism of Organic Compounds; Topics in Current Chemistry, 1998 vol. 198, p. 166.
Chun-Su et al., "Clinical Status of Methylnaltrexone , A New Agent to Prevent and Manage Opioid-Induced Side Effects," J. Supportive Oncology, 2(2): 111-122 (2004).
Chun-Su et al., "Clinical Status of Methylnaltrexone, A New Agent to Prevent and Manage Opioid-Induced Side Effects," J. Supportive Oncology, 2(2): 111-122 (2004).
D. C. Butler et al., "Synthesis of isocyanates from carbamate esters employing boron trichloride", Chem. Commun., pp. 2575-2576 (1998).
Dalzell et al,; "4,5-Alpha-Epoxy-3-Hydroxy- 7,17-DI:Substd.-Morphinan-6-One(s)-Useful as Analgesics and/or Narcotic," Abstract of JP 57-122088, Jul. 29, 1982.
Dalzell et al,; "4,5-Alpha-Epoxy-3-Hydroxy- 7,17-DI:Substd.-Morphinan-6-One(s)—Useful as Analgesics and/or Narcotic," Abstract of JP 57-122088, Jul. 29, 1982.
Dalzell et al.; "4,5-Alpha-Epoxy-3-Hydroxy- 7,17-DI:Substd.-Morphinan-6-One(s)-Useful As Analgesics and/or Narcotic," Abstract of JP 57-122088, Jul. 29, 1982.
Dalzell et al.; "4,5-Alpha-Epoxy-3-Hydroxy- 7,17-DI:Substd.-Morphinan-6-One(s)—Useful As Analgesics and/or Narcotic," Abstract of JP 57-122088, Jul. 29, 1982.
English Translation of International Preliminary Report on Patentability issued by the Japanese Patent Office in International Application No. PCT/JP2011/076034), mailed May 23, 2013 (10 pages).
Fujii et al.; "The First Example of the Steroselective Synthesis of 7β-Carbamoyl-4,5α-Epoxymorphinan Via a Novel and Reactive γ-Lactone," Chem. Pharm. Bull., 52(6): 747-750 (2004).
Fujii et al.; "The First Example of the Steroselective Synthesis of 7β-Carbomoyl-4,5α-Epoxymorphinan via a Novel and Reactive γ-Lactone," Chem. Pharm. Bull., 52(6): 747-750 (2004).
Gao et al.: "Monophenylation of Morphinan-6-Ones With Diphenyliodonium Iodide," J. Org. Chem., 60: 2276-2278 (1995).
Gao et al.: "Synthesis of 7-Arylmorphinans. Probing the "Address" Requirements for Selectivity At Opioid δ Receptors," J. Med. Chem., 41: 3091-3098 (1998).
Gao et al.; "Boron Tribromide-Catalyzed Rearrangement of 7,7-Diphenylhydromorphone to 6,7-Diphenylmorphine: A Novel Conversion of Ketones to Allylic Alcohols," J. Org. Chem., 61: 2466-2469 (1996).
Gao et al.; "Monophenylation of Morphinan-6-Ones With Diphenyliodonium Iodide," J. Org. Chem., 60: 2276-2278 (1995).
Gao et al.; "Synthesis of 7-Arylmorphinans. Probing the "Address" Requirements for Selectivity At Opioid δ Receptors," J. Med. Chem., 41: 3091-3098 (1998).
Herlihy et al.; "Novel Opiates and Antagonists. 5. 7-Carbethoxy-N-(Cycloalkylmethyl)-3-Hydroxymorphinan-6-Ones and -Isomorphinan-6-Ones," J. Med. Chem., 25; 986-990 (1982).
Herlihy et al.; "Novel Opiates and Antagonists. 5. 7-Carbethoxy-N-(Cycloalkylmethyl)-3-Hydroxymorphinan-6-Ones and-Isomorphinan-6-Ones," J. Med. Chem., 25: 986-990 (1982).
Hernández-Gallegos et al.; "A Free-Wilson/Fujita-Ban Analysis and Prediction of the Analgesic Potency of Some 3-Hydroxy- and 3-Methoxy-N-Alkylmorphinan-6-One Opioids," J. Med. Chem., 33: 2813-2817 (1990).
Hernández-Gallegos et al.; "A Free-Wilson/Fujita-Ban Analysis and Prediction of the Analgesic Potency of Some 3-Hydroxy- and 3-Methoxy-N-Alkylmorphinan-6-One-Opioids," J. Med. Chem., 33: 2813-2817 (1990).
International Preliminary Report on Patentability issued Nov. 29, 2007, for Application No. PCT/JP2006/310454.
International Search Report issued by the Japanese Patent Office in International Application No. PCT/JP2011/076034, mailed Dec. 13, 2011 (9 pages).
International Search Report mailed Jun. 20, 2006, for Application No. PCT/JP2006/310454.
Interview Summary, mailed May 3, 2011, for U.S. Appl. No, 11/920,851 (2 pages).
Interview Summary, mailed May 3, 2011, for U.S. Appl. No. 11/920,851 (2 pages).
Koolpe et al.; "Opioid Agonists and Antagonists. 6-Desoxy-6-Substituted Lactone, Epdxide, and Glycidate Ester Derivatives of Naltrexone and Oxymorphone," J. Med. Chem. 28: 949-957 (1985).
Koolpe et al.; "Opioid Agonists and Antagonists. 6-Desoxy-6-Substituted Lactone, Epdxide, and Glycidate Ester Derivatives of Naltrexone and Oxymorphone," J. Med. Chem., 28: 949-957 (1985).
Kotick et al,; "Analgesic Narcotic Antagonists. 8. 7α-Alkyl-4,5α-Epoxymorphinan-6-Ones," J. Med. Chem., 24: 1445-1450 (1981).
Kotick et al.; "Analgesic Narcotic Antagonists. 15. Potent Narcotic Agonist 7β-(Arylalkyl)-4,5α-Epoxymorphinans," J. Med. Chem., 26: 1050-1056 (1983).
Kotick et al; "Analgesic Narcotic Antagonists. 15. Potent Narcotic Agonist 7β-(Arylalkyl)-4,5α-Epdxymorphinans," J. Med. Chem., 26: 1050-1056 (1983).
Leland et al.; "7α- or 7β-(4-Phenylbutyl)Dihydrocodeine Derivatives," J. Org. Chem., 48: 1813-1819 (1983).
Leland et al.; "Analgesic Narcotic Antagonists. 5. 7,7-Dimethyldihydrocodeinones and 7,7-Dimethyldihydromorphinones," J. Med. Chem., 24: 717-721 (1981).
Leland et al.; "Analgesic Narcotic Antagonists. 5. 7,7-Dimethyldihydrocodeinones and 7,7-Dimethyldihydromorphinones," J. Med. Chem., 24: 717-721(1981).
Lester et al.; "Vilsmeier Reactions With 14-Hydroxy-Dihydrocodeinone and Derived Enol Ethers," Tetrahedron, 20: 1407-1417 (1964).
Lester et al.; "Vilsmeier Reactions With Cyclic Ketals of 14-Hydroxy-Dihydrocodeinone and Some New Cyclic Derivatives of 14-Hydroxy-Dihydrocodeinone," Tetrahedron, 21: 771-778 (1965).
M. J. Duggan et al., "Copper(I) Chloride Catalyzed Addition of Alcohols to Alkyl Isocyanates. A Mild and Expedient Method for Alkyl Carbamate Formation", Synthesis, vol. 2. pp. 131-132 (1989).
Munson et al.; "Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems," Analytical Biochemistry, 107(1): 220-239 (1980).
Nagase et al., "Facile Intramolecular O-14→C-7 Acetyl Transfer in Opiate 14-Acetate Esters," J. Org. Chem., 55: 365-367 (1990).
Nagase et al.; "Facile Intramolecular O-14→C-7 Acetyl Transfer in Opiate 14-Acetate Esters," J. Org. Chem., 55: 365-367 (1990).
Notice of Allowance, mailed Aug. 18, 2011, for U.S. Appl. No. 11/920,851 (9 pages).
Office Action (Restriction Requirement), mailed Jan. 3, 2011, for U.S. Appl. No. 11/920,851 (11 pages).
Office Action, mailed Mar. 29, 2011, for U.S. Appl. No. 11/920,851 (10 pages).
Ohkawa et al.; "7-Arylidenenaltrexones As Selective δ1 Opioid Receptor Antagonists," J. Med. Chem., 41.4177-4180 (1998).
Ohkawa et al.; "7-Arylidenenaltrexones As δ1 Selective Opioid Receptor Antagonists," J. Med. Chem., 41: 4177-4180 (1998).
Portoghese et al.; "Synthesis of Naltrexone-Derived δ-Opioid Antagonists. Role of Conformation of the δ Address Moiety," J. Med. Chem., 37: 579-585 (1994).
Portoghese, "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands," J. Med. Chem. 35(11): 1927-1937 (1992).
Portoghese, "The Role of Concepts in Structure-Activity Relationship Studies of Opioid Ligands," J. Med. Chem., 35(11): 1927-1937 (1992).
R. Poulain et al., "Parallel synthesis of 1,2,4-oxediazoles from carboxylic acids using an improved, uronium-based, activation", Tetrahedron Letters, 42, pp. 1495-1498 (2001).
Response to Restriction Requirement, filed Feb. 2, 2011, for U.S. Appl. No. 11/920,851 (5 pages).
Ronzoni et al.; "Synthesis and NMR Characterization of a Novel Class of Thienomorphinans," Organic Letters, 1(3): 513-515 (1999).
S Morissette et al., "High-throughput Crystallization: Polymorphs, Salts, Co-Crystals and Solvates of Pharmaceutical Solids," Adv Drug Deliv Rev, vol. 56, pp. 275-300 (2004).
S.R. Vippagunta et al., "Crystalline Solids," Adv Drug Deliv Rev, vol. 48(1), pp. 3-26 (2001).
Supplementary European Search Report mailed Jul. 11, 2001, in European Application No. EP 06746833.0.
Supplementary European Search Report mailed Jul. 11, 2011, in European Application No. EP 06746833.0.
T. Okano, "Chemical structure and solubility", New General Pharmacy (revised 3rd edition), pp. 26, 111, 256-258 (1987).
T. Okano, "Forms of powder and granular substances", New General Pharmacy (revised 3rd edition), pp. 109-111, 254-259, 327 (1987).
West, Solid State Chemistry and Its Applications, Wiley, New York, 1988, pp. 358 and 365.
West,Solid State Chemistry and Its Applications, Wiley, New York, 1988, pp. 358 and 365.
Yuan et al., The Journal of Supportive Oncology, vol. 2, No. 2 (2004), pp. 111-122.
Yuan et al., The Journal of Supportive Oncology, vol. 2, No. 2, (2004), pp. 111-122. *

Also Published As

Publication number Publication date
FR19C1042I2 (en) 2020-06-19
WO2006126637A1 (en) 2006-11-30
RU2403255C2 (en) 2010-11-10
US20090203723A1 (en) 2009-08-13
USRE46365E1 (en) 2017-04-11
CN101228172A (en) 2008-07-23
EP1889848A4 (en) 2011-08-10
BRPI0610343A2 (en) 2010-06-15
EP1889848A1 (en) 2008-02-20
NL300996I2 (en) 2019-07-30
RU2007148412A (en) 2009-06-27
US8536192B2 (en) 2013-09-17
BRPI0610343B8 (en) 2021-05-25
WO2006126529A1 (en) 2006-11-30
TW200726470A (en) 2007-07-16
ES2525215T3 (en) 2014-12-19
FR19C1042I1 (en) 2019-08-09
CA2609733C (en) 2011-07-19
TWI311056B (en) 2009-06-21
NL300996I1 (en) 2019-07-03
MX2007014588A (en) 2008-01-24
EP1889848B1 (en) 2014-10-15
JP4323547B2 (en) 2009-09-02
JPWO2006126637A1 (en) 2008-12-25
US8084460B2 (en) 2011-12-27
PL1889848T3 (en) 2015-04-30
KR100912782B1 (en) 2009-08-18
AU2006250390B2 (en) 2010-07-08
KR20080014791A (en) 2008-02-14
AU2006250390A1 (en) 2006-11-30
EP1889848B8 (en) 2014-12-17
DK1889848T3 (en) 2014-12-01
CA2609733A1 (en) 2006-11-30
HUS1900034I1 (en) 2019-07-29
US20120135978A1 (en) 2012-05-31
CN101228172B (en) 2013-04-03
BRPI0610343B1 (en) 2020-03-10
PT1889848E (en) 2014-12-09

Similar Documents

Publication Publication Date Title
USRE46375E1 (en) 6,7-unsaturated-7-carbamoyl substituted morphinan derivative
US10532985B2 (en) Heterocycle and carbocycle derivatives having TRKA inhibitory activity
US7935706B2 (en) Nitrogen-containing heterocycle derivatives substituted with cyclic group
AU2020343671C1 (en) RIP1 inhibitory compounds and methods for making and using the same
US7008954B1 (en) Th2 differentiation inhibitors
US20140235626A1 (en) Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them
US9630922B2 (en) 3-spiro-7-hydroxamic acid tetralins as HDAC inhibitors
CN105934246A (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
CN101420955B (en) Dihydrodiazepines useful as inhibitors of protein kinases
US6765096B1 (en) Tricyclic compound having acyloxymethoxycarbonyl side chain
US20180360803A1 (en) Pharmaceutical composition for treatment or prevention of nash
KR20000005366A (en) Novel carboxylic acid derivatives, their production and use
US20230416262A1 (en) Trpml modulators
JP4737495B2 (en) Erythromycin derivative
RU2795850C2 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and variants of their use
US20040034076A1 (en) Novel carbamates and carbamides, production and use thereof as endothelin receptor antagonists

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8